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Abstract
Live or attenuated pathogens are the basis of many successful vaccines due in part to
the orchestrated response of dendritic cells (DCs) triggered by these immunizations,
which includes (1) DC and DC precursor attraction to the immunization site, (2) efficient
antigen delivery to class I and class II MHC loading pathways coincident with maturation
of DCs, and (3) emigration to draining lymph nodes for T cell activation. We have
developed a model immunization system designed to allow these steps in the DC life
cycle to be controlled in the context of a subunit vaccine. The system is comprised of
microspheres encapsulating chemokines and hydrogel nanoparticles; each nanoparticle
contains antigen and DC maturation signals (e.g., TLR ligands). The nanoparticles
remain sequestered within the carrier microspheres but the chemokine is released at a
controllable rate, creating a local chemoattractant gradient centered on each
microsphere. DCs are attracted to individual microspheres where nanoparticles are
concentrated; attracted DCs extract nanoparticles from the carrier microspheres, and
receive maturation signals coincident with the delivery of antigen into both class I and
class II MHC processing pathways. In addition, the nanoparticles may be labeled to
allow subsequent tracking of particle-carrying DCs in vivo. These components allow the
attraction (or if desired, emigration) of dendritic cells and their precursors to be
selectively modulated at an immunization site, and the activation signals received by
these cells when they encounter antigen to be tailored. In vitro experiments indicate that
chemokine-releasing microspheres effectively attract DCs and monocytes over
significant distances, and that the gel nanoparticles efficiently trigger DC maturation and
lead to both CD4* and CD8* T cell activation in vitro and in vivo. This system provides
both a platform for rational immunotherapy as well as a powerful set of tools by which
the function of dendritic cells can be manipulated and dissected to improve our
understanding of how DC trafficking and functional state impacts immune responses.
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1. Introduction and Background
1.1 Adaptive immunity and the role of dendritic cell
The immune system functions to defend the body from extracellular infectious
agents. In addition, it attempts to restrict the growth of tumor cells and virally-infected
cells. The immune system is comprised of innate immunity and adaptive immunity.
Innate immunity is nonspecific and acts as a first line of defense against pathogens
through the recruitment of epithelial cells, macrophages, and dendritic cells. On the
other hand, adaptive immunity develops and adapts according to the encountered
antigen, and is divided into cell-mediated and humoral immunity (Figure 1.1). Cell-
mediated immunity involves activation of T-lymphocytes within secondary lymphoid
organs (SLO), which then migrate to the site of infection and destroy the pathogen or
infected cells by means of cytokines or cytolytic activity. In contrast, humoral immunity is
comprised of B-lymphocytes that when activated form antibody-secreting plasma cells,
and these secreted antigen-specific antibodies neutralize the pathogen [1-3].
Innate Adaptive
immune response immune response
Secreted
receptors
Microbes {complment. MBL) IL-I.IL-6.TNF-a
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Antigen presenting cell T-cell
Figure 1.1. Schematic Diagram of Innate Immunity and Adaptive Immunity linked
through Antigen Presenting Cells [4].
In the primary immune response, dendritic cells, a class of antigen-presenting
cells, phagocytose (and macropinocytose) foreign antigen at sites of infection in
peripheral tissues, process them in the endosomes and/or cytosol, and present peptides
thus obtained on their surface using a multi-subunit protein complex called Major
Histocompatibility Complex (MHC). MHC molecules are subdivided into class I and
class II MHC; MHC class I molecules present antigen to CD8' cytotoxic T-lymphocytes
(CTL) whereas MHC class II molecules are used to present antigen to CD4 + helper T-
lymphocytes (TH-cells). CTLs destroy infected cells presenting the antigen against which
they have been activated. TH-Cells, on the other hand, release soluble mediators called
cytokines that initiate a cascade involving proliferation of macrophages to engulf and
destroy the antigen (Figure 1.2) [5]. Successful elimination of a pathogen is
accompanied by generation of memory T cells to control any future exposure to the
same antigen. Activation of naIve T-lymphocytes by dendritic cells (DCs) requires not
only the presence of peptide loaded onto MHC molecule (pMHC) but also costimulatory
signals provided by DC cell surface molecules (e.g., B7-1 and B7-2) that interact with
specific receptors on T-cells (e.g., CD28) [1-3]. For the vaccine to be developed in this
project, dendritic cells were targeted as they are the only professional APCs known to
prime naIve T-cells (both CD4 + and CD8 +) in vivo [5-7] and along with macrophages
14
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possess a unique ability to cross present antigen [8]. B cells, in contrast to T cells, can
directly bind protein antigens via their B cell receptors (membrane-tethered IgM or IgG
molecules).
PROIfUERATING
IXMPROGEWTOR
NO*PROULFERATING
DCPECMMURSORS
CAM4TU two" SMCOlARnAN,
tat ATOR1
LLOODO 
a 
ao T CoORAS
.- ffu,
Figure 1.2. Activation of CD4+ and CD8+ T cells in cell-mediated adaptive immune
response [5].
Exogenous antigens are processed in the endosomes of APCs and are
presented using MHC class II molecules; in most nucleated cells, endogenous
(cytosolic) antigens are typically processed in the cytosol and are presented on MHC
class I molecules (Figure 1.3). Therefore, the physical location of an antigen is a
determinant of whether CD8 ÷ T cells against the antigen can be generated. However,
dendritic cells are known to transport antigens from endosomes to the cytosol as a
result of which antigenic peptides are presented on MHC class I as well as class II
molecules [9]. This phenomenon that allows DCs (and macrophages) [10] to present
antigens captured from the extracellular milieu to both CD4 ÷ and CD8 ÷ T cells is called
cross priming or cross presentation; the detailed mechanism of this process are still not
clear but formation of ER-phagolysosome fusions has been proposed [11].
15
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Figure 1.3. Mechanisms of antigen presentation on MHC class I and class II
molecules [12].
1.2 Role of chemokines in immune response
The homing and migration of lymphocytes and dendritic cells is determined by
chemoattractants called chemokines. Different cell types are associated with
characteristic chemokine receptors and their cognate ligands, and similarly, expression
of chemokine receptors by dendritic cells depends on the state of the DC (Table 1.1)
[13]. Chemokines are involved in several processes such as angiogenesis, dendritic cell
and lymphocytes homing, wound healing, and organogenesis. Chemokines are able to
specifically target the cells of primary importance and cause concentration and/or
organization of cells of interest at the site of action via the process of chemotaxis.
Immature DCs have a high expression of CCR6, which binds the chemokines MCP-3,
CCL20 and P3-defensins [14-16]. Another set of receptors for immature DCs comprises
the formyl peptide receptor (FPR) and the formyl peptide-like receptor (FPLR), which
bind to the bacterially-derived peptide fMet-Leu-Phe (fMLF, commonly written as fMLP)
and related peptides [17,18]. These receptors are thought to direct immature DCs to
sites of infection for antigen loading. Maturing DCs, on the other hand, downregulate
16
CCR6 and FPR, and upregulate CCR7, the lymph node homing receptor that binds
macrophage inflammatory protein-3p3 (MIP-3p3) or CCL21 [5,19].
Table 1.1. Expression of various chemokine receptors in cells of immune system.
Receptor Cellular Distribution igands
CCRI N. M. T. NK. B. Ms. As., NTES, MIP-lc,. HCC-1. MCP-2.3. MIP-5,
CCR2A M MCP-1.3.4
CCR2B M, T. B. Bs MCP-1.2.3.4. HI'
CCR3 Eo. Bs. T Eotaxin. Eotaxin-2.3. RANTES. MCP-2.3.4. MIP-5
CR4 T. P TARC. MDC
CR5 T. M. DC RlANTES. MIP-lct.. MCP-2. NM tropic HIV-1
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1.3 Dendritic cell activation
As outlined in Figures 1.1 and 1.2, the two key early steps for dendritic cell
function are antigen uptake and dendritic cell maturation. Maturation is caused by
various agents most of which have been obtained from bacterial and viral sources like
lipopolysaccharide (LPS), bacterial oligonucleotides with unmethylated CpG motifs,
lipoteichoic acid (LTA), and Papillomavirus-like particles (VLP) [20-22] and is
characterized by several phenotypic changes. These maturation agents also known as
Pathogen-Associated Molecular Patterns (PAMPs) or 'danger signals' bind with surface
receptors on antigen-presenting cells called Toll-like receptors (TLRs) resulting in
initiation of a signaling pathway and transcription of various inflammation-associated
genes causing molecular and cellular-level changes in APCs. Most of the Toll-like
receptors are present on the cell surface where they bind their ligand but TLR3 and
TLR9 which bind dsRNA and unmethylated CpG oligonucleotides are localized in the
endosomes of dendritic cells and macrophages. First, maturation triggers an increase in
the surface expression of MHC and costimulatory molecules, secretion of inflammatory
cytokines, and a switch in chemokine receptor expression as mentioned above. Second,
phagocytosis/endocytosis of extracellular antigen, which is avid in immature DCs, is
greatly reduced and peptide-MHC complexes are exported to the cell surface for
antigen presentation to T cells. If either of these steps (antigen uptake or maturation) is
missing, it can result in generation of tolerance to the antigen or autoimmunity. Failure
to specifically chemoattract immature DCs may reduce the efficacy of a vaccine as
mature DCs, being inefficient phagocytes, may not be able to out-compete other
phagocytic cells such as macrophages and neutrophils in antigen uptake. Removal of
antigen delivery from the sequence of events may lead to autoimmunity as the
expression of costimulatory signals will be upregulated for self-antigens [23].
Alternatively, DCs that receive antigen but no maturation signal may promote tolerance
to the antigen [24]. Thus, it is important to be able to provide DCs with both antigen and
activation stimuli in a programmed manner and with high efficiency, possibly similar to
infection of cells by viruses.
1.4 Vaccines in practice and study
Since the first vaccine against small pox was discovered by Edward Jenner, a
tremendous effort has been made to develop prophylactic vaccines against various
bacterial and viral infections. In addition, therapeutic vaccination for patients with
persistent viral infections such as HIV, and cancer are envisioned. Traditional vaccines
such as live or attenuated virus/ bacteria; inactivated viruses; recombinant envelope
protein; and the use of neutralizing antibodies [25,26] have led to successful
immunizations against self-limiting infections including smallpox, mumps, measles,
hepatitis B, and polio. Several of these traditional approaches are unable to generate an
effective CTL responses and immunological memory in cases of persistent viral
infections (Table 1.2) [27,28], which has led to interest in vaccines like plasmid DNA
encoding for cytokines; live recombinant bacteria; fusion proteins (e.g., antibody +
pMHC); dendritic cell vaccine therapy; antisense RNA; and adoptive T-cell therapy.
Some of these have shown promising results but still suffer from the same limitations as
traditional vaccines (Table 1.2) [27,28].
Table 1.2. Categories of vaccines currently in practice or in study, their
mechanisms, and limitations associated with them.
Vaccine Mechanism Observed limitations
Live, attenuated Immune response against
virus/bacteria [29] bacteria/viruses; in vitro culture Danger of pathogenicity
reduces mutation frequency
Inactivated viruses Immune response against viral Absence of CTLs
with adjuvants envelope proteins; mutation
[30,31] frequency reduced
Recombinant Generation of immune response No neutralizing antibodies;
envelope protein against pathogenic protein Absence of CTLs
[32]
Neutralizing Antibodies bind to epitopes and Diversity of antigens; no
antibodies [25,26] initiate immune response immunological memory
Plasmid DNA [33] Cytokines produced by infected Poor DNA delivery to target
cells to initiate immune response cells
Live recombinant Immune response against Limited immunogenicity,
bacteria [34] bacteria; bacteria has low limited experience in humans
pathogenicity
Fusion proteins Anti-CD3 and pMHC coupled to Low efficacy
[35] activate CTLs
Dendritic cell Dendritic cells cultured ex vivo Laborious process, diversity of
vaccine therapy with tumor antigen to activate human MHC
[36] immune system when
transplanted back
Antisense RNA Double stranded mRNA Non-specificity, RNA delivery
[37] formation; removal of regulatory
markers
Adoptive T-cell T-cells withdrawn, activated Laborious process, low and
therapy [38] against antigen and injected back non-specific in vivo activity of
Sinto the patient transferred cells, autoimmunity
1.5 Significance and design of the proposed vaccine
Vaccines that fail to induce cytotoxic T cells often lead to incomplete immunity, and
current evidence supports the idea that activation of CD8* T cells will be a critical
component of a successful vaccine for HIV and other persistent viral infections. Tumors
and virally-infected cells share several common features in their resistance to the
immune system [39]. Using the proposed vaccine, we propose to generate an immune
response against the infected cells by providing corresponding antigen (e.g., tumor-
associated antigen or spike proteins) as well as maturation signals to the dendritic cells
to generate an effective CTL response as well as immunological memory to the antigen.
The proposed vaccine sought to meet the following cellular and molecular level
objectives, while offering better safety than live vectors: 1) specifically employ DCs in
their efficient antigen-loading immature state; 2) concentrate DCs at the vaccine site to
obtain a strong response; and 3) provide antigen and maturation signal in a coupled
manner for effective dendritic cell activation and to prevent any tolerance or
autoimmunity (Figure 1.4). In order to achieve a high concentration of immature DCs at
the immunization site, we used controlled release systems to create suitable
concentration gradients of CCR6 and/or FPR ligands that chemoattract immature DCs.
To initiate a primary effective immune response, it is necessary that recruited DCs take
up both antigen and a maturation agent; this was achieved with the help of hydrogel
nanoparticles that delivered both components to DCs. Particulate delivery of antigen
was able to induce cross-presentation thus facilitating MHC class I presentation.
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Figure 1.4. Schematic diagram depicting the mechanism of action of the
proposed vaccine.
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Once the DCs are matured, they migrate towards the lymph node. Through cross
priming, antigen is loaded onto MHC class I as well as class II molecules to provide
effective CTL and TH responses, respectively. It was shown by Shen et al. that antigen
immobilized on microspheres increased antigen presentation on both MHC class I and
class II by as much as two orders of magnitude compared to soluble forms of the
antigen [10]. Kumamoto et al. constructed a device made from poly(ethylene-co-vinyl)
acetate in which MIP-33 and a tumor-associated antigen were loaded in two separate
controlled release devices [40,41]. The implant chemoattracted mature DCs and loaded
them with the antigen; the subsequent immune response resulted in tumor regression.
However, we hypothesized that attraction of immature DCs can provide more potent
immune responses, and provide a better control over as well as understanding of the
working of the vaccine. Furumoto et al. demonstrated that expression of CCL20
chemokine at the tumor site results in a more effective anti-tumor response resulting in
complete tumor regression [42]. Similarly, Sumida et al. showed that intramuscular
injection of plasmids that recruit and expand DC population at the site of immunization
resulted in strong humoral and cellular responses against vaccinia virus [43].
Collectively, these studies suggest that increasing the recruitment of dendritic cells at
the site of immunization directly correlates with higher efficacy of immune response. For
the design of the vaccine, the materials we used were biocompatible materials and have
been approved by FDA for clinical use.
1.6 Overall objectives and specific aims
The steps required to prepare dendritic cells (DCs) for the desired initiation of an
effective primary immune response are primarily antigen loading and maturation of
immature DCs. We hypothesized that these two steps may be triggered in a
programmed manner by mimicking structural aspects of pathogens in a synthetic
particulate antigen-delivery system. In addition, we hypothesized that immune
responses could be enhanced by mimicking the chemoattraction of immature DCs to an
infection site in the context of a vaccine. To test these hypotheses, we developed a
vaccine in the form of injectable biodegradable microparticles that could elicit a tailored
response from the immune system. Our approach was based on a general theory of
vaccination, which in principle may be used to develop vaccines for a variety of cancers
or persistent viral infections such as HIV and hepatitis C, and possibly diseases in
genetically immunodeficient persons.
To trigger potent immune responses, the vaccine was designed to first chemoattract
immature DCs to the site of immunization. Chemoattractants specific for immature
dendritic cells were encapsulated in biodegradable microspheres and released the
chemoattractant in a controlled fashion, thereby creating and maintaining a
chemoattractant gradient in the environment around the microspheres. Chemoattracted
immature DCs were then delivered hydrogel particles containing antigen and maturation
factors (Figure 1.5). Uptake of hydrogel particles delivered antigen and maturation
signals intracellularly to dendritic cells and antigen was presented on MHC class I and
class II molecules. The maturation signals induced significant upregulation of
expression of costimulatory molecules- MHC II, CD40, CD86 and CD80, and secretion
of inflammatory cytokines such as IL-12, IL-6, and TNF-a; DC maturation is also
associated with downregulation of CCR6 receptor and upregulation of CCR7 receptors
on dendritic cells surface. After maturation in vivo, these matured DCs will migrate
towards the nearest lymph nodes for interaction with T-lymphocytes.
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Figure 1.5. Schematic diagram of the proposed vaccine depicting function of
individual components.
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Based on this design concept, the specific aims of this research were as follows:
1. Chemoattraction:
a. Identification and encapsulation of suitable chemoattractant(s)
b. Study of controlled release of the chemoattractant(s)
c. Response of DCs and DC precursors to the chemoattractant gradient(s) thus
created.
2. Antigen delivery:
a. Encapsulation of antigen in hydrogel nanoparticles
b. Study of cross-priming for stimulation of CD8 ÷ T cells by class I peptide-MHC
c. Study of class II peptide- MHC loading for activation of CD4 ÷ T cells
3. Maturation agent delivery:
a. Identification of a suitable maturation agent
b. Immobilization of the maturation agent
c. Study of the maturation of (chemoattracted) immature dendritic cells.
4. In vivo T cell and B cell activation with hydrogel nanoparticles
5. Assembly and functional testing of the device:
a. Co-encapsulation of chemokine and hydrogel nanoparticles for coincident
delivery to dendritic cells
b. Analysis of antigen uptake by dendritic cells and DC responses in vitro.
2. Reverse Targeting of Dendritic Cells by Chemotaxis
2.1 Introduction
Cells of immune system exhibit complex patterns of trafficking among the primary
and secondary lymphoid organs and the peripheral tissues as part of homeostasis and
immune surveillance [44-46]. Spatial and temporal orchestration of lymphocyte
migration is achieved by a diverse family of chemokines, typically ~ 10 kDa polypeptides,
which bind related families of G protein-coupled receptors [47-49]. Chemokines and
other chemoattractant molecules are produced at local sites and diffuse to form soluble
or solid-phase concentration gradients; cells expressing the appropriate chemokine
receptors typically migrate up chemoattractant gradients towards their source.
Chemokines and cognate receptors are now known, which guide naive T and B cells to
their local niches within secondary lymphoid organs [50,51]; attract antigen-presenting
cells (APCs), effector and memory T and B cells, and innate immune cells to sites of
infection [52]; and guide antigen-loaded APCs to lymph nodes [53].
The sensitivity of immune cells to specific chemokines might be exploited in the
design of novel immunotherapies and vaccines, by inducing specific cell types to
concentrate local depot of antigen. For example, primary immune responses are
initiated when professional APCs known as dendritic cells (DCs) engulf foreign antigens
and become activated, migrate to draining lymph nodes, and present these captured
antigens to T cells to initiate T cell activation [5,54,55]. In the presence of a pathogen,
stromal and inflammatory cells in the periphery initiate this cascade by secreting
chemokines that selectively attract immature (unactivated) DCs and their precursors
(e.g., monocytes) to the sites of infection or inflammation [55,56]. A number of
chemoattractants are known to elicit directed migration of DCs and monocytes in this
context, including monocyte chemotactic protein-1 (MCP-1), MCP-2, MCP-3,
macrophage inflammatory protein-la (MIP-Iu), MIP-13, Regulated upon Activation
Normal T cell Expressed and Secreted (RANTES), C5a, p-defensins, and bacterially-
derived formyl peptides [15,16,18,57-60]. Because the frequency of DCs in blood and
peripheral tissues is low (typically -1% of cells or fewer [61,62]), vaccines that mimic
DC recruitment to inflamed tissues by creating a local chemoattractant source may
significantly enhance immune responses. Attraction of resting 'immature' DCs to an
immunization site could increase the number of DCs loaded with antigen, and
subsequently, the number of nai"ve T cells activated in draining lymph nodes. Recently,
Martin-Fontecha et al. showed that naive T cell activation increases in proportion to the
number of antigen-loaded DCs injected subcutaneously in a mouse [63].
Several prior studies have sought to develop vaccines that apply this principle, by
immunizing with DNA plasmids that encode an antigen of interest as well as a
chemoattractant molecule [42,64-69]. This approach has been shown to trigger
enhanced DC infiltrates at injection sites and improved protection against tumors and
model pathogens. However, DNA immunization provides little control over the amount
of chemokine produced or the time course of its expression, which limits the ability of
this approach to control magnitude and duration of DC attraction. These characteristics
also make DNA immunization an intractable method for dissecting the biology of
chemokine functions in immune cell trafficking.
As an alternative, Kumamoto et al. [40,41] demonstrated that implanted
poly(ethylene-co-vinyl acetate) (EVAc) rods releasing a model protein antigen and MIP-
3P (a chemoattractant for activated 'mature' DCs) drew DCs to the implant site and
resulted in enhanced protection against E.G7 and 3LL tumors in mice. This approach
allowed a known amount of chemokine to be implanted with defined release kinetics.
However, the use of non-degradable polymer rods that require implantation and
eventual retrieval is not attractive for a practical vaccine. In addition, EVAc releases
protein rapidly, over a course of -24 hours due to rapid swelling of the matrix with water;
such a system cannot deliver chemokine over longer time periods which may be optimal
for maximization of the immune response [42].
Given these promising prior results, we developed a system which could serve
both as a potential platform for manipulating lymphocyte trafficking in immunotherapies
and as a basic tool for quantitatively studying the role of chemokines in controlling
immune cell migration in vitro and in vivo. We prepared degradable poly(lactide-co-
glycolide) controlled release microspheres as an injectable formulation that could mimic
the generation of chemoattractant gradients generated in situ in natural acute infections
and enrich professional APCs at an immunization site. Two chemoattractants with
different physical properties were chosen for these studies: a hydrophobic formyl
peptide variant formyl-Nle-Leu-Phe-Nle-Tyr-Lys (fN'LFN'YK), representative of
pathogen-derived chemoattractants present during bacterial infections [70] and the 7.9
kDa C-C chemokine MIP-3a (CCL20) [71-73]. These chemokines attract immature
dendritic cells and their monocyte precursors, via binding to the formyl peptide receptor
and CCR6, respectively. To assay the ability of controlled release microspheres to
guide migration of DCs and monocytes to a local site, we developed an assay for
chemotaxis based on time-lapse videomicroscopy observation of live cell migration
through three dimensional (3D) collagen gels in vitro, which is related to direct
observation assays used in prior cell migration studies of immune cells [74-76] and
other cell types [77]. Chemoattractants released from PLGA microspheres were found
to elicit strong, sustained attraction of human DCs and monocytes as well as murine
DCs for at least 8 hours. Slow release of chemokine from microspheres was found to
provide significantly stronger attraction compared to bolus delivery of freely diffusing
attractant. These microspheres allow defined total amounts of chemokine to be
delivered to known sites with known release kinetics, making them of interest both for
the design of improved vaccines and as tools for dissecting the role of chemoattractants
in immunobiology. In addition, control of cellular chemotaxis via chemoattractant-
releasing biomaterials could be a powerful strategy for tissue engineering (e.g., for
guided angiogenesis), where guided physical organization of multiple cell types
according to wound healing or developmental principles is of interest.
2.2 Materials and Methods
2.2.1 Dendritic cell migration through a membrane filter in Boyden
Chamber
Various dilutions of fN'LFN'YK or CCL20 ranging from 10 [ig/mL to 0.1 [g/mL
were prepared in phosphate-buffered saline with 1% BSA; 31 pil of chemokine solution
was added to each well of a 96-well Boyden chamber (NeuroProbe, USA). A membrane
(5 ýim pore size) was placed on top of the wells and 50 pl bone marrow-derived
dendritic cells (day 6) (1 x 106 cells/mL) labeled with 10 [M Carboxyfluorescein
succinimidyl ester (CFSE) dye (as described in the Appendix) were pipetted onto each
well of the Boyden chamber. The plate was incubated at 37 OC/ 5% CO2 for 90 min
followed by incubation at 4 OC for 20 min. Membranes were then removed and the total
fluorescence from cells that migrated into the lower chamber was measured for each
well using a spectrafluorometer (SpectraMax Gemini, Molecular Devices) at kex/kem of
490/510 nm. Migration of cells as a function of chemokine concentration was reported
as a Chemotactic Index defined as the ratio of number of cells with directed migration to
number of cells with random migration and was calculated as:
Chemotactic Index Fluorescence Intensity with ChemokineChemotactic Index = [ 1]
Fluorescence Intensity without Chemokine
2.2.2 Encapsulation of fN'LFN'YK in PLGA Microspheres
PLGA microspheres encapsulating the hydrophobic peptide fN'LFN'YK or
fN'LFN'YK-FITC (Sigma-Aldrich, USA) were synthesized by a solid-in-oil-in-water
emulsion process [78,79]. Ten milligrams of formyl peptide was added to 200 mg PLGA
(Sigma, 40-75 kDa; Alkermes, 4.4 kDa) in 1 mL of dichloromethane (DCM) and the
mixture was vortexed for 1 min to form a uniform suspension. The organic mixture was
then emulsified in 20 mL of 2% w/v (aq) polyvinyl alcohol (PVA, 25 kDa, 88 mol%
hydrolyzed, Polysciences) solution by homogenizing (Ika, Ultra-Turrex T-25) at 10,000
rpm for 1 min at 20 oC. The suspension was stirred at 1000 rpm for 4 h at 20 oC to
evaporate DCM followed by centrifugation and washing (4x). The resulting
microspheres were lyophilized and stored at 4 OC until used.
2.2.3 Encapsulation of CCL20 in PLGA microspheres
CCL20 was encapsulated in PLGA microspheres by a water-in-oil-in-water
double emulsion process. First, 20 pg CCL20 and 20 mg Bovine Serum Albumin (BSA)
were co-dissolved in a 2% (w/v) aqueous PVA solution and then emulsified in an
organic phase comprising 100 mg PLGA in 1 mL dichloromethane by homogenization at
10,000 rpm for 1 min at 20 oC. Microspheres were formed by homogenizing the first
emulsion in 50 mL of 2% (w/v) aqueous PVA at 10,000 rpm for 1 min at 20 oC. The
resulting double emulsion was diluted in 100 mL of 1% (w/v) aqueous PVA solution and
stirred at 400 rpm for 3-4 h at 20 oC to evaporate dichloromethane. The particles were
collected by centrifugation, washed in milliQ water 4x, and lyophilized. The freeze-dried
particles were stored at 4 OC until used.
2.2.4 Microsphere Characterization
2.2.4.1 Chemokine Loading, Encapsulation Efficiency, and Particle Size
The microspheres were analyzed for encapsulation efficiency by degrading the
PLGA matrix in alkaline medium and analyzing the released protein concentration by
bicinchoninic acid (BCA) colorimetric assay (Pierce Chemical Co., USA). Ten milligrams
of particles were suspended in 3 mL of 0.5 M NaOH/2% sodium dodecyl sulfate (SDS)
solution, and incubated at 37 oC overnight. The protein/peptide concentration in solution
was then estimated by the BCA assay following the manufacturer's instructions.
Chemokine loading and encapsulation efficiency were calculated as follows:
Protein concentration as determined by BCA assay x 3Chemokine Loading = [2]
10 mg microspheres
Measured Chemokine Loading
Encapsulation Efficiency = xasured 100 % [3]
Theoretical Chemokine Loading
Endotoxin contamination in microspheres was measured by the LAL assay
(Cambrex, USA); endotoxin levels were < 0.15 EU/mL.
Microsphere sizes were determined using a Coulter Counter (Beckman Coulter
Multisizer II). Mean diameters were calculated from the measured particle size
distribution curves as:
Mean Particle Diameter Particle Size x Number of Particles in the interval
MenPril imtr= [ 4]Z Number of Particles in the interval
2.2.4.2 Measurement of bulk chemokine release kinetics
Release of formyl peptides from microspheres was quantified in vitro using BCA
assay. Microspheres (20 mg) were suspended in 5 mL phosphate-buffered saline (PBS),
0.1% Tween 20 and shaken at 37 OC for 30 days. Every 24 h, microspheres were
pelleted by centrifugation and supernatant was removed for analysis; fresh buffer was
added to replace the removed supernatant.
The kinetics of CCL20 release from double emulsion microspheres were
analyzed following a similar procedure. Chemokine present in the release medium was
quantified using a sandwich ELISA kit (R&D Systems, USA) according to
manufacturer's instructions and as described in Appendix.
2.2.5 Monocyte and monocyte-derived dendritic cell culture
Freshly elutriated human monocytes were obtained from Advanced
Biotechnologies Inc. (Columbia, MD). Cells were resuspended in 10% DMSO/ 90% fetal
calf serum (FCS), and stored at -80 oC until used. For migration assays using
monocytes, cells were thawed rapidly at 37 oC and cultured in complete RPMI medium,
and used in gel microscopy assay after 48 h.
Human monocyte-derived dendritic cells were generated as previously reported
[80] by plating 1 x 106 monocytes in 1000 U/mL GM-CSF and 1000 U/mL IL-4 (R&D
Systems) in 1 mL complete RPMI medium. Cytokines were replenished in the culture
on days 2, 4, and 6 by addition of 100 mL complete RPMI containing 1000 U/mL GM-
CSF and 1000 U/mL IL-4. Cells were used for migration on days 7-9.
2.2.6 Collagen gel direct visualization migration assay
In vitro chemotaxis of cells in response to chemokine-loaded microspheres or
control samples was measured by direct visualization in 3-D collagen gels. Purified low-
endotoxin bovine type I collagen (BD Biosciences, USA) was diluted in an equal volume
of complete RPMI 1640 medium to 1.2 mg/mL and cast (2 mL) in 35 mm tissue culture
polystyrene dishes around plastic inserts suspended from the dish lids, which molded
wells -7 mm in diameter and -1 mm depth in the resulting gels. Two different
geometries were used for the videomicroscopy experiments as illustrated in Figures
2.1A and 2.1B. In the first geometry (2.1A), two wells were molded in the collagen
separated by a 5 mm gap. In this configuration, microspheres and cells were each
added separately to the wells after gelling of the collagen matrix. In the second
geometry (2.1B), a single well was molded in the collagen gel surrounded by cells
suspended at a density of 1.5 x 106 cells/mL in collagen. In this case, collagen was
diluted to the desired concentration (1.2 mg/mL) with complete RPMI 1640 medium
containing cells. For all samples, the collagen matrix was gelled at 37 OC/ 5% CO2 for 30
min. After gelling, samples prepared with the two-well geometry were completed by
adding microspheres suspended in 25 il collagen to one well, and 5 x 104 cells
suspended in 25 pil collagen to the second well; cell migration at the 'cell source' well
was then immediately tracked by time-lapse videomicroscopy. For samples prepared in
a single-well geometry, microspheres suspended in collagen were added to the source
well and time-lapse imaging was immediately begun adjacent to the source well.
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Figure 2.1. Schematic of two-well (A) and single-well (B) time-lapse
videomicroscopy migration assays.
Time-lapse videomicroscopy was carried out using a Zeiss Axiovert 200
microscope equipped with a motorized stage (Ludl), Roper Scientific CoolSnap HQ
CCD camera, and an environmental chamber (Zeiss), which maintained samples at 37
oC with a 5% CO2 atmosphere. A total field of view of 2600 x 1910 pm 2 was recorded
every 1 min by rapid collection of 9 adjacent brightfield images using a 10x objective,
where each single field of view was 900 x 670 Pm 2 and the 9 fields collected formed a 3
x 3 array in the x-y plane of the overall observation area (Figure 2.1). Image acquisition
and the motorized stage were controlled using MetaMorph software (Universal Imaging
Corp.).
2.2.7 Analysis of cell migration data
Individual cells from the nine visualized fields in each experiment were tracked
via a software-assisted centroid determination algorithm using MetaMorph imaging
software. Cells areas in each frame were identified by auto-thresholding the intensity of
brightfield images, and centroid tracking (x-y position as a function of time) was
performed using the thresholded area. Cells leaving the field of view of migrating out of
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focus in the z-direction were discarded from analysis. Endpoint position and cell path
data were pooled from 2-5 independent experiments.
The chemotactic index (CI) was defined after method of Moghe et al. [76] as the
distance traveled by each cell in the direction of attractant source divided by the total
path length (a ratio also known as McCutcheon Index [81]). Mean values of Cl over time
((CI)) were calculated by averaging the Cl of 20 individual cells selected randomly from
the nine fields of observation at each time point.
2.3 Results
2.3.1 Dendritic cell migration in response to formyl peptide and CCL20 in a
modified Boyden chamber
We first measured the response of murine bone marrow-derived dendritic cells
(BMDCs) to formyl peptides or CCL20 using a Boyden chamber equipped with a 5 Im
filter that separated the chemokine source from the dendritic cells by a distance of 100
[m. Both formyl peptide and CCL20 induced significant migration of BMDCs through the
membrane filter and a chemotactic index > 1 was observed over a range of chemokine
concentrations. The chemotactic index peaked at 2.0 for CCL20 and 1.5 for formyl
peptide at 1 tg/mL and 10 tg/mL respectively, and was observed to be reduced at
higher and lower chemoattractant concentrations (Figure 2.2). This reduction in cell
migration at high concentration of chemokine is possibly due to the saturation of
chemokine receptors and consequent inability of cells to sense the chemokine
concentration gradient effectively. In addition to absolute concentration, the specific
gradient (1/c dc/dx)is a second important factor in chemotaxis, and must be in a limited
range appropriate for support of chemotaxis [76,82,83]. Theoretical [83] and
experimental analyses [76,83] suggest that soluble chemokines must form a specific
gradient on the order of -5-10 cm' to elicit a directed migration, corresponding to a
minimum 0.5% change in attractant concentration over the length of a typical cell (10
lm in diameter). Moreover, in addition to chemokine receptor saturation, cells may
endocytose chemokine receptors upon binding of chemokine molecules, resulting in
desensitization of the cell and reduced migration. The concentration for maximum
chemotactic index is representative of the binding affinity of the chemokines to their
cognate receptors. Formyl peptide binding to formyl peptide receptors occurs with a
binding affinity (KD) of 30 nM [84] whereas signaling through murine CCR6 is triggered
by -0.01 - 0.1 nM CCL20 and has a KD of - 1 nM for CCL20 binding [73].
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Figure 2.2. Chemotactic index for murine BMDC migration to different doses of
formyl peptide and CCL20 as measured in a modified Boyden chamber assay.
2.3.2 Encapsulation and release of formyl peptides from PLGA
microspheres
To experimentally examine controlled release of chemoattractants for DCs and
monocytes, we fabricated degradable microspheres encapsulating either the
chemoattractant peptide fN'LFN'YK or the C-C family chemokine MIP-3(c (CCL20). In
choosing these two molecules, we sought to test delivery of two attractants with
significantly different properties: fN'LFN'YK is a hydrophobic, low molecular weight (824
Da) peptide with low water solubility, while CCL20 is a more hydrophilic polypeptide with
~10-fold greater molecular weight (7.9 kDa). To provide sustained slow release, the
chemoattractants were encapsulated in degradable poly(lactide-co-glycolide) (PLGA)
microspheres. We also studied the effect of the molecular weight of PLGA on release
kinetics by encapsulating formyl peptide in microspheres formed from low (4.4 kDa) and
high (40-75 kDa) molecular weight PLGA.
Table 2.1. Characteristics of formyl peptide and CCL20-1oaded microspheres.
Chemokine Matrix Encapsulation Total chemokine Mean
encapsulated PLGA MW efficiency encapsulated microsphere
(KDa) (wt %) (pg chemokine/mg diameter (pm)
microspheres)
fN'LFN'YK 75 90 45 4.8
fN'LFN'YK 4.4 80 40 5.0
fN'LFN'YK-FITC 75 80 40 6.6
CCL20 75 50 0.1 4.3
First, the hydrophobic formyl peptide and its fluorescein-labeled derivative were
encapsulated by a s/o/w emulsion process using dichloromethane as the oil phase.
Characteristics of the resulting microspheres are given in Table 2.1. Peptides were
efficiently encapsulated (Encapsulation Efficiency = 80-90%, Chemoattractant loading =
40-45 p~g/mg microspheres) in microspheres prepared from high or low molecular
weight PLGA. The kinetics of fN'LFN'YK and fN'LFN'YK-FITC release from
microspheres into well-mixed PBS at 37 oC are shown in Figure 2.3. As shown in Figure
2.3A, fN'LFN'YK was steadily released for at least 3 weeks when encapsulated in a high
molecular weight matrix. As observed for other PLGA drug release systems [85], the
initial release rate increased when the molecular weight of the matrix was decreased to
4.4 kDa and the chemokine was released in less than a week from the matrix. The burst
release of the unlabeled chemoattractant from 75 kDa PLGA microspheres over the first
several hours was low (typically 10-15%) and the release rate remained greater than 50
ng (mg microspheres)-1 h-' for more than 1 week (Figure 2.3B). Encapsulated
fN'LFN'YK-FITC showed a significantly greater burst release at short times relative to
the unlabeled peptide, followed by a slowly decaying release rate on days 2-10.
A. B.
7,C
4C,
0-4
0 6 10 16 20 D 1 15 26
Time (days) Time (days)
Figure 2.3. Kinetics of fN'LFN'YK chemoattractant release from PLGA
microspheres in vitro. (A) Percentage of encapsulated peptide-released versus
time in well-stirred PBS solution at 37 oC. (B) Release rates calculated from
release profiles shown in (A). Measurements were made for fN'LFN'YK
encapsulated in (e) 4.4 kDa PLGA or (o) 40-75 kDa PLGA microspheres and
fN'LFN'YK-FITC encapsulated in 40-75 kDa PLGA (A).
2.3.3 Chemoattraction of human monocytes and DCs toward formyl
peptide-releasing microspheres in vitro
Human monocytes and DCs express a formyl peptide receptor that binds to
formyl-Met-Leu-Phe and structurally related peptides with an affinity of -30 nM [84], and
these cells chemotax in response to concentration gradients of formyl peptides. To
determine the effect of microsphere-mediated formyl peptide release on human
monocyte and dendritic cells chemotaxis, cell migration through 3-D collagen gels was
assayed in the presence of fN'LFN'YK-FITC-releasing microspheres by time-lapse
videomicroscopy. Though the release characteristics of fluorophore-labeled peptide
were inferior to those of unlabeled formyl peptide (higher burst release, lower and more
rapidly decaying release rate), we performed migration experiments with the labeled
chemoattractant in order to have a qualitative marker of fN'LFN'YK gradients present
(by collecting fluorescence images to detect FITC gradients) during the assays.
Because the high burst release of the labeled peptide could lead to saturation and
downregulation of the responding cells' formyl peptide receptors, fN'LFN'YK-FITC
microspheres were 'pre-released' in PBS for 48 h prior to use in the chemotaxis assays,
to remove burst and provide release kinetics starting at -75 ng/h (mg microspheres).
For these experiments, collagen gels were molded in a two-well geometry
(Figure 2.1A). Monocytes or monocyte-derived dendritic cells were suspended in
collagen in one well, while 0.25 mg microspheres in collagen (or collagen alone) were
added to opposite well. Upon addition of cells and microspheres, the samples were
placed at 37 oC, 5% CO2 on the microscope stage, and time-lapse imaging of central
region of the cell well was initiated. Brightfield images were recorded at 1-min interval
over 1-3 h to track cell migration. From the resulting time-lapse images, individual cell
paths were determined using software-assisted single cell tracking. Migration of cells in
the absence of microspheres was compared to that observed when the chemokine
source well was loaded with empty microspheres (no peptide encapsulated) or
microspheres releasing fN'LFN'YK-FITC.
Representative paths for motile monocytes in the x-y plane over 3 h are shown in
Figures 2.4 for cells responding to source wells containing no microspheres, empty
microspheres, and microspheres releasing fN'LFN'YK-FITC, respectively. Each trace on
the 4-quadrant plots identifies the x-y path of a single cell relative to its starting point
(placed at the origin); tracks for 10 individual cells are shown overlaid on each plot. The
bold arrows indicate the direction toward chemoattractant source well in each case. In
the absence of microspheres, migrating cells showed persistent random walk motion,
but no preferential migration toward or away from the opposite (empty) collagen well
(Figure 2.4A). The migration behavior of monocytes was similar to when empty PLGA
microspheres were loaded in the opposite well of the gel (Figure 2.4B). In contrast,
when fN'LFN'YK-FITC- loaded microspheres were added to the attractant source well,
monocytes migrated with a strong bias toward the microsphere well (Figure 2.4C). This
directed migration response was seen in the entire monocyte population. Endpoint
positions of 50 individual cells at the end of 3 h are shown in Figures 2.4D and 2.4E for
cells responding to empty microspheres or formyl peptide-releasing microspheres,
respectively. In response to microsphere-released fN'LFN'YK, 90% of the cells at the
end of 3 h observation period occupied an x position closer to the microspheres, while
empty microspheres elicited a random distribution of cell endpoints in the x-y plane
(48% and 52% of cells ended with an x position closer or farther from the
chemoattractant well, respectively). Thus peptide release from the microspheres elicited
strong directed migration from human monocytes.
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Figure 2.4. Formyl peptide chemoattractants released from PLGA microspheres
induce directed migration of human monocytes. (A-C) Paths of 10 single cells in
the x-y plane from time 0 to 3 h are shown overlaid, with each cell's starting
positions placed at the origin. Shown are the paths of the cells in the two-well
migration assay responding to source wells loaded with (A) no chemoattractant,
(B) 0.25 mg blank PLGA microspheres, or (C) 0.25 mg fN'LFN'YK-FITC-releasing
microspheres. (D, E) Endpoint relative positions of 50 cells after 3 h in the two-
well migration assay. The starting point of each cell is placed at the origin. Shown
are cell responses to source wells containing (D) empty microspheres or (E)
fN'LFN'YK-FITC-releasing microspheres. Axes in (A-E) are distances in gm and
arrows denote direction toward the chemoattractant source well. (F) Time
evolution of the mean chemotactic index <CI> for monocytes migrating in
response to source wells containing no chemoattractant (dashed line), blank
PLGA microspheres (solid gray line), or fN'LFN'YK-FITC-releasing microspheres
(solid black line).
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To provide a quantitative measure of the response for the cell population
examined, we determined the CI, defined as the mean total distance migrated by each
cell toward the attractant source well divided by the cell's total path length. A mean CI
((CI)) was determined by averaging the chemotaxis index obtained from 20 cells at
each time point. As shown in Figure 2.4F, the chemotaxis index of responding
monocytes evolved over the first -60 min of the experiment, plateauing to a value of ~0
for cells responding to empty microspheres and cells incubated without microspheres-
indicative of random migration (each cell equally likely to migrate toward or away from
the attractant source well). In response to chemokine released from microspheres, the
(CI) steadily rose to a maximum value of 0.21 ±0.06 over 3 h, comparable to the
maximum chemotactic response observed for human neutrophils responding to
chemoattractants in fibrin gels [76]. The lack of any downturn in (C)l> over time course
indicates that monocytes were continuously attracted throughout the observation period.
We next assayed the migration response of human monocyte-derived dendritic
cells (MDDCs) to fN'LFN'YK-FITC-releasing microspheres (Figure 2.5). Shown in
Figures 2.5A and 2.5B are 10 overlaid single-cell paths for MDDCs recorded over 1 h
for the case of an empty attractant source well or a source well containing 0.25 mg
fN'LFN'YK-FITC-loaded microspheres. Similar to the results obtained with monocytes,
the population of MDDCs migrated in all four x-y quadrants approximately equally when
no chemoattractant was present, while MDDCs responding to the fN'LFN'YK-release
microspheres exhibited strongly biased migration toward the microsphere source well.
Similar behavior was exhibited by majority of cells as shown by the 1 h path endpoint
plots shown for MDDCs incubated with no chemokine (Figure 2.5C) or fN'LFN'YK-FITC-
release microspheres (Figure 2.5D). The (CI) achieved by MDDCs responding to
microspheres-released fN'LFN'YK plateaued after -2 h, reaching a mean value of
0.32±0.07 indicating significantly biased migration toward the microspheres, while
MDDCs migrating in the absence of chemokine had a (CI) -0.
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Figure 2.5. Formyl peptide-releasing microspheres chemoattract human
monocyte-derived DCs. Shown are plots of DC migration over 1 h in the absence
of chemoattractant (empty chemoattractant well) (A,C) or in response to 0.25 mg
fN'LFN'YK-FITC-releasing PLGA microspheres (B,D). (A,B) Representative paths
of 10 single cells in the x - y plane over 1 h are shown overlaid, with each cell's
starting position placed at the origin. (C,D) Endpoint relative positions of 50 cells
after 1 h, with the starting position of each cell placed at the origin. Axes are
distances in gm, and arrows denote direction toward chemoattractant source well.
2.3.4 Encapsulation and release of CCL20 chemokine from PLGA
microspheres
The results obtained with slow release of formyl peptide from PLGA provide a
proof of concept that microspheres can induce sustained attraction of responsive
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monocytes and MDDCs. However, formyl peptides are not highly selective
chemoattractants for monocytes and unactivated, immature DCs; these peptides also
attract neutrophils, eosinophils, and macrophages [86,87]. To avoid competition among
cells for the chemoattractant and maximize the specific cellular infiltrate desired for
priming of immune responses, we examined a second chemokine, MIP-3cC (CCL20),
whose receptor CCR6 is expressed by immature (unactivated) DCs, but not mature
DCs, macrophages, eosinophils, or neutrophils [72,73,88,89]. In addition, to preface in
vivo testing in mice, we encapsulated murine CCL20, and tested the response of mouse
bone marrow-derived DCs (BMDCs) to these microspheres.
CCL20 was co-encapsulated in PLGA (40-75 kDa) with an excess of the carrier
protein, bovine serum albumin (BSA) to protect the chemokine during encapsulation by
a double emulsion process. Because CCL20 has been shown to trigger calcium
signaling in CCR6-expressing cells at concentrations as low as < 0.1 nM, we
encapsulated lower total amounts of protein in the CCL20 microspheres compared the
formyl peptide experiments, to avoid paralyzing cells with saturating levels of chemokine,
as indicated in Table 2.1.
Release of CCL20 from the PLGA microspheres was assayed in vitro at 37 oC
using sandwich ELISA, to detect conformationally intact chemokine in solution. As
shown in Figure 2.6A, the microspheres exhibited sustained release over 2 weeks. The
release rate decayed gradually from -1.5 ng/mg-h after 1 day to -0.25 ng/mg-h at 7
days (Figure 2.6B). By day 15, -90% of the encapsulated chemokine was detected by
the ELISA in the microsphere supernatant, indicating that the carrier protein was
effective in protecting the chemokine from degradation.
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Figure 2.6. Kinetics of CCL20 chemokine release from 40-75 kDa PLGA
microspheres in vitro. (A) Percentage of chemokine released versus time into
well-stirred PBS at 37 'C. (B) Release rate calculated using data from (A).
2.3.5 Phenotyping of murine BMDCs for kinetics of CCR6 expression on
cell surface
Bone marrow cells from femur and tibia of a 6-8 weeks old C57BI/6 mouse were
plated in a 24-well tissue culture polystyrene plate in complete RPMI 1640 medium with
5 ng/mL rmGM-CSF. Cells were pipetted on days 2, 4, 6, 8, and 9, stained with CD11c-
FITC and CCR6-phycoerythrin and analyzed by flow cytometry for the expression of
these surface markers. As shown in Figure 2.7 depicting the overlays of CD11c and
CCR6 expressions on different days, CCR6 expression increases as bone marrow cells
differentiate into dendritic cells (characterized by the increase in CD1 1c+ cells); CCR6 is
expressed on ~ 50% cells on day 6 and reaches a maximum of -70% on day 8. BMDCs
were therefore used between days 7-8 for all migration experiments.
A. 
S.
UFigure 2.7. Surface expression of CD11c and CCR6 on bone marrow dendritic
cells on days 2 (-), 4 (-), 6 (-), 8 (), and 9 (-)
2.3.6 Chemoattraction of murine BMDCs toward CCL20 -releasing
microspheres
Attraction of murine BMDCs to CCL20 microspheres was tested in vitro using the
collagen gel videomicroscopy assay. For these experiments, we sought to better
approximate the situation for immunotherapy/ vaccination, where microspheres might
be co-injected with antigens and other adjuvant factors; ideally, immature DCs and DC
precursors would be attracted from an immediately surrounding tissue to within very
close proximity of the microsphere depot where antigen and DC activation factors have
been co-localized. To model this situation, collagen gels with single wells were formed,
with BMDCs suspended throughout the gel surrounding the 'immunization site' (Figure
2.1B). Microspheres and collagen were then added to the source well, and the migration
of BMDCs near the source well was tracked by time-lapse videomicroscopy.
Time-lapse imaging experiments were carried out, recording nine fields adjacent
to attractant source well for 8 h in 1-min intervals. Similar to experiments with fN'LFN'YK,
control microspheres containing no protein or containing carrier protein BSA only
elicited no chemoattraction of BMDCs. In contrast, Figure 2.8A shows path endpoints
for x-y migration of cells in response to microspheres releasing CCL20, where
pronounced chemoattraction toward the microsphere source was observed. BMDCs
C-1
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were continuously attracted toward the microspheres during the course of 8 h migration
assays. Figure 2.8B shows representative instantaneous velocities for two single cells,
demonstrating that DCs were continually motile during the time-course of the
experiment, as opposed to exhibiting transient motility followed by paralysis. The mean
velocity for chemotaxing DCs in our collagen gel system was 3.2 gm/min, comparable to
the rates of DC migration measured in intact lymph nodes ex vivo [90] and in vivo by
intravital imaging [91]; the constant stop-and-go motion of these cells observed is also
qualitatively similar to data reported in these prior studies.
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Figure 2.8. CCL20-releasing microspheres elicit sustained chemoattraction of
murine BMDCs. (A) Path x - y endpoints for the migration of 50 single cells after 8
h in the single-well migration assay, with their relative initial positions placed at
the origin. Axes are distances in pm, and the arrow denotes the direction toward
the attractant source well. (B) Example of single-cell instantaneous velocities
over 3 h at 1-min intervals for DCs responding to CCL20 -releasing microspheres.
(C) Mean final x positions for DCs responding to attractant source wells loaded
with CCL20-releasing microspheres, BSA-containing microspheres, or different
amounts of freely diffusing CCL20. Positive <Xfinal> values denote migration
toward the attractant source.
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We next compared the migration of BMDCs toward a source well containing
bolus CCL20 to DC migration toward a source well containing microspheres releasing
CCL20. Initial screens of BMDC chemotaxis in response to freely diffusing CCL20
revealed maximal attraction to -0.2 ng of free chemokine in our collagen gel assay. We
thus tested the chemotaxis of BMDCs to 25 Rg of CCL20 -releasing microspheres
(which release 0.2-0.3 ng CCL20 over 8 h). Shown in Figure 2.8C is the mean final x
position of cells relative to their starting points in the gel after 8 h in response to CCL20
microspheres or different doses of free CCL20; positive values of (xfinal> indicate net
motion toward the chemokine source well. Microsphere-released CCL20 was
significantly more potent in attracting BMDCs relative to comparable total doses of
chemokine delivered as a bolus at time zero. In addition, higher doses of free
chemokine could not compensate for this weaker attraction, as seen in the (xfnal)> data.
This result agrees with the expectation that higher concentrations of chemokine lead to
chemokine receptor saturation/ desensitization and blockade of directed cell migration.
BMDCs up to -2.5 mm from the source (the maximum distance from the source
monitored in the assay) exhibited directed migration in response to the CCL20-releasing
microspheres during the assay. Strikingly, BMDCs migrating in response to
microsphere-released chemokine did not appear to exhibit receptor saturation-driven
paralysis or loss of directed motion over the course of 8 h of observation, and the cells
could be attracted to the point of contact with CCL20-releasing microspheres. Large
discrete microspheres occasionally observed at the edge of the gel source well potently
attracted large number of DCs in a 'swarming' motion to their surface, and retained
these cells over several hours, as illustrated by the time-lapse images of Figure 2.9.
Thus, chemokine-releasing microspheres can potently attract cells over prolonged time
periods (here, evaluated for 8 h) and draw DCs over distances of several hundred
microns to the point of contact with attracting microspheres.
Figure 2.9. DCs can chemotax into direct contact with controlled release
microspheres. Shown are five frames from a time-lapse imaging experiment near
one isolated large PLGA microsphere (denoted in the first frame by black arrow).
DCs continuously accumulated around this particle over 8 h of observation.
Elapsed times (min: s) are shown in the lower left of each frame and the scale
bars are 50 mm. A quicktime movie of this time-lapse data can be viewed at:
http://web.mit.edulbiomaterials/swarm.html; password: swarm.
2.3.7 Modeling spatio-temporal chemokine concentration profiles in
collagen
As shown in Figure 2.1, chemoattractants diffuse from 'vaccination site' source
well into a relatively large volume of collagen gel. To understand the diffusion of
chemoattractants into collagen and attraction of dendritic cells and DC precursors, we
modeled the chemoattractant diffusion into collagen by approximating the system as
diffusion of chemoattractant from a point source into a semi-infinite sink. We first
determined the diffusion coefficient for formyl peptide and CCL20 in collagen gel using
this model, and then used the model to predict spatio-temporal concentration profiles of
formyl peptide in collagen gel for bolus delivery and controlled-delivery of the
chemoattractant. The simplified model of our system has the limitation that it assumes
the 'vaccination site' is maintained at a constant concentration and ignores the end
effects of the system. Moreover, chemokines are known to bind to the ECM, which
means that diffusion may not be the only process determining the concentration profile
of chemoattractants. For diffusion from a point source into a semi-infinite sink, Fick's law
for diffusion of chemokine in direction x defines flux as:
J c x cx __ x D_ _ _ _D 2CxJ_ - ;_ -- ax -D= [5]x ax at ax aX 2
where,
Jx = Flux of chemokine in x-direction
D = Diffusion coefficient of chemokine through matrix
The initial and boundary conditions for chemokine diffusion into collagen from a source
well into an infinite sink are:
c = 0 at t = 0 for all x > 0 I.C.
c = co at x = 0 for all t B.C. 1
c= 0 at x -o forallt B.C. 2
The solution to Equation 5 with the above initial boundary conditions to estimate
concentration profile as a function of space and time is:
c = co erfc[ 2 6]
Since, MetaMorph can provide us average fluorescence intensity in a given field, we
decided to reduce Equation 9 into a form containing one variable only. Equation 6 was
further averaged over distance x (0 to L) to estimate average concentration, <c> as a
function of time:
< C > rfc L 2 Dt L4 Dt
2-fc L-- ( 1 - e 4D t) [7]co 2 fDt L f-
2.3.7.1 Determination of diffusion coefficient of formyl peptide in collagen gel
The diffusion coefficient of formyl peptide in collagen gels was calculated from
direct observation of fluorophore-labeled peptide. The peptide, fN'LFN'YK-FITC (1
[tg/mL) was mixed with collagen (1.2 mg/mL, 40 pl) and gelled in a corner of an eight-
well labtek chamber slide followed by addition of collagen gel (1.2 mg/mL, 400 Ipl) to
create an infinite sink (Figure 2.10A); time-lapse videomicroscopy was initiated
immediately by taking green-fluorescence images for 2 hours at 5-min intervals using a
40x objective lens (Figure 2.10B). The average fluorescence intensity for plane of
observation next to the source well was fit with Equation 7 and the diffusion coefficient
was estimated to be 6 x 10- 10 m2/sec, which indicates that formyl peptide diffuses freely
into collagen.
When this experiment was repeated with fN'LFN'YK-FITC-loaded microspheres,
average fluorescence intensity was observed to fit very closely with Equation 10 using
the diffusion coefficient in collagen determined above (Figure 2.10B). It must be noted
that fluorescein has poor photostability resulting in photobleaching when exposed to
light. Therefore, the intensities observed do not necessarily reflect the chemoattractant
concentrations in the collagen gel accurately.
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Figure 2.10. (A) Schematic of FITC-fMLP release assay into collagen gel for
estimation of diffusion characteristics of the chemokine into collagen (B)
Fluorescence micrographs depicting diffusion of FITC-fMLP as a function of
space and time into collagen gel. The chemokine source is located at the lower
right corner of each image (C) Average fluorescence intensities for the field of
view determined experimentally and obtained from Equation 10.
2.3.7.2 Determination of diffusion coefficient of CCL20 in collagen gel
Similar to the experiment for formyl peptide diffusion in collagen, triblock
copolymer (acrylate-PLGA-PEG-PLGA-acrylate) was synthesized as described in
Appendix 11 and polymerized along with CCL20 conjugated to FITC (Appendix 7) by
photopolymerization initiated by IrgacureTM for 2 min in the center of a 2-well labtek
chamber slide (Figure 2.11A). Following polymerization, 1 mL of 2.4 mg/mL of collagen
gel was added and the slide placed in environmental chamber maintained at 37 OC, and
time-lapse videomicroscopy was initiated. Nine fields adjacent to triblock copolymer in a
3 x 3 array as described above in Section 2.2.5 were taken for green-fluorescence and
phase contrast (Figure 2.11B). Figure 2.11C shows the fluorescence profiles of labeled
chemokine as a function of distance from source and time. The average intensity was
again fit with the Equation 7 and the diffusion coefficient was determined as 1 x 10-11
m2/sec.
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Figure 2.11. (A) Schematic of FITC-CCL20 release assay into collagen gel for
estimation of diffusion profile of the chemokine into collagen (B) Fluorescence
micrographs depicting diffusion of FITC- CCL20 as a function of space and time
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into collagen gel. The chemokine source is located along the left edge of each
image (C) Diffusion profile of labeled chemokine as a function of distance from
the chemokine source and time.
2.3.7.3 Prediction of chemokine concentration profiles
Based on the diffusion coefficient of formyl peptide diffusion into collagen gel, we
predicted the chemokine concentration profiles in collagen gels as a function of distance
from the chemokine source and time by fitting the parameters into Equation 6. These
predictions were used to compare concentration profiles that exist when chemokine is
delivered as a bolus versus when delivered at a controlled rate, in order to understand
the sustained chemoattraction observed with encapsulated chemokine. For the
predictions, we assumed a chemokine source at 1 gg/mL for free fMLP versus the same
amount of chemokine released at a constant rate for a period of 10 days (equivalent to
a release rate of -1 pg/mL/sec in source region of collagen gel). It must be noted that
the source concentration will not stay constant during the course of chemoattractant
diffusion due to limited amount of chemoattractant in the source well. The assumption
that source concentration is constant may however be valid during the initial time points.
Figures 2.12A and 2.12B depict the predicted concentration profiles for bolus
chemokine and controlled release of chemokine, respectively. As can be seen in the
plots, the concentration of chemokine rises quickly in bolus delivery situation reaching
near-saturating concentration of chemokine in about 1 h. On the other hand, sub-
saturating conditions could be maintained with controlled release system for several
hours to days, which agrees with our observation that controlled release of chemokine
creates and maintains an optimal gradient of chemokine resulting in sustained
chemoattraction of cells towards the chemokine source, which is not possible with bolus
delivery of chemokine.
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Figure 2.12. Predicted concentration profiles of fMLP using Equation 9 as a
function of distance from chemoattractant source and time for (A) bolus delivery
of chemokine and (B) Controlled release of chemokine for -10 days.
2.4 Discussion
Chemotaxis is a ubiquitous mode of directed cell migration in development [92],
wound healing [93,94], disease states [48,95,96], and proper function of the immune
system [49,97]. In immunity, chemotaxis controls many aspects of cellular trafficking.
For example, during induction of a primary immune response, resting (immature) DCs
and other inflammatory cells chemrnotax to sites of infection, DCs activated (matured) by
interactions with pathogens or inflammatory cytokines chemotax to the draining lymph
nodes to activate T cells, and na've T cells chemotax to lymph nodes from the blood to
rendezvous with DCs [47,49,53,55,97].
Of particular interest for the design of vaccines is the role of chemotaxis in
controlling DC (and DC precursor) recruitment to sites of infection. Studies examining
DC attraction to an immunization site in vivo by a single bolus injection of freely diffusing
chemokines have shown that DC attraction in this situation is transient (peaking at ~24
h) [98], as expected given the relatively fast diffusion rates of these small molar mass
attractants. By simply sustaining the concentration of a chemoattractant at the injection
0 .... -
site, controlled release of chemokines could thus be expected to offer enhanced DC
accumulation.
Based on promising prior studies seeking to trigger chemotaxis in the setting of
immunization and the results of this theoretical analysis of controlled release versus
bolus chemokine delivery, we sought to develop an injectable, biodegradable, controlled
release formulation that would allow the total dosage of chemokine delivered, its
location, and its release rate to be tailored. Biodegradable controlled release
microspheres could meet these requirements, and poly(lactide-co-glycolide) is an
attractive first choice as a matrix material due to its long record of safe application in
vivo and use in clinically licensed products. Polylactide and PLGA microspheres have
previously been studied as carriers for the delivery of vaccine antigens in the form of
peptides [99], recombinant proteins [100-102], inactivated virus preparations [103,104],
or DNA [105-107] and have been shown to enhance both antibody production [100,102-
104,106] and T cell immune responses [99,102,105-107] in vivo. Microspheres
releasing chemokines could be readily combined with these or other antigen delivery
strategies, or even co-encapsulate antigen with chemokine - drawing DCs directly to
the spatial center of delivered antigens.
We encapsulated two different types of chemoattractants in PLGA microspheres.
Formyl peptides are inexpensive, low molecular weight chemoattractants that can be
prepared by solid-phase synthesis methods. They attract immature DCs, but also
numerous other inflammatory cell types. In contrast, CCL20 is currently produced as a
recombinant protein, making it significantly more expensive (an important issue in
design of vaccines [108]). However, CCL20 offers enhanced selectivity for attraction of
immature DCs to the immunization site: it is the only chemokine known to bind CCR6
and binds only to CCR6, while in contrast most chemokine receptors bind multiple
chemokines, and many chemokines are promiscuous in their receptor binding [14].
CCR6 expression is restricted to DCs and memory lymphocytes [73], and CCL20 is the
most potent attractant known for several subtypes of human DCs and their precursors
[52,56].
We found that both formyl peptides and CCL20, when released from PLGA
microspheres, could trigger chemotaxis in DCs millimeters away from the attractant
source, elicit directed migration of up to 500 mm toward the source, and maintain
attraction for at least 8 h in vitro through a 3D collagen gel model of the extracellular
matrix. A limiting factor in chemotaxis is the potential for receptor saturation and/or
downregulation, blocking directed migration at high chemoattractant concentrations [76].
As shown in Figure 2.9, DCs could chemotax to the point of contact with controlled
release microspheres without exhibiting paralysis or loss of directionality. Based on the
experimental release data and modeling results, we hypothesize that this is due to the
low, sustained rate of chemokine delivery from the microspheres. It is also likely that the
concentration profile of free chemokine very near individual microspheres is modulated
at late times by binding to the high density of DCs in the immediate vicinity.
What temporal characteristics are appropriate for chemokine delivery in the
setting of an optimal vaccine? Ideally, chemoattractant-releasing microspheres would
increase the number of recruited DCs significantly and this amplifies the number of
subsequently trafficking DCs to lymph nodes for T cell activation. Daily bolus injections
of free CCL20 into tumors have been found to be insufficient to promote significant anti-
tumor immunity, under conditions where continuous production of CCL20 (via
transduced tumor cells expressing the chemokine) led to tumor regression [42].
Similarly, other studies of chemoattractant-encoding DNA vaccines reporting improved
immune responses have observed enhanced DC infiltration at immunization sites from 5
to 15 days post-immunization [65,66,69]. These results suggest that continuous
maintenance of a chemokine gradient up to several weeks may be important for
sustaining DC influx to an injection site and obtaining enhanced immune responses.
In addition to their potential application directly to vaccine design, chemokine-
releasing microspheres should be a powerful tool for the study of chemotaxis in vitro
and in vivo. The ability to create local gradients of one or more factors, which at the
extreme can be delivered from single large microspheres as 'point' sources is of interest
for studies of cell trafficking in immunity, development, and angiogenesis. These
characteristics are complementary to other recent tools developed for the study of
chemotaxis such as the use of laminar flows in microfluidics to control chemokine
concentrations [109] and enhanced diffusion chambers for the study of cells migrating at
different rates [77].
Several issues are relevant in regard to application of chemokine-releasing
microspheres in vivo. Concentration profiles of chemokines in vivo may be modulated
by uptake by cells, proteolysis, binding to ECM components, as well as efflux into blood
and lymph [110]. Chemokines are known to bind heparin sulfate and other proteoglycan
in vivo and may be functional from the solid phase [111-113], which will also alter the
dynamics of chemotaxis. Thus, optimal release rates and doses in vivo may differ from
those observed in vitro. In addition, microsphere size must be carefully considered in an
application to real vaccines. DCs and macrophages have been shown to phagocytose
particles smaller than ~ 5 jm (including PLGA microspheres and other synthetic
particles) both in vitro and in vivo [114-119]. Small microspheres may only transiently
attract cells prior to internalization and removal by phagocytic cells; to obtain a
sustained depot of chemoattractant, large microspheres may be required to avoid
phagocytic removal from the injection site. Though the microspheres in the present
study had mean diameters of ~ 5 jm, the size of PLGA microspheres prepared by
emulsion techniques is readily varied vial alteration of several of fabrication conditions,
including continuous phase viscosity, relative oil/water phase volumes, surfactant
concentrations, stirring speeds, and choice of solvents [120,121]. Finally, in order to
selectively attract target immune cells, the controlled release matrix itself must not
trigger unintended chemotaxis e.g., due to chemoattractive breakdown products or the
induction of inflammatory chemokines triggered in surrounding tissue. In the present in
vitro studies carried up to 8 h in culture, we did not observe chemotaxis triggered by
empty PLGA microspheres or microspheres loaded only with the carrier protein.
However, in vivo and over longer times in vitro, acid breakdown products from PLGA
could influence the cellular response.
2.5 Conclusions
Injectable, biodegradable PLGA microspheres releasing chemoattractants that
induce directed cell migration have been developed. Microspheres releasing either
formyl peptide attractants or the chemokine CCL20 elicited sustained chemotaxis of
human and mouse DCs over distances up to 500 pm and sustained the attraction of
these cells up to 8 h in an in vitro collagen gel model. DCs could be attracted directly
into contact with controlled release microspheres, suggesting that they could be
effective for enriching DCs at the immunization site in vivo under conditions where the
dosage, release rate, and location of the chemoattractant could be fully predetermined
by the composition of the microspheres. The use of such controlled release
microspheres to create defined gradients of chemoattractants in vitro and in vivo offers
the possibility to both quantitatively probe the role of specific attractants in
chemoattraction and to manipulate cell migration for therapeutic purposes.
3. Delivery of antigen and maturation factor by hydrogel
nanoparticles
3.1 Introduction
Synthetic vaccines designed to prime the adaptive immune system are sought for
a broad range of infectious diseases and for the treatment of cancer, in both
prophylactic and therapeutic settings [122-124]. From a conceptual point of view,
vaccines are comprised of an antigen- the biomacromolecule component that the
immune system must be primed to recognize- and an adjuvant, a second component
that may play multiple roles in augmenting the immune response generated against the
antigen, such as 'depoting' of antigen for sustained immune stimulation or providing
inflammatory signals designed to activate cells of the immune system [125]. An ideal
vaccine would lead to the stimulation of two key cellular effectors, T cells and B cells,
which are triggered by two very different pathways. T cell activation occurs when a
cellular intermediate, the dendritic cell (DC), internalizes a protein, proteolyses this
antigen into short peptides, and presents these peptides to T cells in the cleft of their
major histocompatibility complex (MHC) molecules (Figure 1.1). In contrast, B cells can
directly bind protein antigens via their B cell receptors (membrane-tethered IgM or IgG
molecules). DCs and B cells must also receive stimulation through 'danger signal
receptors', such as the Toll-like receptors, which alert the cell to mount an immune
response against the encountered protein [22,126]. Ideally, one function of adjuvants is
to provide these danger signals to DCs and B cells when they encounter antigen.
It is now generally believed that protection against many of the diseases for
which vaccines are currently sought (e.g., HIV, Hepatitis C, and tuberculosis) will
require both T cell and B cell responses, but the design of synthetic vaccines that
potently stimulate both arms of adaptive immunity remains a significant challenge [127-
130]. In contrast, natural pathogens such as viruses and bacteria potently elicit both T
cell and B cell activation. Na've CD8 ÷ and CD4' T cell responses to pathogens are
triggered when DCs present pathogen-derived peptides to the T cells on class I or class
II MHC molecules, respectively. Exogenous foreign proteins are normally internalized by
dendritic cells, processed in endosomes, and presented on MHC class II molecules
[5,10,131], while MHC class I molecules are typically loaded with peptides derived from
intracellular molecules (Figure 1.3). Dendritic cells and macrophages have the unique
capability to present exogenous (extracellular) proteins on MHC class I molecules by a
process called cross-presentation [11,132]. Cross-presentation is not efficient for
soluble protein antigens and is typically observed only when high concentrations of
exogenous protein are used. However, it has been shown that whole intact microbes (or
purified protein antigens adsorbed to latex particles) taken up by phagocytosis can elicit
cross-presentation of the delivered antigen very efficiently; these antigens are then
processed and presented on MHC class I molecules to nalve CD8 ÷ T cells [10,132,133].
Cross presentation of particulate antigens allows dendritic cells to potently activate both
CD4 ÷ and CD8' na've T cells in response to microbes such as bacteria. For B cells, the
natural repeating molecular motifs present on the surface of pathogens allows multiple
B cell receptors to bind to a single pathogen particle, causing receptor aggregation and
strong B cell activation [129,130]. The required immunostimulatory signals are thus
'built in' to the physical structure of pathogens, such that multiple danger signal
receptors on DCs and B cells are triggered when pathogens are bound/internalized
[134].
Given these favorable characteristics, it has been recognized that synthetic
vaccines mimicking pathogens structurally and/or functionally might take advantage of
the evolutionarily engineered response of the immune system to these particulate
antigens [135,136]. Examples of antigen carriers previously studied in this context
include degradable poly(lactide-co-glycolide) microspheres[137-140], latex particles with
surface-adsorbed protein [10,141], and gel particles [142-145]. Shen et al. showed that
when a dendritic cell clone internalized latex particles coated with the model protein
antigen ovalbumin, cross-presentation was induced, and DCs were capable of
stimulating IL-2 secretion by a CD8 ÷ T cell clone at >100-fold lower doses of antigen
given to DCs compared to antigen delivered to DCs as soluble protein [10]. Mimicking
pathogen danger signals, Kempf et al. immobilized antibodies against Fc-y receptors,
CD40, or integrin receptors on the surface of PLGA microspheres [146]. These
microparticles triggered enhanced maturation of human dendritic cells as well as
upregulation of surface markers and IL-12 cytokine secretion.
Based on the wealth of information on activation of naYve T cells and B cells in
vivo, synthetic vaccines have been designed to co-deliver antigen and activation signals
(often Toll-like receptor ligands) in concert. Different strategies have been employed to
co-deliver antigen and maturation signals such as co-injection of the two agents into the
host [24,147-149], use of DNA plasmids encoding for antigen of interest that contain
unmethylated CpG motifs or co-express inflammatory cytokines [150,151], conjugation
of antigen with maturation factors such as ova-CpG conjugates [152,153], or co-
encapsulation of antigen and maturation factors into polymeric microparticles
[102,135,154]. In vivo, immunization of mice with antigen and CpG oligonucleotides co-
encapsulated in cationic liposomes elicited enhanced cytokine secretion by lymphocytes
and antibody titers were observed to increase an order of magnitude compared to that
elicited by immunization with soluble antigen [155]. Similarly, a hepatitis B vaccine
based on the hepatitis B core antigen and the immunostimulatory molecule
monophospholipid A (MPLA) encapsulated in poly(lactide-co-glycolide) nanoparticles
elicited a stronger cellular immune response than immunization with soluble protein
antigen mixed with MPLA [156]. Virus-like particles formulated directly from viral
membrane components have also been successfully developed to provide coincident
antigen and activation signal delivery in nonliving vaccines [157-159]. Co-delivery of
antigen and maturation factor to dendritic cells using the above strategies resulted in
strong immune responses compared to delivery of antigen alone.
Ongoing practical challenges facing many of these approaches are (1)
maximizing antigen loading in carriers (to elicit robust immunity with reasonable vaccine
doses), (2) avoiding denaturation/destruction of protein antigens during synthesis and
storage within the carrier prior to release, and (3) minimizing toxicity associated with
vaccine carriers and adjuvants to acceptable levels for clinical applications. Typically,
the amount of antigen delivered per total mass of carriers is low (observed weight
fractions of antigen in particulate carriers are typically < 15 wt% for protein
encapsulation in PLGA microspheres [137-140], <: 5 wt% for adsorption on latex
particles [10,132,141,148], and -1 wt% for hydrogel particles [142-144]). Low protein
loading limits the levels of antigen that can be delivered in an immunization.
Encapsulation of proteins in synthetic polymers like PLGA microspheres is also known
to lead to antigen degradation both during the encapsulation process itself and during
'storage' within the particles, limiting the effective dose delivered in such vaccines
[125,160-163]. In addition, various adjuvants used in conjunction with particulate
antigen delivery carriers such as lipopolysaccharide, cholera toxin, Quil-A, Freund's
adjuvant, and lipid-based adjuvants (e.g., murapalmitine and murametide [148,164])
have unacceptable levels of toxicity and therefore have limited clinical application
[127,165].
A direct examination of the value of presenting immunostimulatory and antigenic
epitopes together at the surface of synthetic particulate vaccines is lacking, but data
from prior studies is consistent with a potential positive impact of such structural mimicry
on immunological outcomes [136]. Prior studies have demonstrated that intact protein
antigens immobilized to the surface of biodegradable microparticles significantly
enhance B cell and T cell responses [148,166,167]; although the objective of this
strategy was to prevent degradation of the antigen during encapsulation, it is possible
that microspheres transported to draining lymph nodes were directly accessed by B
cells, enabling improved B cell stimulation via multivalent, microsphere-bound antigen.
Likewise, peptide antigens tethered to the surface of synthetic nanoparticles have been
shown to elicit highly elevated antibody responses relative to soluble peptide antigen
[148,168]. Other strategies utilized for particulate delivery of surface-displayed antigen
epitopes include conjugation of antigen to immune complexes [9], liposomes [169-172],
and the use of virus-like particles [21]. To our knowledge, surface co-display of TLR
ligands and antigen by synthetic particle vaccines has not been tested. However,
conjugation of CpG oligonucleotides (short single-stranded DNA sequences mimicking
bacterial DNA, which bind TLR9) directly to model protein antigens [152,153], mixing of
CpG-bearing particles with antigen-bearing particles [106], and co-encapsulation of
antigens and TLR ligands within biodegradable particles [102,173,174] have all been
found to enhance both T cell and antibody responses. In addition, the potency of TLR
ligands is enhanced by particulate delivery, allowing significantly lower total doses of the
TLR ligands to be used, which may alleviate potential side effects from these strong
immunostimulatory signals [175].
Based on these earlier findings, we sought to develop a particulate protein carrier
synthesis strategy that would allow high levels of protein to be encapsulated under
aqueous conditions that preserve the integrity of the antigen, provide antigen accessible
at the surface of the carrier for binding to B cell receptors, and permit subsequent
functionalization of the particle surfaces with immunostimulatory 'danger' signals to
drive na've T and B cell responses. To this end, we investigated a two-phase aqueous
miniemulsion polymerization to encapsulate protein within submicron hydrogel particles
in the absence of organic solvents. Near-saturated salt solutions of a poly(ethylene
oxide-b-propylene oxide-b-ethylene oxide) (PEO-PPO-PEO) triblock copolymer,
pluronic TM F-68, mixed with the model protein antigen ovalbumin (ova) and the
methacrylate monomers poly(ethylene glycol) methacrylate, methacrylic acid, and
poly(ethylene glycol) dimethacrylate, phase separated on heating to 400C to form a
stable emulsion. Free radical polymerization of the emulsion provided submicron-sized
(-500 nm diameter) hydrogel particles encapsulating up to -750 pg ova per mg of dried
particles. The particles were surface-functionalized post-synthesis by electrostatic
adsorption of CpG oligonucleotides, to provide immunostimulatory signals to dendritic
cells or B cells encountering the particles. These mesoscale particles, which mimic
pathogens in size and in their functional co-delivery of antigen and activation signals,
were avidly phagocytosed by dendritic cells, and DCs that internalized ovalbumin-
loaded particles primed naive CD4 ÷ and CD8 ÷ T cell responses at -10-fold lower doses
of protein than DCs pulsed with soluble ovalbumin (ova). Dendritic cells were effectively
matured by hydrogel particles, secreting inflammatory cytokines and upregulating
expression of costimulatory molecules. In vivo, CpG-coated hydrogel particles caused
activation of naYve T cells and resulted in high anti-ovalbumin IgG antibody titers. This
hydrogel particle encapsulation strategy may be of utility for higher potency vaccines
and drug delivery applications requiring the delivery of high levels of fragile proteins.
3.2 Materials and Methods
3.2.1 Hydrogel particle synthesis
A salting out-based miniemulsion polymerization technique was used to
synthesize protein-loaded hydrogel particles. Sodium chloride (16 g) was added to 50
mL of 4% (w/vol) aqueous pluronicTM F-68 (Sigma) solution in a 100 mL round bottom
flask and stirred until dissolved. The solution was degassed for 15 min with nitrogen
followed by the addition of 50 mg ova and (for experiments with labeled particles) 250
Vg Texas Red-conjugated ova (or 1 mg DQ-conjugated ova, Molecular Probes) to the
solution with stirring. Poly(ethylene glycol) methacrylate (PEGMA, 300 mg, 5.7x10 4 mol,
Sigma), poly(ethylene glycol) dimethacrylate (PEGDMA, 15 mg, 1.71x10 5 mol, Sigma),
and methacrylic acid (MAA, 15 mg, 1.74x10-4 mol, Sigma) were mixed and degassed
with nitrogen; the monomers were then added to the pluronic/protein/salt solution with
stirring to form a clear solution. The solution was heated in a water bath to 400C,
causing phase separation/emulsion formation driven by salting-out of the pluronic
copolymer. Polymerization was initiated by the addition of 10 mg ammonium persulfate
(Pierce Chemicals Co.) and 10 mg sodium metabisulfite (Sigma) in 1 mL of water.
Owing to the rapid polymerization in miniemulsions [176,177], particles were formed
and the reaction was stopped after 7 min. The resulting particle suspension was diluted
with 50 mL of deionized water and the particles were collected by centrifugation. The
recovered gel particles were washed with 50 mL water three times (until no free protein
was detected in the supernatant), resuspended in 5 mL of 0.4% w/vol pluronicTM F-68
solution in PBS (-10 mg/mL particle concentration), and stored at 40C until further use.
3.2.2 Electrostatic assembly of CpG oligonucleotide on hydrogel particles
To provide a high density of dendritic cell- and B cell-activating ligands at the
surface of each particle, the initially anionic hydrogel particles obtained from the
miniemulsion synthesis were modified by sequential adsorption of poly(L-arginine) (10
kDa, Sigma) followed by anionic CpG oligonucleotides (TCC ATG ACG TTC CTG ACG
TT, Integrated DNA Technologies, USA). Hydrogel particles (10 mg in lmL PBS) were
incubated with 5 mg/mL poly-L-arginine at 370C with shaking overnight. The poly-L-
arginine coated particles were centrifuged and washed four times to remove unbound
polycation. For CpG functionalization, the poly(L-arginine)-coated particles were then
resuspended in 1 mL PBS, mixed with CpG oligos (final CpG concentration 100 pM),
and incubated for 3 hrs at 370C. The CpG-modified particles were pelleted by
centrifugation and the supernatant was collected to measure the amount of unbound
CpG remaining in solution using a spectrophotometer (ThermoElectron SpectronicTM
HeliosTM Gamma UV-Vis Spectrophotometer) via the absorption at 260 nm. Based on a
standard curve determined for CpG 1826, the efficiency of CpG coupling was
determined as:
CpG concentration in supernatantCpG Conjugation Efficiency = [1 - Cp concentration in supernatant ] x 100% [8]
initial CpG concentration
3.2.3 Hydrogel particle characterization
3.2.3.1 Hydrogel particle size
The size distributions of hydrogel particles were characterized by dynamic light
scattering using a 657 nm laser source at a fixed angle of 900 (Brookhaven 90Plus
particle sizer). Typical count rates were 350,000 per second and collection times were
15 min. Surface charge on poly-L-arginine-coated hydrogel particles was characterized
by measuring the zeta potential of particle suspensions in PBS (300 gg/mL dry weight of
particles) using a Zeta Pals (Brookhaven Instruments Corporation).
3.2.3.2 Protein encapsulation efficiency
To determine the amount of protein encapsulated and the protein encapsulation
efficiency, supernatants from the particle synthesis were collected, pooled, and
fluorescence from the tracer protein texas red ovalbumin ( Xexc = 584 nm, Xem = 612 nm)
was measured in a spectrofluorometer (Molecular Devices SpectraMax Gemini
Spectrofluorometer) to detect unencapsulated protein. The protein encapsulation
efficiency was calculated as:
Encapsulation Effciency Amount of protein in supernatant
Encapsulation Efficiency = 1- x 100% [9]
Amount of protein added
3.2.3.3 Determination of presence of surface protein epitopes
In order to detect the presence of encapsulated protein accessible at the surface
of particles, 2 mg (10 mg/mL) particles were incubated with 50 [g/mL mouse anti-
ovalbumin monoclonal antibody or with isotype control antibody for 30 min at room
temperature. Particles were then washed and incubated with 50 Pg/mL Alexa fluor 488-
conjugated anti-mouse IgG secondary antibody for 30 min at room temperature. The
labeled particles were washed again and finally imaged at 40X using a Zeiss Axiovert
200 epifluorescence microscope equipped with a CoolSnapHQ CCD camera (Roper
Scientific).
3.2.3.4 In vitro digestion of encapsulated antigen by endosomal protease
cathepsin D
To assess in vitro digestion and release of encapsulated ova from particles
incubated with phagolysosomal proteases, hydrogel particles were resuspended (7
mg/mL particles, equivalent to 5 mg/mL ovalbumin) in 0.1 M Gly-HCI buffer pH 5.5 and
incubated for 48 hours with 200 pg/mL bovine spleen cathepsin D. The sample was
then centrifuged and the supernatant analyzed by size exclusion chromatography
(Hitachi LaChrom D-7000 HPLC system) in phosphate buffered saline using a
Superdex200 column (Amersham Biosciences). Eluting proteins or peptide fragments
were analyzed by a UV-vis detector (Hitachi L-7420) measuring absorbance at 280 nm.
3.2.3.5 Determination of hydrogel particle density in suspension
Particle concentrations obtained from each synthesis were determined by
analyzing serial dilutions of fluorescent gel particle suspensions on a flow cytometer
(FACS Scan, BD Biosciences), and counting the total number of events in a known
volume.
3.2.3.6 Determination of water content in hydrogel particles
To estimate the water content of protein-loaded particles, 1 mL of 10 mg/mL
particles were blotted on filter paper and the initial mass of the particles was measured.
The sample was then dried to constant weight in a vacuum oven at 700C for 12 hours
and the dry mass was determined to calculate the weight fraction of water in the gels.
3.2.4 Hydrogel particle uptake by bone marrow-derived dendritic cells
3.2.4.1 Fluorescence imaging of hydrogel uptake and cell viability
DCs (1 million/mL) were incubated with DQ-ovalbumin-containing hydrogel
particles (50 pg/mL ovalbumin) for 1 hour at 370C in complete RPMI medium. The
medium was replaced to remove free particles, and particles/DCs were imaged at 40X
using the fluorescence system described above. Fluorescence from non-internalized
particles bound to cells was quenched by the addition of 0.4% w/vol trypan blue [10].
Dendtitic cells incubated with hydrogel particles for 24 hours were stained with 5 [tg/mL
propidium iodide and analyzed by flow cytometry for cell viability.
3.2.4.2 Kinetics of antigen uptake by bone marrow-derived dendritic cells
BMDCs (1 x 106 cells in 1 mL) were incubated with Alexa fluor 488-conjugated
ovalbumin-containing hydrogel particles (1:50 labeled: unlabeled protein) equivalent to
50 pg encapsulated ovalbumin or a corresponding amount of soluble protein with or
without soluble CpG oligonucleotide for 1, 4, or 18 hours at 370C. Cells were washed,
stained with phycoerythrin (PE)-conjugated anti-CD11c (clone HL3, Pharmingen), and
uptake of antigen by DCs was determined by analyzing Alexa fluorescence of CD11c ÷
cells on a Becton Dickinson FACS Scan flow cytometer.
To obtain a measure of the amount of class I ova peptide-MHC complexes
generated following antigen pulsing in different conditions, BMDCs were incubated for
18 hrs with 50 mg soluble ova or ova-loaded particles, stained with monoclonal antibody
25.D1.16 that recognizes SllNFEKL-Kb class I ova peptide-MHC complexes [178] ,
followed by PE-conjugated rat anti-mouse IgG1 antibody (clone A85-1, Pharmingen,
USA). Stained BMDCs were analyzed for levels of surface antigen presentation using
flow cytometry (FACS Scan, BD Biosciences).
3.2.5 Assesment of dendritic cell maturationlactivation by hydrogel
nanoparticles
3.2.5.1 Upregulation of costimulatory molecules on dendritic cells surface
BMDCs (1 x 106 cells/ml) were incubated 24 hrs with 1 gM soluble CpG, 100 jg
nanoparticles-lacking CpG, CpG-coated hydrogel particles (100 jg particles, 1 PM
equivalent CpG concentration), 1 pg/mL lipopolysaccharide (LPS), or were left
untreated. Dendritic cell Fcy-Il/III receptors were blocked using anti-CD16/CD32
antibody (Pharmingen, USA), and cells were then stained with monoclonal antibodies
against CD11c, I-Ab (clone AF6-120.1), CD40 (clone 3/23), CD80 (clone 16-10A1), and
CD86 (clone GL1) (Pharmingen, USA) and analyzed on a BD FACS Scan flow
cytometer.
3.2.5.2 Secretion of inflammatory cytokines by dendritic cells
Cytokine secretion by DCs exposed to soluble CpG or CpG-conjugated
nanoparticles was measured by ELISA. BMDCs (5 x 105 cells/mi) were cultured with
various dilutions of soluble CpG, hydrogel particles coated with poly(L-arginine) but not
with CpG, or CpG-coated hydrogel particles in a 96-well plate for 48 hrs. Supernatants
from the cultures were analyzed for the presence of IL-12p40, IL-12p70, IL-6, TNF-Q,
and IL-10 by ELISA (R&D Systems, USA).
3.2.6 In vitro antigen presentation to T cells by dendritic cells
To determine whether protein antigen in gel particles internalized by dendritic
cells was processed to allow antigen presentation to T cells, activation of naive T cells
by particle-pulsed or control DCs was assessed by measuring production of IL-2 by T
cells in response to stimulation by DCs. DCs (1 x 105) were plated in 96-well round-
bottom tissue culture plates and incubated with either soluble ova mixed with 1 jiM CpG
or CpG-modified ova gel particles (-14 nmol CpG/mg encapsulated ovalbumin) for 4
hours, after which the DCs were washed with RPMI medium to remove free antigen.
CD4* or CD8* naive ovalbumin-specific T cells were isolated from spleens of OT-II or
OT-I transgenic mice (Jackson Laboratories) respectively, using CD4* or CD8+
Magnetic-Assisted Cell Sorting (MACS) beads (CD4 ÷ T cell and CD8+ T cell negative
selection kits, Miltenyi Biotech) according to the manufacturer's instructions. Purified T-
cells (1 x 105) were added to each well and co-cultured with DCs for 72 hours; IL-2
concentrations in the culture supernatants were then determined by ELISA. CD8 ÷ OT-I
splenocytes were blasted for 5-7 days and co-cultured with dendritic cells as described
above for naive T cells. IL-2 secretion was measured by ELISA after 48 h to study
antigen presentation to T cells by dendritic cells.
To assess the proliferation of naive T cells upon activation by activated dendritic
cells, BMDCs (1 x 105 cells/well) were incubated for four hours with 10 jig/mL ovalbumin
delivered as soluble protein or hydrogel particles in a 96-well round bottom tissue
culture plate. Free antigen was removed and CFSE-labeled CD4* (OT-Il) or CD8* (OT-I)
na've T cells (1 x 105 cells/well) were co-cultured with equal number of dendritic cells at
370 C, 5% CO2 for 60 h. Cells were extracted from the tissue culture plate, and stained
with anti-CD4/CD8-APC (for OT-I or OT-II T cell identification) and propidium iodide (for
live cells), and T cell proliferation was assessed by CFSE dilution upon cell division
3.2.7 In vivo activation of lymphocytes by hydrogel particles in C57B11/6
mice
3.2.7.1 In vivo activation of ovalbumin-specific nalive T cells measured by in vitro
restimulation and SIINFEKL-Kb tetramer staining
C57BI/6 mice (8-10 weeks old) were immunized s.c. in the lower flanks with 100
pL PBS (control) or 100 pg of ova in different forms: soluble ova in 100 tL PBS, soluble
ova mixed with soluble CpG (1.4 nmoles), soluble ova in 50 [iL PBS emulsified in 50 pL
CFA, uncoated ova nanoparticles in 100 tL PBS, or CpG-coated ova nanoparticles (1.4
nmole total CpG) in 100 pL PBS. Mice were sacrificed after 7 d, and cells were isolated
from spleen or inguinal (draining) lymph nodes using 400 U/mL collagenase D (Roche
Applied Science, USA) for 45 min at 37 'C. RBCs were lysed in splenocyte samples,
and cells were plated at 500,000 cells/ well in 96-well round bottom plates. Dominant
ovalbumin-derived peptides known to be presented by C57B1/6 MHC class I (SIINFEKL)
or class II (ISQAVHAAHAEINEAGR) (AnaSpec, USA) [133] were added at a final
concentration of 5 [g/ml in each well in a total volume of 200 p1. IFN-y secretion from
the ex vivo-restimulated cells was determined by sandwich ELISA (R&D Systems, USA)
after 48 hrs to quantify T cell activation. Statistical analysis of data was carried out by
Student's t-test; differences were considered significant when P-values were <0.05.
To determine the role of CpG display from particle surfaces, C57B1/6 mice (8-10
weeks old, 4 mice per condition) were immunized in lower flanks with 100 tL PBS or
100 pg ova nanoparticles in 100 pL PBS, ova nanoparticles mixed with soluble CpG
(1.4 nmol), or CpG-bound nanoparticles. One week later, splenocytes were isolated by
treatment with collagenase D. Splenocytes (1 x 106 cells) from each mouse were
stained directly ex vivo with anti-CD8a and SIINFEKL-MHC class I phycoerythrin-
conjugated streptavidin tetramers (a gift of Dr. Norman Letvin, Harvard Medical School),
and analyzed by flow cytometry to determine the frequency of ova-specific CD8 ÷ T cells
from mice immunized by each condition. In parallel, splenocytes were restimulated with
class I and class II peptides as described above and IFN-y secretion was measured in
the supernatants after 48 hrs by sandwich ELISA.
3.2.7.2 Anti-ovalbumin IgG titers in sera of mice immunized with hydrogel
particles
Groups of two C57B1/6 mice (8-10 weeks old, groups of 2) per condition were
immunized s.c. in their lower flanks with 100 pg total ovalbumin in different forms:
soluble ova in 100 ýtL PBS, soluble ova mixed with 1.4 nmoles (8.5 pg) soluble CpG
1826, soluble ovalbumin (in 50 tL PBS) mixed with 50 pL complete Freund's adjuvant
(CFA), ovalbumin-containing hydrogel particles in 100 jtL PBS, or CpG-coated hydrogel
particles (1.4 nmole (8.5 pg) total CpG) in 100 tL PBS. Control mice received injections
of PBS only. Serum IgG titers were determined from blood samples collected after 1, 3,
5, and 7 weeks by sandwich ELISA using ova-coated microtiter plates. Antibody titers
are reported as the serum dilution at which the sample O.D.450 was 2-fold greater than
the O.D.450 measured for naive mice (Equation 10). The data was analyzed for
statistical significance using Student's t-test; differences were considered significant
when P-values were < 0.05.
Antibody Titer in Serum = (Serum dilution at which Asmple -- 2 x A nnim m une serum
[10]
3.2.7.3 In vivo cytolytic activity of memory T cells
To measure the induction of CD8* T cell memory, an in vivo CTL assay was
employed [149]. C57B1/6 mice were immunized s.c. in lower flanks with PBS, 100 pg
ova in nanoparticles mixed with 8.5 pg soluble CpG, or CpG-coated nanoparticles (100
pg ova, 8.5 pg CpG). 60 days later, syngeneic splenocytes labeled with 0.5 pM
(unplulsed) or 5 ptM (pulsed with 1 ptg/mL SIINFEKL for 1 h) were injected at 6 x 106
cells of each type per mouse. 24 h later, mice were sacrificed and splenocytes were
analyzed for in vivo cytolytic activity calculated as:
1- ratio primed 1CFSEIto
Cytolytic Activity ratio primed x 100 %, where ratio = CFSE 11]Cytolytic Activity = ratio unprimed] CFSEhi
3.3 Results
3.3.1 Hydrogel particle synthesis and characterization
To develop a strategy for all-aqueous encapsulation of antigen, we first
investigated the effect of monovalent salts on the phase separation behavior of pluronic
F-68 by means of dynamic light scattering. Pluronic F-68 solution (0.04 g/mL) in a near-
saturated (5.5 M) NaCI solution was heated to various temperatures followed by
determination of the size of block copolymer aggregates in the solution using Dynamic
Light Scattering (DLS); as shown in Figure 3.1. We found that the cloud point of F-68
could be lowered from -108'C in pure water (a theoretical value) to ~ 370C in a near-
saturated sodium chloride solution. The measured hydrodynamic diameter of pluronic
aggregates in 5.5 M NaCI solution with 0.04 g/mL increased from -35 nm at 32 OC to ~
400 nm at 37 0C, coincident with obvious clouding of the initially clear solution. The
phase separation behavior and the cloud point of pluronic F-68 in saturated salt solution
was unaffected by presence of PEG monomers and protein (Figure 3.1). This is
possibly a result of small relative concentrations of protein (0.1% w/v) and PEG
monomers (0.66% w/v) compared to the weight fraction of pluronic F-68 (4% w/v) in the
salt solution. The mesoscale polymer-rich droplets formed on heating to 37 oC (visible
by light microscopy) were stable in a stirred solution and showed no change in mean
diameter for up to 4 h at constant temperature.
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Figure 3.1. Mean diameter of pluronic aggregates as a function of temperature in
0.04 g/mL pluronic F-68 aqueous solution containing 5.5 M NaCI with (o) or
without (a) the addition of 1 mglmL ovalbumin and 6.6 mg/mL monomers (6
mglmL PEGMA, 0.3 mglmL PEGDMA, and 0.3 mg/mL MAA).
303.4 3
For synthesis of hydrogel particles, a model protein antigen, ovalbumin, and the
gel precursor monomers PEGMA, PEGDMA, and MAA were added to a 5.5 M NaCI
solution containing 0.04 g/mL pluronic F-68. Heating of the solution to 40 oC followed by
addition of the free-radical initiator ammonium persulfate (APS) led to rapid
polymerization of monomer within protein/ polymer-rich phase of the emulsion, and
hydrogel particles formed by this process were recovered by centrifugation of the
resulting suspension (Figure 3.2).
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Figure 3.2. Schematic diagram of monomer chemical structures, hydrogel particle
synthesis, and functionalization with CpG oligonucleotides.
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To characterize the steps in this synthesis, dynamic light scattering was used to
monitor the state of the emulsion at each step before and after polymerization (Figure
3.3). The pluronic (0.04 g/mL) in pure water at 250C is well below its Critical Micelle
Temperature (CMT) (-37°C); F-68 unimers had a measured hydrodynamic diameter of
4.5 nm, in agreement with previously reported values. Addition of 5.5M sodium chloride
induced the formation of micelles at 25°C (measured diameters ~23nm). The size of
these aggregates is somewhat larger than that reported for F-68 micelles formed in pure
water at temperatures above the CMT (13-15.6 nm); this discrepancy in the size of
aggregates formed by temperature- vs. salt-driven assembly has also been observed
for F-68 in potassium fluoride aqueous solutions [179]. Addition of protein to the
pluronic/salt solution at 250C did not cause a statistically significant change in the
aggregate size detected by DLS. Addition of the hydrogel precursor monomers to the
pluronic/salt/protein solution caused a further increase in the size of the (still unimodal)
aggregate population to ~33 nm. Upon heating of the solution containing pluronic,
protein, and monomer to 400C, the pluronic phase separated as in the absence of
protein and monomer, forming an emulsion with relatively monodisperse droplets 440
nm in diameter (Figures 3.1 and 3.3A), the same size as droplets formed by pluronic
alone in salt solution. The pluronic-dominated phase behavior of the system is
consistent with the lower relative concentrations of protein and monomers present (4%
w/v pluronic versus 0.1% w/v ovalbumin and 0.66% w/v monomers). The particles
formed after polymerization had diameters by DLS slightly larger than the size of the
emulsion droplets detected prior to initiation (490 + 30 nm after polymerization, Figure).
The uniform submicron size of the particles formed was also confirmed by direct
observation of rhodamine-labeled particles by fluorescence microscopy (data not shown
and Figure 3.7 discussed below).
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Figure 3.3. (A) Mean diameter of pluronic aggregates/ emulsion droplets at each
stage of particle synthesis obtained by DLS. (B) Size distribution of emulsion
droplets at 40 oC (o) and hydrogel particles post-polymerization (m) as measured
by DLS.
Notably, no particles were recovered if salt, initiator, or gel precursor monomers
were excluded from the synthesis. Exclusion of protein from the synthesis resulted in a
significantly reduced yield of particles that were difficult to pellet. Typically -50 mg of
.... F |
particles (dry mass) were obtained from the synthesis, comprised of -37.5 mg ova
(discussed below) and 12.5 mg polymer, a yield of 75% protein encapsulated and 4% of
the monomers incorporated into the particles. Measurement of the 'wet' mass of the as-
synthesized particles by blotting on a filtration membrane followed by drying to constant
mass revealed a water content of 74±14 wt% in the hydrogels. The density of
polymerized particles formed during the synthesis, based on the measured particle size
and mass of the hydrated particles, was 6.24x10 10/mL, in good agreement with the
average density of particles directly measured by flow cytometry (5.35x10 10/mL). The
stability of the mesoscale pluronic emulsion droplets and relatively close
correspondence between the pre-polymerization emulsion droplet size and the diameter
of the resulting gel particles is consistent with a miniemulsion mechanism of
polymerization in this system, where individual emulsion droplets template the final gel
particles formed.
Based on the measurements above, the total polymer concentration within the
gel particles is approximately 65 mg/mL. Because the pluronic exists in the unimer
state below 360C in pure water at concentrations below 0.05 g/mL, we believe that any
pluronic in the particles should be largely removed during washing of the gels into water
at 250C post-synthesis, due to its small molecular size (Scheme). Assuming the
polymer measured in the dried particles is comprised solely of crosslinked
poly(PEGMA-co-MAA) chains formed during polymerization, the mesh size of the
network making up the gel particles, 4, can be calculated using the theory of Canal and
Peppas [180]:
1= Cn/2 1/3 1/2 [12]- , Q N [121
where, 4 is the mesh size of the polymer network, Cn is the characteristic ratio of the
polymer, Q is the degree of swelling = VswollenNdry, N is the degree of polymerization
between crosslinks, and I is the bond length in the polymer backbone. Using these
values, 4 is determined to be 6.04 nm, which should facilitate retention of the
encapsulated ova protein, which has a hydrodynamic diameter of 6.1 nm.
Table 3.1. Ovalbumin-loaded hydrogel particle characteristics as a function of
Pluronic F-68 concentration in synthesis.
PluronicT F-68 1% 2% 4% 6% 8%
content (w/v)
Particle size Flocs >10 pm Flocs >10 pm 488 ± 30 nm 520 ± 20 nm 504 ± 20 nm
Encapsulation
Efficiency 83% 85% 73% 52% 34%
Protein content
(mg protein/mg 0.735 0.739 0.735 0.634 0.523
dry particles)
High protein encapsulation efficiency and protein loading in particle-based
vaccines are desirable to maximize immune responses. In the present system, we
found that the concentration of pluronic was a key parameter controlling the formation of
particles, the protein encapsulation efficiency, and net protein loading per particle, as
shown in Table 3.1. Macroscopic aggregates formed if the pluronic content was reduced
from 4% (wt/vol) to 2% or lower. For pluronic concentrations ranging from 4% to 8%,
mesoscale particles were obtained with a mean particle diameter of -500 nm. However,
as the pluronic content increased, both the net amount of protein encapsulated per
particle and the protein encapsulation efficiency decreased significantly. Maximal
protein encapsulation (0.74 mg protein/mg dry particles) and encapsulation efficiency
(73%) were achieved at an intermediate pluronic concentration of 4%. These high
values are a notable strength of this aqueous encapsulation strategy. This technique
also appears to have at least moderate generality as the same procedure also allowed
the successful encapsulation of bovine albumin and human serum albumin, in addition
to ovalbumin (data not shown).
3.3.2 Functionalization of hydrogel particles with CpG oligonucleotide
To provide activation signals to dendritic cells and B cells for a productive
immune response, short single-stranded CpG oligonucleotides, ligands for Toll-like
receptor 9 (TLR9) known to promote robust DC and B cell activation, were bound to the
surface of particles by a two-step electrostatic self-assembly process (Figure 3.2). First,
poly(L-arginine) was adsorbed to the anionic (methacrylic acid)-containing hydrogel
particles to obtain a positively charged particle surface, followed by electrostatic
adsorption of the negatively-charged CpG oligonucleotides. The amount of CpG
adsorbed depended strongly on the zeta potential of the particles and thus on the
poly(L-arginine) concentration used in the first adsorption step (Table 3.2). As the
concentration of poly(L-arginine) was increased from 0.5 mg/mL to 5 mg/mL, the CpG
adsorption efficiency in the second step increased from 30% to -100% (Table 3.2) in
parallel with the steadily increasing zeta potential of the poly(L-arginine)-coated
particles.
We initially sought to synthesize cationic hydrogel particles directly by
encapsulating protein in gel networks containing the monomer 2-aminoethyl
methacrylate instead of methacrylic acid, but these particles, which presumably
contained their positive charges distributed throughout the particle volume instead of
concentrated at the surface, had a lower zeta potential (+1.05 mV) and bound CpG
inefficiently (-20% of CpG adsorbed). Adsorbed oligonucleotides were well retained on
the surface of polyarginine-coated particles; functionalized particles were observed to
release only -10% of the adsorbed CpG oligos after incubation in PBS at 370C for one
week (Figure 3.4), and less than 10% of the initially bound CpG desorbed from
particles stored three weeks at 40C in PBS. This simple electrostatic functionalization
approach should also be applicable to a variety of other DC-stimulating ligands,
including anionic single- and double-stranded RNAs (ligands for Toll-like receptors 3, 7,
and 8).
Table 3.2. Zeta potential and CpG conjugation efficiency for hydrogel particles
coated with poly(L-arginine).
Poly-L-arginine Zeta Potential of CpG conjugation
concentration in first poly(L-arginine)- efficiency in second
adsorption step (mg mL"1) coated particles (mV)* adsorption step (%)t
0.5 -14.77 30
1.0 -14.47 50
2.0 -1.45 88
5.0 +5.13 98
*Uncoated particles = -16.40mV.
t 100 % CpG conjugation efficiency = 10 nmol CpG ODN/mg dried hydrogel particles
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Figure 3.4. Kinetics of CpG oligonucleotide desorption from the surface of
functionalized hydrogel particles when incubated in PBS at 37 oC.
To determine whether there was an optimal density of CpG per particle for DC
stimulation, dendritic cells were first incubated with particles functionalized with different
quantities of CpG; the total amount of particles added to the cells was varied so that in
each case a fixed total amount of CpG (1 nmole/ 106 cells/ mL) was added to each
culture. As shown in Figure 3.5A, significant IL-12p40 secretion was observed even at
the lowest density of CpG/particle tested (3.4x10 5 oligos per particle). IL-12 production
was increased when fewer nanoparticles bearing more CpG/particle were added to DCs.
(Note that even at the highest CpG-per-particle density the particles were in significant
excess over the number of DCs (particle:DC ratio -540:1)). When DCs were instead
incubated with a fixed number of particles (particle:DC ratio 540:1) coated with different
quantities of CpG (Figure 3.5B), a dose-dependent response was observed with an
onset of IL-12 production triggered by -5.5x10 5 oligos/particle. Based on these results,
for subsequent studies we fixed the CpG density at _106 oligos per particle, the highest
density tested, which gave maximal IL-12 secretion from DCs among the conditions
tested.
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Figure 3.5. (A) IL-12p40 secretion at 1 [LM hydrogel particle-bound CpG
concentration after 48 hours of incubation of bone marrow dendritic cells with
hydrogel particles adsorbed with different concentrations of poly-L-arginine as a
function of CpG loading per particle; (B) IL-12p40 secretion by dendritic cells
when incubated with same number of hydrogel particles but with different CpG
Ioadings per particle.
3.3.3 Encapsulated antigen release by protease digestion of hydrogel
particles
We hypothesized that by encapsulating protein in a hydrogel network, DC
proteolytic enzymes with sizes smaller than the mesh size of the gel particle network
might directly diffuse into the network and cleave entrapped protein antigen; the
resulting low molar mass peptides would readily diffuse back out of the gel particle, to
be processed by the native antigen presentation machinery of the dendritic cell. To test
of this hypothesis, we determined the effect of incubating ova-loaded gel particles with a
phagolysosomal protease in vitro. The enzyme tested, cathepsin D (catD), is a
ubiquitous protease involved in antigen processing in the endosomes/phagosomes of
antigen presenting cells, which is known to digest ova. Though catD is one of the larger
known phagosomal proteases, it has a reported end-to-end distance (~4.5nm) smaller
than the estimated size of the particle network mesh size, and also eluted later than
ovalbumin in size exclusion chromatography experiments (discussed below). CpG-
- t""
modified, ovalbumin-loaded hydrogel particles were incubated at a phagosomal pH of
5.5 with catD for 48 hrs, and the supernatant from this co-incubation was then analyzed
for the presence of protein/peptide fragments by size exclusion chromatography. The
resulting chromatogram (Figure 3.6A) showed the production of fragments ranging in
approximate molecular size from 2-30 KDa, and was comparable to that observed for
soluble ovalbumin digestion by catD (Figure 3.6B) as well as previously reported gel
electrophoresis data on catD proteolysis of ova. The supernatant from particle digestion
was clearly demarcated from controls containing catD alone (Figure 3.6C) or undigested
ova (not shown), and no peptide fragments were detected in the supernatant of
ovalbumin particles incubated in the absence of the catD enzyme. In the absence of
specific protease treatment, ova was stably encapsulated; < 5% of the encapsulated
protein was released after incubation of gel particles in serum-containing medium at
370 C for one week. Thus, protein antigens encapsulated in the gel particles are stable in
the presence of serum, but can be degraded by acid proteases normally present in the
phagolysosomal compartments of dendritic cells.
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Figure 3.6. Size-exclusion chromatograms of supernatants collected after 48 h co-
incubation of mixtures of 200 pg/mL cathepsin Dwith (A) 5 mglmL CpG-modified
ova hydrogel particles, (B) 5 mglmL soluble ova, or (C) catD alone. Arrows mark
the elution times for intact soluble ova and catD.
3.3.4 Accessibility of native protein epitopes at the surface of hydrogel
particles
We hypothesized that the entrapment of protein antigens at or near the surface
of gel particles during synthesis might permit direct binding of antibodies to exposed
antigen epitopes. To examine this possibility, CpG-modified, ova-loaded gel particles
were stained with mouse anti-ovalbumin monoclonal antibodies and imaged by
fluorescence microscopy (Figure 3.7). The hydrodynamic diameter for these IgG
molecules measured by DLS was 11.9 nm, significantly larger than the calculated mesh
size of the gel particle network; we thus expected that antibody binding would reflect
U I
ova epitopes available primarily at or near the surface of the gel particles. The clear
specific staining of the gel particles by anti-ova antibody implies that the encapsulated
protein is in a native state and is accessible from the particle surface. Surprisingly,
similar intensities of specific antibody staining were observed for gel particles that had
not been coated with polyarginine and CpG oligos (not shown), suggesting that the thin
polyelectrolyte bilayer formed during the gel particle surface modification does not
significantly obscure access to protein near the particle surface. In line with this in vitro
result demonstrating accessibility of encapsulated antigen to antibody binding, we found
that immunization of mice subcutaneously with hydrogel particles primed >100-fold
greater anti-ova IgG antibody titers in vivo compared to soluble ova immunization as
discussed in Section 3.3.8.2.
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Figure 3.7. (A) Fluorescence images of ova-containing hydrogel particles stained
with either anti-ova (left) or isotype control (right) primary antibody followed In
both cases by Alexa fluor 488-conjugated IgG secondary antibody. (B) Histogram
of fluorescence intensities from anti-ova-labeled particles (solid line) and isotype
control-stained particles (dashed line).
3.3.5 Hydrogel particle uptake and cross-presentation of antigen by dendritic
cells
3.3.5.1 Fluorescence imaging of hydrogel particle uptake by BMDCs
Professional antigen presenting cells such as dendritic cells are highly efficient
phagocytes, and rapidly internalize submicron-sized biological or synthetic particles. To
assess the uptake of ova-loaded gel particles by dendritic cells, murine bone marrow-
derived DCs were incubated with fluorescent DQ-ovalbumin-loaded hydrogel particles
(50 gg/mL ovalbumin) for 1 hour, washed to remove unbound particles, and then
0
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imaged by fluorescence microscopy. Trypan blue (0.4% w/v) [10] was added to the
medium to quench extracellular fluorescence and confirm that visualized particles were
internalized by the cells. As expected, DCs efficiently phagocytosed the gel particles
(Figure 3.8).
A. B.
Figure 3.8. Hydrogel particle uptake by dendritic cells. Dendritic cells were
incubated with DQ-ovalbumin-containing particles (A) or control medium (B) for 1
h. Extracellular and membrane-bound fluorescence was quenched with trypan
blue, and cells were then imaged by fluorescence microscopy.
3.3.5.2 Toxicity of hydrogel particles in dendritic cell culture
Nontoxicity of vaccine carriers and adjuvants is required for clinical application,
and cytotoxicity is a limitation of several studied vaccine adjuvants despite their ability to
effectively activate cells of immune system. To test for potential toxicity associated with
internalization of the nanoparticles, DCs were incubated for 24 hours with hydrogel
particles followed by staining with propidium iodide to assay cell viability by flow
cytometry. As shown in Figure 3.9, the hydrogel particles were non-cytotoxic and cell
viability was indistinguishable from control samples. These hydrogel particles were also
well-tolerated in vivo in mice with no apparent inflammation at sites of injection.
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Figure 3.9. Cell viability assessed by propidium iodide when dendritic cells were
cultured with hydrogel particles for 24 h.
3.3.5.3 Enhanced antigen uptake by dendritic cells
Dendritic cells are highly phagocytic and have been observed to avidly
phagocytose particulate antigen in their environment [115,181-183]. In order to quantify
the efficiency of ova-loaded particle uptake by dendritic cells relative to internalization of
soluble ova, DCs were incubated with alexa fluor 488-conjugated ova-containing gel
particles (50 pg total ovalbumin, 1:50 labeled: unlabeled protein) or 50 pg soluble ova
for 1-18 hrs and the amount of internalized protein was analyzed by flow cytometry.
Alexa fluor 488, unlike fluorescein, is a relatively pH-insensitive dye and does not
undergo quenching in the phagosomal/ lysosomal environment, enabling tracking of
antigen into these acidic intracellular compartments [184]. DC internalization of ova-
loaded nanoparticles was significant within 1 hr (31% and 38% ova+ cells after
incubation of DCs with nanoparticles or CpG-modified nanoparticles, respectively),
whereas almost no soluble antigen was detected in DCs at this time-point (Figure 3.10).
After 18 hrs of incubation, -1.5-fold more DCs were ova when incubated with ova
nanoparticles relative to soluble antigen, and the median amount of ova per cell was
2.2-fold higher for DCs incubated with CpG-modified ova particles. CpG-modified
particles were internalized slightly more efficiently than unmodified ova particles,
suggesting that DNA receptors on the DC surface enhanced their binding/internalization.
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Figure 3.10. Antigen delivery to dendritic cells by soluble protein, hydrogel
particles, and CpG-coated hydrogel particles after 1, 4, and 18 hours of
incubation. Grey histograms represent unmanipulated cells and solid lines
represent corresponding samples.
3.3.5.4 Cross-presentation of antigen by dendritic cells
Once internalized, protein antigen must be processed into peptides and loaded
onto class I and class II MHC molecules for presentation to T cells. Exogenous antigens
taken up by antigen presenting cells are normally processed and presented only by
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class II MHC molecules. However, dendritic cells and macrophages are capable of
loading peptides derived from exogenous antigens onto class I MHC molecules for
presentation to CD8 ÷ T cells via a set of processes collectively termed cross-
presentation [11,132], and particulate systems for delivery of protein antigen have been
found to strongly promote cross-presentation [10,132,185]. To determine whether
hydrogel nanoparticle delivery of ova promoted cross-presentation of ova peptides, we
analyzed the expression of ova peptide-MHC class I complexes generated by DCs
incubated with ova protein or ova nanoparticles for 18 hrs. The monoclonal antibody 25-
D1.16, which recognizes the ova-derived peptide SIINFEKL bound to H-2Kb class I
MHC molecules, was used to detect ova peptide-MHC I complexes on the surface of
DCs by flow cytometry [178,186,187]. The frequency of ova peptide-MHC l1 cells was
5.3-fold greater for DCs incubated with nanoparticles compared to soluble ova, and the
mean expression level of Kb-SIINFEKL complexes was 4.4-fold higher for DCs
incubated with ova particles (whether CpG-modified or not) relative to DCs incubated
with soluble ovalbumin (Figure 3.11A and B). The presence of CpG on the surface of
hydrogel particles did not enhance the expression of peptide-MHC complexes,
indicating that particulate delivery of the antigen alone induced significant cross-
presentation of antigen, without the additional cross-presentation signals provided by
CpG [178,186-191]. Thus, the hydrogel particles not only deliver antigen efficiently to
dendritic cells but trigger cross-presentation, enabling enhanced presentation of peptide
to naYve CD8 ÷ T cells compared to soluble antigen.
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Figure 3.11. (A) Expression of SIINFEKL-Kb on the surface of dendritic cells based
on staining with 25-D1.16 antibody after incubating dendritic cells with antigen for
18 hours. Solid histogram represents isotype control staining, dotted line is
solution control, and solid lines are samples; (B) Shown are the mean
fluorescence intensity (MFI) values obtained for SIINFEKL-Kb staining on
dendritic cells and % cells with peptide-MHC I complex expression above isotype
control.
Ova
X
0E1
CpG-
Particles
15-
10-
5-
=.-6 I t
D 4 10 0 10 1 102 103 ()4
-
+
3.3.6 Dendritic cell maturation by CpG-coated hydrogel particles
3.3.6.1 Upregulation of costimulatory molecules on dendritic cell surface
CpG oligonucleotides bound to the surface of protein-loaded nanoparticles are
expected to drive maturation and activation of dendritic cells that internalize the particles
via signaling through Toll-like receptor-9 [192,193]. Maturation of dendritic cells
incubated with soluble CpG oligonucleotides or CpG-coated particles was quantified by
analyzing the surface expression of MHC II and costimulatory receptors on DCs
incubated for 24 hrs with 1 pM soluble CpG or an equivalent concentration of CpG
coated on hydrogel nanoparticles. After incubation, DCs were stained for MHC class II,
CD40, CD80, and CD86 and analyzed by flow cytometry; DCs left untreated or treated
with 1 pg/mL LPS were also analyzed for comparison. Interestingly, although CpG
coating was required for the nanoparticles to trigger cytokine secretion by DCs, both
CpG-coated and uncoated particles induced upregulation of all 4 cell surface markers
on DCs relative to untreated cells (Figure 3.12). However, upregulation of MHC II and
CD40 on DCs with uncoated particles was less pronounced than with CpG-coated
particles (Figure 3.12A). CpG-functionalized nanoparticles triggered stronger
upregulation of the costimulatory ligand CD86 than soluble CpG (Figure 3.12B), while
soluble CpG triggered slightly greater CD40 upregulation than CpG-particles (Figure
3.12A).
SolubleCpG-Untreated Soluble Particles CpG- LPSCpG Particles
(U)
I
CD11 c-FITC
B.
CpG Particles CpG- LPS
Particles
A
(U
L CD86
10' 10' 
10' 10' 
10
100 100 10 100
80 80 80 so CD80
60 60 60 0
40 40 40 40
20 20 20  20
00 0 0
100 101 102 103 10 100 101 102 103 104 100 101 1 02 10 10l 101 102 103 104
Intensity
Figure 3.12. Surface phenotype of dendritic cells incubated with different agents
for 24 hours followed by staining with specific antibodies. (A) Expression of IAb
and CD40 versus CD11c on bone marrow dendritic cells. The numbers in marked
regions represent fraction of maximally matured dendritic cells; (B) Grey
histograms represent corresponding isotype controls, dotted lines represent
solution control, and solid lines represent samples.
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3.3.6.2 Secretion of inflammatory cytokines by dendritic cells
Activated dendritic cells secrete a battery of pro-inflammatory cytokines such as
IL-12, IL-6, and TNF-a. We thus examined the secretion of inflammatory cytokines by
DCs incubated with CpG-modified nanoparticles, compared to the cytokine production
elicited by culturing DCs in the presence of equivalent amounts of soluble CpG or with
particles lacking CpG. Uncoated ova particles triggered low/neglible levels of IL-12p40,
IL-12p70, IL-6, and TNF-a [194,195] (Figure 3.13A-D). In contrast, DCs incubated with
CpG-coated hydrogel particles secreted high levels of these inflammatory cytokines,
and in comparison to soluble oligonucleotides, the onset of cytokine secretion was
triggered by ~10-fold lower total CpG doses using CpG-coated nanoparticles. By
contrast, IL-10 secretion (Figure 3.13E) was low in response to both soluble CpG and
CpG-coated hydrogel particles treatment.
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Figure 3.13. Secretion of various cytokines - (A) IL-12p40; (B) IL-12p70; (C) IL-6;
(D) TNF-a; and (E) IL-10 - by dendritic cells when incubated with soluble CpG (,),
unmodified particles (m), and CpG-coated particles (A).
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3.3.7 In vitro T cell activation by activated dendritic cells
3.3.7.1 In vitro activation of primed T cells
In order to study the effect of efficient antigen delivery to dendritic cells on T cell
activation, antigen-incubated dendritic cells were co-cultured with ova-specific CD8+
(OT-I ) or CD4' (OT-Il ) T cell blasts for 48 h followed by measurement of IL-2 secretion
by activated T cells. As shown in Figure 3.14, both CD4+ and CD8+ T cells secreted
significantly higher levels of cytokine and the onset of cytokine secretion occurred at
lower antigen concentration when antigen was delivered as hydrogel particles than
when delivered as soluble antigen. In addition, no cytokine secretion was observed with
BSA-containing hydrogel particles suggesting that T cell activation is antigen-specific
and cytokine secretion is not a result of phagocytosis of particulate matter.
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Figure 3.14. IL-2 secretion by primed T cells when incubated for 48 h with bone
marrow dendritic cells and unmodified ova-loaded hydrogel particles (m) or
soluble ovalbumin (+) (A) CD4* T cells (B) CD8* T cells. CD8+ T cell blasts
activation was also studied with BSA-loaded hydrogel particles (x).
3.3.7.2 In vitro activation of naive T cells
Dendritic cells that internalize particulate antigen proteolyze engulfed protein into
short peptide fragments, which are intracellularly loaded onto Major Histocompatibility
Complex (MHC) molecules and trafficked to the cell surface for presentation to T cells.
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T cells expressing the cognate receptor for antigen presented by DCs secrete a battery
of cytokines and proliferate after prolonged contact with the antigen-loaded dendritic cell.
To measure the efficacy of the endpoint of particle-based antigen delivery to dendritic
cells- presentation of antigenic peptides to T cells- we measured the production of IL-2
(a critical cytokine for T cell proliferation produced in an autocrine manner by activated
T cells) by T cells incubated with gel particle-pulsed or control dendritic cells. For these
experiments, DCs were 'pulsed' for 4 hrs by incubation with different doses of ova
protein (mixed with soluble CpG to drive DC activation) or CpG-modified ova gel
particles. The cells were washed to remove uninternalized protein/particles and then
co-cultured with naYlve CD8 ÷ or CD4 + ova-specific T cells for 72 hrs. Finally, IL-2
present in the supernatant was measured by ELISA to quantify T cell activation. CD8 ÷
ova-specific T cells incubated with soluble ova-pulsed DCs secreted IL-2 only in
response to high soluble ova pulse concentrations, with negligible activation for pulse
concentrations less than 50 pg/mL. However, when ovalbumin was delivered in gel
particles, T cells were activated at ~10-fold lower doses of antigen (Figure 3.15A). This
is likely due to the enhanced internalization of antigen in a particulate form relative to
soluble protein, as well as CpG-enhanced uptake of ova-loaded particles via DC cell
surface DNA receptors. A similar trend was observed for the activation of CD4 + ova-
specific T cells (Figure 3.15B); IL-2 production reached higher levels and was induced
at -10-fold lower total ova doses when delivered in the gel particle form. When CFSE-
labeled na've T cells were co-cultured with dendritic cells incubated with hydrogel
particles, T cells were observed to proliferate as determined by CFSE-dilution; soluble
ova did not induce detectable proliferation of na've T cells (Figure 3.15C and 3.15D).
Altogether, these results indicate that the ova-loaded hydrogel particles efficiently
deliver antigen into both the MHC class I and MHC class II antigen presentation
pathways, and provide DCs with the ability to activate naYve CD8 ÷ and CD4 + T cells, as
required for robust T cell-mediated immune responses in vivo.
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Figure 3.15. Na've T cell activation by dendritic cells incubated with hydrogel
particles. (A,B) IL-2 secretion by activated T cells after 72 h of co-culture with
dendritic cells. Solid line represents hydrogel particles and dotted line is soluble
ovalbumin. (C,D) Na've T cell proliferation after 60 h when co-cultured with
dendritic cells in presence of antigen in different forms. The CFSE fluorescence
intensity of the labeled T cells is halved by each cell division that occurs. (A,C)
CD8 ÷ (OT-I) T cells, (B,D) CD4 ÷ (OT-II) T cells.
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3.3.8 In vivo activation of lymphocytes by hydrogel particles
3.3.8.1 Activation of B cell and generation of anti-ova IgG antibodies in
immunized mice
To determine the effect of antigen-loaded hydrogel particles on B cell activation
in vivo, C57BI/6 mice were immunized with soluble ovalbumin in the presence or
absence of soluble CpG oligonucleotide, ova-loaded hydrogel particles, or CpG-coated
hydrogel particles, and anti-ova IgG titers in serum were traced over 7 weeks; mice
immunized with PBS or ovalbumin mixed in CFA were used as negative and positive
controls, respectively (Figure 3.16). In these experiments, the total quantity of antigen
(100 jig) and CpG (8 gg) were fixed for each mode of delivery. Mice immunized with
soluble ovalbumin had IgG titers < 100 for the duration of the experiments, and the
addition of soluble CpG had no effect on the soluble ova response. By contrast, ova
nanoparticles, CpG-modified particles, and ova emulsified in CFA all elicited significant
IgG titers by 7 weeks. CpG coating of the nanoparticles significantly enhanced the
kinetics of antibody titer development but the final levels of IgG obtained after 7 weeks
were not significantly higher for CpG-modified particles (p =0.07). The slightly higher
total IgG titers elicited by ova in CFA at 7 weeks relative to CpG-coated hydrogel
particles was statistically significant (p = 0.015). Antibody titers elicited by CpG-coated
particles showed a marginal increase compared to soluble CpG mixed with CpG-free
hydrogel particles at 7 weeks but the increase was not statistically significant (p = 0.42).
Thus, CpG-coated hydrogel particles activate B cells effectively within one week of
immunization resulting in high antigen-specific antibodies in the sera of immunized mice
and the antibody titers increase rapidly to reach comparable levels as ova in CFA
without any apparent toxicity associated with the nanoparticles.
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Figure 3.16. Anti-ovalbumin total IgG titers in the serum of C57BI/6 mice 1, 3, 5,
and 7 weeks after s.c. immunization with 100 pg ovalbumin in different forms:
soluble ova, soluble ova mixed with 8.5 pg CpG, hydrogel nanoparticles,
nanoparticles coated with 8.5 pg CpG, or ova emulsified in CFA. Antibody titers
were calculated by endpoint dilution assay. Asterisks denote 7 week data
statistically different from ova + soluble CpG (p < 0.01); **, statistically different
from CpG-particles at 7 weeks (p < 0.05). Data shown from one representative of
two independent experiments.
3.3.8.2 Immunization with CpG-nanoparticles triggers CD4 ÷ and CD8 + T cell
responses comparable to antigen in CFA
Activated dendritic cells loaded with antigen can trigger nai"ve T cells to
proliferate and differentiate into effectors capable of secreting characteristic cytokines
such as interferon-y (IFN-y) [196,197]. To assess T cell responses, C57B1/6 mice were
immunized with soluble ova, ova nanoparticles, CpG-coated nanoparticles, or ova
emulsified in CFA, as described above for assessing B cell responses. When
lymphocytes were isolated from draining lymph nodes and spleens of immunized mice 7
d after a single immunization and restimulated ex vivo with MHC class I or class II ova
peptides, cells from soluble ova-immunized mice (with or without added soluble CpG)
showed no statistically significant IFN-y secretion compared to cells from sham-
immunized mice (Figure 3.17A and B). Splenocytes from mice immunized with ova-
loaded hydrogel nanoparticles lacking CpG modification also failed to produce IFN-y
except in CD8 ÷ T cells from the draining lymph nodes. However, when antigen and CpG
were co-delivered by hydrogel particles, responding CD4 ÷ (Figure 3.17A) and CD8'
(Figure 3.17B) T cells were detected. In comparison, mice immunized with ovalbumin
and CFA showed insignificant T cell responses in the spleen. Thus, CpG-coated
nanoparticles were able to induce primary systemic responses from both CD4 ÷ and
CD8 ÷ T cells detectable after a single immunization, comparable to or greater than the
response elicited by CFA, one of the strongest adjuvants known in mice.
In most vaccine strategies, antigen and immunostimulatory factors are physically
mixed and delivered by co-injection. To determine whether delivery of CpG bound to the
surfaces of nanoparticles would enhance the T cell response compared to mixing the
same quantity of soluble CpG with unfunctionalized nanoparticles, mice were
immunized with ova in nanoparticles, nanoparticles mixed with soluble CpG, or
nanoparticles coated with CpG, and T cell responses were assessed after 7 d. As
shown in Figure 3.18A, IFN-y secretion by splenocytes from mice immunized with ova
nanoparticles without CpG or with soluble CpG was low and significantly lower than that
induced by splenocytes from mice immunized with CpG conjugated to nanoparticles;
CD8÷ T cell activation was significantly higher for CpG-particles than for nanoparticles
delivered with soluble CpG (p = 0.03) . To determine if this functional difference was
accompanied with higher effective primary T cell expansion, we stained splenocytes
with peptide-MHC class I tetramers (SllNFEKL/H-2Kb) to determine the frequency of
ova-specific CD8 ÷ T cells (Figure 3.18B and C). Ova nanoparticles without CpG
contained -0.32% of ova-specific CD8 ÷ T cells; this frequency increased to 1.23% with
co-delivery of soluble CpG with ova nanoparticles, and further increased to 2.29% when
CpG and antigen were co-delivered on a single particle (Figure 3.18C). Thus, CpG-
coated hydrogel nanoparticles activate na've T cells in vivo effectively resulting in
proliferation of CD8* antigen-specific T cells and elicitation of effector function relative to
unmodified nanoparticles and soluble antigen.
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Figure 3.17. C57BI/6 mice were immunized with antigen in different forms and
lymphocytes from the inguinal (draining) lymph nodes (hashed bars) and spleen
(solid bars) were restimulated in vitro with MHC class II or class I peptides to
measure (A) CD4 + and (B) CD8 ÷ T cell responses, respectively. Shown are IFN-y
levels measured in supernatants of restimulated lymphocytes after 48 hrs.
Asterisks denote samples statistically different form PBS control (p < 0.05). Data
shown from one representative of two independent experiments.
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Figure 3.18. (A) C57BI/6 mice were immunized with ova nanoparticles without
CpG, soluble CpG, and particle-bound CpG. Splenocytes were isolated after 1
week and restimulated with MHC class I or class II peptides and IFN-y levels were
measured after 48 hrs as described in Section 3.3.8.2. Asterisks denote samples
statistically different from PBS control (p < 0.05), and ** denote statistically
significant difference from ova nanoparticles delivered along with soluble CpG (p
< 0.05). (B) Splenocytes from experiment in (A) were stained with anti-CD8a and
ova-tetramer, and analyzed by flow cytometry to determine frequency of ova-
specific CTLs in immunized mice. Shown are the density plots with CD8 ÷
tetramer ÷ cells in upper-right quadrant. (C) Mean frequency (n = 4) of ova-specific
CTLs for ova nanoparticles delivered without CpG, soluble CpG, or particle-
bound CpG.
3.3.8.3 Generation of CD8 ÷ memory T cells in mice immunized with hydrogel
particles
Generation of memory T cells and B cells is an important aspect of vaccination in
order to protect the host from the pathogen of interest during infection. An effective
prophylactic vaccine for viral infections or cancer should elicit a long term CD8* memory
T cell response. To determine whether conjugation of CpG directly to nanoparticles
influenced levels of memory T cells induced by vaccination, we measured ova-directed
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in vivo cytolytic activity 60 days after immunization of mice with ova nanoparticles, by
injecting immunized mice with a mixture of syngeneic ova-pulsed splenocytes and
unpulsed splenocytes labeled with high and low levels of CFSE, respectively. Loss of
the ova-pulsed splenocytes relative to the unpulsed transferred cells was measured
after 24 hrs by flow cytometry. As shown in Figure 3.19, immunization with CpG-coated
nanoparticles elicited 35% specific cytolytic activity; ova particles delivered with soluble
CpG elicited only 23% specific killing. Thus, co-delivery of antigen and TLR ligands from
the hydrogel nanoparticles led to more effective long-term CD8' T cell memory.
These results indicate that physical co-display of antigen and TLR ligands
together on pathogen-sized particles enhances not only the initial T cell responses but
also the induction of long term memory relative to soluble co-injection of these same
signals.
Particles + CpG CpG-Particles Ova + CFA
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CFSE
Figure 3.19. Mice were immunized as described in Section 3.3.8.2 followed by
intravenous injection of CFSE-labeled syngeneic splenocytes loaded with
SIINFEKL peptide after 60 days. Memory response was quantified as % cytolytic
activity. Shown are cell populations depicting control (CFSEIo) and ova peptide-
pulsed target splenocytes (CFSEhi). Grey solid histograms represent results from
immunized animals and black solid lines are cells recovered from a sham-
immunized control. The values shown in the histogram charts are the mean
values of cytolytic activity.
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3.4 Discussion
Pluronic PEO-PPO-PEO triblock copolymers form micelles in aqueous solutions
when present at concentrations above the CMC (critical micellization concentration) and
CMT (critical micellization temperature) [198]. At higher temperatures, the poly(ethylene
oxide) blocks of pluronics dehydrate, phase-separating into polymer-rich and polymer-
poor phases above the cloud point temperature. The PEO-PPO-PEO triblock F-68 is a
relatively hydrophilic member of the pluronic family of copolymers, with a cloud point in
the pure water of ~105 oC (obtained by extrapolation) [179]. The cloud point of pluronics
is strongly influenced by the presence of monovalent salts, which is thought to be due to
repulsion between small, weakly polarizable ions and the weakly polarizable PEO
blocks [179,199], an effect also observed for PEO homopolymers in salt solutions [200].
For pluronic F-68, Bahadur et al. [179] have previously demonstrated that the cloud
point can be lowered by 50 oC on addition of 1 M KF to an aqueous F-68 solution.
Similarly, we observed that presence of -5.5 M NaCI lowered the cloud point of pluronic
F-68 to 37 OC resulting in phase separation of pluronic as evident by obvious clouding of
initially clear solution and an increase in the hydrodynamic diameter of pluronic
aggregates from ~35 nm at 32 oC to -400 nm at 37 oC. In previous work, Drummond
and Peppas reported that poly(ethylene glycol) methacrylate (PEGMA) could be
successfully polymerized in a suspension polymerization by salting out PEGMA
monomers in a saturated sodium chloride solution [201]. This report and the interesting
phase behavior of F-68 in aqueous salt solution inspired us to utilize the temperature-
induced phase separation of pluronic combined the with well-known salting out behavior
of both poly(ethylene glycol) [202] and proteins [203] in high ionic strength solutions to
co-localize protein and hydrogel precursor monomers together for polymerization in an
organic-solvent free system. Hydrogel particles thus formed were monodisperse with a
mean hydrodynamic diameter of 500 nm, and contained up to 80% of the particle dry
weight as protein. High protein loading per particle helps in delivering high doses of
antigen intracellularly to dendritic cells, which was shown to elicit strong T cell activation.
To elicit a protective T cell response, vaccines must deliver both antigen and an
activating danger signal to dendritic cells, which triggers their differentiation from an
immature antigen-collecting state to a mature antigen-presenting and T cell-activating
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state [5,22]. Likewise, productive nalve B cell responses only occur if B cells contact
antigen coincident with danger signals. Hydrogel particles provided negatively-charged
groups on their surfaces through the incorporation of methacrylic acid into the gel
particles, which were used for adsorption of immunostimulatory CpG oligonucleotides
via sequential adsorption of poly(L-arginine) followed by CpG. Poly(L-arginine) was
found to be a suitable cationic biopolymer for functionalization of hydrogel particles as it
is less cytotoxic than poly(L-lysine) [204,205]. We found that coating the anionic
nanoparticles with low molecular weight poly(L-arginine) (~1 kDa) did not result in high
loading of CpG oligonucleotides on the particles, whereas high molecular weight poly(L-
arginine) (> 70 kDa) caused cytotoxicity in DCs; 10 kDa poly(L-arginine) was however
found to be optimal (data not shown). This is in contrast with studies in which Jurkat
cells were incubated with poly(arginine) of different lengths and a low molecular weight
polymer (~2 kDa) was found to be effective in transporting dye to the interior of cells
[206]. We observed that as poly(L-arginine) concentration was increased from 0.5
mg/mL to 5 mg/mL, CpG coupling efficiency increased from 30% to ~100% with a
corresponding increase in IL-12p40 secretion from dendritic cells incubated with these
CpG-coated hydrogel particles. Thus, poly(L-arginine) coating of hydrogel particles
provided functional groups on the particle surface for electrostatic coupling of
immunostimulatory CpG oligonucleotides, and these functionalized hydrogel particles
delivered CpG to dendritic cells intracellularly at high doses for interaction with their
cognate receptor TLR9. In general, this electrostatic adsorption approach should be
applicable to a variety of other DC-stimulating ligands to stimulate dendritic cells
through different Toll-like receptors.
Professional antigen presenting cells such as dendritic cells are highly efficient
phagocytes and rapidly internalize submicron-sized biological or synthetic particles
[5,10,115]. We incubated DQ-ovalbumin-loaded hydrogel particles with dendritic cells
and antigen uptake was found to be highly efficient when antigen was delivered in
particulate form compared to antigen delivery as soluble protein even after 18 h.
Efficient delivery of antigen coupled with delivery of high doses of antigen per particle
not only induced cross-presentation of antigen but also in efficient processing of antigen
and subsequent presentation of antigen on MHC molecules to T cells.
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For protein antigens to elicit T cell responses, these biomacromolecules must be
delivered to intracellular processing compartments in dendritic cells, where DCs localize
a variety of enzymes designed to degrade (digest) proteins into short polypeptides that
can be loaded onto class I and class II major histocompatibility complex molecules.
Typically, protein carriers are designed to release antigens once the carrier is
internalized into the acidic vesicles (phagolysosomes) used by dendritic cells to
internalize particles [127]. In recent elegant studies, this release has been engineered to
be selectively triggered by the pH change encountered in this intracellular compartment
(from pH 7.4 outside the cell to pH 5.5-6.5 in the phagolysosome [207]) [142,208,209].
Such a selective release could clearly be engineered into the hydrogel particle synthesis
approach studied here via flexible nature of free-radical polymerization chemistry
through incorporation of degradable crosslinkers on the basis of protease-sensitive
peptides [210], hydrolysable polyesters [211,212], reducible disulfide-bonded repeat
units [213], phosphazene derivatives [214,215], or acid-sensitive cross-linkers [142].
However, when hydrogel particles were incubated with a phagolysosomal protease,
cathepsin D, ovalbumin encapsulated in hydrogel particles was digested by the enzyme
and fractions were found to be identical to those obtained from cathepsin D digestion of
soluble ovalbumin. The peptide fragments were found to range between approximate
molecular size of 2 to 30 kDa as reported previously also for ova digestion by cathepsin
D [216]. The enzyme tested, cathepsin D, is a ubiquitous protease involved in antigen
processing in the endosomes/phagosomes of antigen presenting cells [216,217]. This
demonstrates that encapsulated ovalbumin can be processed by phagolysosomal
proteases when hydrogel particles are phagocytosed by dendritic cells resulting in
generation of peptides that will be loaded onto MHC molecules.
As expected from prior studies of particulate antigen delivery, hydrogel
nanoparticles elicited greatly enhanced MHC class I presentation of ova epitopes. As
stated above, antigen uptake by DCs via nanoparticles was much faster than soluble
ova internalization. However, if DCs were incubated with antigen for 18 hrs, allowing
time for soluble ova uptake to occur (nanoparticles afforded only a 1.4-fold greater
fraction of DCs positive for antigen uptake relative to soluble ova at this time-point), the
amount of ova-derived class I peptide-MHC complexes per cell was still ~4.5-fold
105
greater for DCs loaded with nanoparticles, suggesting that enhanced class I peptide
presentation by DCs encountering particulate antigen is not simply a matter of
enhanced antigen uptake alone. Studies of antigen presentation by ova-CpG
conjugates have shown that CpG signaling enhances cross presentation of soluble ova
protein [188,189,191]. In the case of ova-loaded nanoparticles, CpG-functionalization
did not elicit further enhancement of cross-presentation above that obtained with the
'bare' particles, suggesting that in the present case, cross-presentation is already
maximally induced by the particulate mode of delivery.
Hydrogel particles delivered high doses of CpG oligonucleotide to dendritic cells
resulting in effective interaction between CpG oilgos and their cognate receptor, TLR9
in the phagolysosomes of dendritic cells. CpG-coated hydrogel particles resulted in
significantly increased expression of costimulatory molecules such as CD40, CD80,
CD86, and MHC class II on the surface of dendritic cells compared to when dendritic
cells were incubated with soluble CpG alone. CpG-coated hydrogel particles also
induced secretion of pro-inflammatory cytokines such as IL-12, IL-6, and TNF-a by
dendritic cells; cytokine secretion could be detected at nearly 10-fold lower CpG
concentration when delivered in particulate form than when delivered as soluble
oligonucleotide. CpG has a dissociation constant of ~ 200 nM with TLR9 [192], and in
agreement with that, soluble CpG induced cytokine secretion at oligo concentration -
500 nM. However, hydrogel particles result in a high concentration depot of CpG oligos
in the phagolysosomes and cytokine secretion was detectable at an overall
concentration as low as 50 nM for all cytokines analyzed. This is in contrast with
molecular ova-CpG conjugates that resulted in increased antigen uptake through
receptor-mediated endocytosis involving nonspecific DNA receptors on dendritic cells
surfaces, but reduced cytokine secretion compared to soluble CpG [152].
In vivo, we found that while soluble ova adjuvanted with CpG elicited no antibody
response (a result seen by others [102]), a single injection of hydrogel nanoparticles
activated B cells and induced levels of anti-ova IgG comparable to ova emulsified with
CFA. We showed by staining hydrogel nanoparticles with a monoclonal anti-ova
antibody that the particles present ova epitopes on their surfaces [181], and we believe
this multivalent presentation of antigen epitopes may be responsible for the enhanced
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antibody response seen with the ova-loaded nanoparticles. On the T cell side of the
immune response, a single injection of CpG-coated particles, but not uncoated particles
or soluble ovalbumin, elicited IFN-y-producing CD4' and CD8 ÷ T cells in the spleen and
draining lymph nodes to levels comparable to or greater than ova in CFA. Notably,
these responses were obtained without overt inflammation visible at the injection site, in
contrast to the strong inflammation typical of CFA (data not shown). Furthermore,
although conjugation of CpG to nanoparticles did not appear to influence the magnitude
of antibody responses, we observed that CpG bound to nanoparticles resulted in a
greater frequency of ova-specific CD8' T cells, higher CD4 ÷ and CD8 ÷ T cell responses
in the spleen, and eventually creation of a stronger long term memory CD8 ÷ T cell
response compared to soluble CpG mixed with the nanoparticles. These results are
consistent with previous studies showing that co-encapsulation of antigen and CpG
within synthetic biodegradable particles improves T cell activation significantly relative to
antigen encapsulated in particles mixed with soluble CpG [102,149,154]. Development
of a strong and long-lasting memory response is necessary for targeting virally infected
cells or tumor cells in both therapeutic and prophylactic settings [197,218-220]. Notably,
the frequency of antigen-specific CTLs elicited by this nanoparticle-based vaccine
(Figures 3.17D and 3.17E) is comparable to that observed with various DNA- and
protein-based vaccines that resulted in tumor regression or strong anti-viral response
[149,221-223]. The lasting significant specific CTL activity detected in immunized mice
suggests the potential for this system to be highly effective in prophylactic applications.
Altogether, these results suggest that co-display of antigen epitopes and TLR ligands on
the surface of antigen-loaded nanoparticles is an effective strategy for potent B cell and
T cell activation in vivo.
3.5 Conclusions
Aqueous two-phase systems have long been utilized for protein purification,
because the phase-separation process drives aggregation of proteins without
denaturation. Pathogen-mimetic hydrogel particles were synthesized by a salting out-
based miniemulsion polymerization technique to deliver antigen and CpG
oligonucleotide in concert to dendritic cells. By this process, ovalbumin was
107
encapsulated in poly(ethylene glycol) particles in the absence of organic solvents at
near-physiological temperatures. These hydrogel particles were 500 nm in size which is
intermediate between the sizes of bacteria and viruses and co-display antigen and TLR
ligands at their surfaces mimicking the gross structure of pathogens. Protein antigen
was stably encapsulated in the hydrogel particles in the presence of serum but was
accessible to antigen-processing enzymes in vitro and was processed and potently
presented to both CD4 ÷ and CD8 ÷ T cells by dendritic cells that phagocytosed the gels.
Delivery of immunostimulatory signals at high dose by hydrogel particles resulted in
efficient antigen presentation by dendritic cells and dendritic cell maturation measured
as secretion of inflammatory cytokines and upregulation of costimulatory molecules.
The activation of B cells and T cells in vivo resulted in high anti-ovalbumin antibody
titers and na've T cell activation in draining lymph nodes and spleen, and generation of
memory CD8 ÷ T cells detectable at 60 days post-immunization. Thus, co-delivery of
antigen and TLR ligands to dendritic cells is highly effective for dendritic cell activation,
and as observed in our studies, absence of any signal is unable to induce effective
lymphocyte activation in vivo. This system may be used as a potent vaccine for
diseases that require recruitment of both B and T cells. Moreover, the ability to use
multiple dendritic cell modulation factors on the surface of pathogen-mimetic particles
could allow the induction of a range of cytokines in dendritic cells tailored to combat
specific pathogens.
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4. Co-delivery of Chemokine and Antigen/Activation Signals
to Dendritic Cells
4.1 Introduction
Dendritic cells are sentinels of the immune system, which scan their environment
in search of pathogens. Pathogens are processed by dendritic cells resulting in antigen
presentation on MHC molecules and DC maturation [5]. Dendritic cells are thought to be
the only antigen presenting cells capable of priming naive T cells in vivo and are
superior to other antigen presenting cells (namely, macrophages and B cells) in antigen
processing and T cell activation [54]. Therefore, vaccines have been designed to target
dendritic cells for delivery of antigen for most effective immune response. However,
dendritic cells are rare and therefore targeting strategies need to be highly specific and
efficient to locate dendritic cells and deliver antigen to them with high efficiency. Martin-
Fontecha et al. demonstrated by injection of antigen-loaded dendritic cells that the
magnitude of T cell responses correlated with the number of dendritic cells injected into
mice [63]. In an attempt to apply this concept directly in the clinic, dendritic cell vaccines
involve the ex vivo differentiation of monocytes from a patient that are then cultured in
presence of antigens and adjuvants to activate the cells effectively. These activated
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dendritic cells are injected back into the patient to prime the immune system against the
antigen of interest [36,224,225]. Despite promising results obtained with dendritic cell
vaccine therapy, various subunit vaccines are sought due to the ease of application of
subunit vaccines and their much lower cost. To enhance efficiency of antigen delivery to
DCs, subunit vaccines are often based on the principle of using a targeting ligand for
intracellular delivery of antigen to dendritic cells along with a maturation signal.
Strategies have been designed to target nonspecific DNA receptors through CpG
conjugation to antigen [152,153], DEC205 by conjugating anti-DEC205 to antigen or
antigen-loaded nanoparticles [24,149,226], Fcyreceptors through use of IgG-conjugated
antigens [227], glycolipid globotriacylceramid, by fusing Shiga toxin B to the tumor
antigen [228], use of bi-specific antibody to target antigen-encoding adenovirus to
dendritic cells via CD40 [229-231], or targeting of antigens conjugated to a TLR2 ligand,
S-[2,3-bis(palmitoyloxy)propyl]cysteine [232]. These strategies have shown promising
results in vitro and in vivo.
In contrast to the DC-targeting strategies mentioned above, attraction of dendritic
cells and DC precursors to the immunization site by means of a chemoattractant
(reverse-targeting) has been studied by some groups to mimic the physiological
sequence of events that occur in case of a pathogen infection. In case of an infection,
inflammatory signals comprising of chemokines released by epithelial cells [15,16],
bacterial fragments [16], and neutrophils [233] form a gradient in the environment by
diffusion, which induces DC chemotaxis along the concentration gradient towards the
site of infection [49,52,234]. Chemokines targeting dendritic cells such as fMLP [235],
CCL20 [42,68,69], MIP-3P3 [40,41,236], CCL27 [237] have been used in vitro and in vivo
to attract dendritic cells to tumors or sites of immunization where dendritic cells were
primed to present antigen to T cells and initiate an immune response [238]. Interestingly,
attraction of DCs to tumor sites via constitutive production of chemokine from
transfected tumor cells or fibroblasts caused significant tumor regression, while injection
of single bolus doses of recombinant chemokines did not elicit anti-tumor immunity
[42,67,69]. However, the use of plasmids encoding chemokine may not give control
over chemokine gradient and duration of immune response as is with the controlled
release systems that release recombinant chemokines [239]. Comparing these systems
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that modulate DC trafficking with physiological events, inflammatory signals that attract
dendritic cells are present for the duration of the inflammation following which
chemokine levels return to basal levels [240]. Taking this into consideration, we
developed microparticles that release chemokines for a specific duration to attract
dendritic cells followed by delivery of antigen and maturation factor to the attracted cells.
This system was designed to mimic a pathogen infection whereby inflammatory signals
from individual microparticles mimicked local epithelial cells secreting chemokines into
their microenvironment (Figure 1.5).
Our approach was to use alginate microparticles that encapsulated the
chemokine CCL20 and the hydrogel nanoparticles described in Chapter 3. We initially
sought to co-encapsulate CCL20-loaded PLGA microspheres and hydrogel
nanoparticles in the alginate microparticles. However, chemokine release from PLGA
microspheres was not effective in sustained attraction of DCs possibly due to low
chemokine loading in PLGA microspheres and loss of chemokine as a result of acidic
products of PLGA hydrolysis; direct loading of CCL20 in alginate microparticles allowed
higher loading of the chemokine in the microspheres with minimal damage to the protein
during or after encapsulation process. Alginate is a bacterially-derived or algae-derived
polysaccharide-based biopolymer that has been widely studied and used in
biotechnology applications. Alginate is formed from blocks of guluronic acid and
mannuronic acid monomers that possess a negative charge, which was used for
electrostatic coupling of cationic chemokine to the polymer matrix. Multivalent cations
such as calcium cross-link guluronic acid between chains causing formation of a cross-
linked matrix that was used to encapsulate hydrogel nanoparticles. We observed that
controlled release of chemokine from alginate microparticles attracted dendritic cells to
the individual microparticles which were then delivered antigen and CpG
oligonucleotides. This system resulted in an enhanced and selective delivery of antigen
to dendritic cells in vitro. The simplicity of the system also enables us to co-deliver
various chemokines and other DC modulating factors to dendritic cells and other
immune cells for a desired immune response. In addition, ultra-localization of
nanoparticles prevents delivery of antigen and maturation signals to non-responding
cells, which contributes towards effective use of an antigen to obtain a productive
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immune response. Localized drug delivery has been proposed to be useful in inducing a
localized effect of the therapeutics, reducing the side effects of the therapy, and in
obtaining a more productive response [241]. This was achieved in our system through
ultra-localization of hydrogel nanoparticles that were delivered only to the cells that were
in the immediate vicinity of the microparticles. In addition, use of controlled release of
chemokines to localize cells of interest in a certain location can have applications in
design of medical devices, organogenesis, and embryonic development.
4.2 Materials and Methods
4.2.1 Synthesis of alginate microparticles for co-encapsulation of CCL20
and ova-loaded hydrogel nanoparticles
Alginate microparticles were synthesized using a water-in-oil single emulsion
technique. Tween 80 (0.5 mL) and Span 80 (1.5 mL) were added to iso-octane (50 mL)
with stirring. Addition of Tween 80 turned the solution cloudy, but the cloudiness
resolved as Span 80 was added. The surfactant solution was stirred at 8,000 rpm using
an Ultra Turrex T-25 homogenizer for 4 min before use. An aqueous phase was
prepared by adding 1 gg of CCL20 to 400 [iL 1% w/v low viscosity sodium alginate
(Sigma, USA), and then dissolving 10 mg low endotoxin BSA (Sigma, USA) in the
sodium alginate solution followed by addition of 100 iL of a CpG-coated DQ-ova-
containing hydrogel nanoparticles suspension (10 mg/mL). The suspension was well-
mixed, added to the iso-octane/ surfactant solution, and homogenized for 3 min at 8,000
rpm. This was followed by addition of 25 iL CaCI2 (5% w/v) to the emulsion to crosslink
the alginate, and homogenization for 4 min at 8,000 rpm. The resulting alginate
microparticles were pelleted at 4,500 g for 10 min and washed once in iso-octane at the
same speed, then resuspended in 1 mL unsupplemented RPMI imaging medium and
transferred to an eppendorf tube. The microparticles were pelleted at 10,000 g for 3 min
and the aqueous-phase supernatant was collected for estimation of the chemokine
encapsulation efficiency. Alginate microparticles were washed 3x in RPMI imaging
medium. To remove unencapsulated hydrogel nanoparticles or nanoparticle aggregates,
112
alginate microparticles were pelleted at 100 g for 30 sec, and the supernatant was
gently pipetted off. Alginate microparticles were resuspended in 1 mL RPMI medium
and stored at 4 'C until use.
4.2.2 Characterization of alginate microparticles
4.2.2.1 Encapsulation efficiency of chemokine in alginate microparticles
Supernatants were collected during the aqueous washes of the alginate
microparticle synthesis for estimation of the chemokine encapsulation efficiency.
Suitable dilutions of supernatants were analyzed by ELISA to determine the chemokine
concentration and encapsulation efficiency was calculated as:
Encapsulation Efficiency = I1 - Amount of CCL20 in supernatant 100% [13]En slto iny=1- x 
Amount of CCL20 added
4.2.2.2 Kinetics of chemokine release from alginate microparticles
An alginate microparticle suspension (100 [L) was diluted to 500 pL with
complete RPMI medium containing 10% FCS. The microparticles were incubated at 37
oC with shaking, and 500 [L supernatant samples were collected by pelleting the
microparticles at 10,000 rpm for 3 min. Supernatant removed was replaced with fresh
complete RPMI medium. The supernatants were analyzed using a CCL20 ELISA kit
(R&D Systems, USA) to determine the concentration of CCL20 released into the
medium.
4.2.2.3 Determination of hydrogel nanoparticle encapsulation efficiency
Supernatants were collected during the aqueous wash of the alginate
microparticle synthesis for estimation of the hydrogel particle encapsulation efficiency.
Known volumes of supernatants were analyzed by flow cytometry (FACS Scan, Becton
Dickinson, USA) to quantify the number of unencapsulated nanoparticles remaining in
the supernatants.
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4.2.2.4 Determination of alginate microparticle water content
Alginate microparticles were pelleted at 16,000 g for 4 min, and the pellet was
blotted on a filter paper to remove excess water. The pellet was transferred to pre-
weighed filter paper and the wet mass was measured. The particle pellet was then dried
at 70 oC under vacuum overnight followed by measurement of the dry particle mass.
The water content of the microparticles was directly determined as the difference of
these two measurements.
4.2.2.5 Determination of alginate microparticle density and mean diameter
Alginate microparticle suspension was directly counted for particle density using
a hemocytometer. The particle size distribution and mean diameter of alginate spheres
was determined using a Vi-Cell Counter (Beckman Coulter).
4.2.3 Analysis of antigen uptake by dendritic cells by flow cytometry
As an in vitro model of DC responses to alginate injected subcutaneously, DCs
and alginate microspheres were suspended together in collagen gels. Bone marrow
dendritic cells (1 x 106 cells) were uniformly mixed with 10 pL alginate microparticles
with or without chemokine and containing CpG-coated DQ-ova-containing hydrogel
nanoparticles (3.2 x10 6 particles/mL), or 1 pL CpG-coated fluorescent DQ-ova-
containing hydrogel nanoparticles (5.35 xl1010 particles/mL) in 1 mL of 1.2 mg/mL bovine
collagen (BD Biosciences, USA), and added to 24-well tissue culture treated plates.
Collagen was gelled at 37 OC, 5% CO2 and the cells were incubated for 24 hr within the
gels. After 24 hr incubation, 100 ptL of 4000 U/mL collagenase D was added to each
well, and the collagen matrix was broken down into small fragments by pipetting. The
samples were incubated with collagenase D for 1 hr at 37 'C with shaking to digest the
collagen. The resulting cell suspensions were transferred to 1.2 mL microtiter tubes,
washed 2x in FACS buffer, and stained with anti-CD11c and anti-CD16/CD32
antibodies. The stained cells were analyzed using flow cytometry (FACS Scan, Becton
Dickinson, USA) to determine antigen uptake by dendritic cells.
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4.2.4 Time-lapse videomicroscopy analysis dendritic cell attraction to
alginate microparticles
Bone marrow dendritic cells (1 x 106 cells) were uniformly mixed in 1.2 mg/mL
bovine collagen with 10 tL/mL alginate microparticles containing CCL20 and CpG-
coated DQ-ova-containing hydrogel nanoparticles (3.2 xl06 particles/mL). The
cell/alginate microparticle suspension was added to a 35 mm petridish or 2-well labtek
chamber (Nunc) and the collagen was gelled for 30 min at 37 OC, 5% CO2. The sample
was then placed on the environmental stage of a Zeiss Axiovert 200 microscope stage
maintained at 37 OC, 5% CO2 during the course of imaging. Phase contrast and
fluorescence images were collected from 9 fields of view every 2 min as described
earlier in Chapter 2. Motile cells in the culture were analyzed for determining cell paths
and migrated distances using MetaMorph software (Universal Imaging).
4.2.5 Bone marrow-derived macrophage cell culture
Bone marrow-derived macrophages were generated by a procedure similar to
that for bone marrow-derived dendritic cells in Appendix 10 [242]. Briefly, bone marrow
progenitor cells were plated in 24-well tissue culture treated plates at 1.5 x 106
cells/mL/well with 10 ng/mL rmM-CSF in complete RPMI medium. On days 2, 4, and 6,
80% of the medium was replaced with fresh complete medium supplemented with 10
ng/mL rmM-CSF. Cells were used on days 7 and 8.
4.3 Results
4.3.1 Synthesis of alginate microparticles and characterization
Alginate microparticles were synthesized using a water-in-oil single emulsion
approach to co-encapsulate hydrogel nanoparticles and chemokine as illustrated in
Figure 4.1B. This strategy was modified from Lemoine et al. [243] and a similar
approach has been used for synthesizing hydrogel nanospheres and microspheres
[244,245]. Homogenization of alginate/protein/particle aqueous suspension in iso-
octane with 3:1 ratio of Span 80: Tween 80 resulted in a uniform emulsion. Addition of
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calcium chloride cross-linked alginate polymer chains within the emulsion droplets to
form microparticles that contained both the hydrogel nanoparticles and CCL20.
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Figure 4.1. (A) Chemical structure of alginate. G = Guluronic Acid and M =
Mannuronic Acid. (B) Schematic diagram for encapsulation of hydrogel
nanoparticles and chemokine in alginate microparticles.
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DQ-ova-containing hydrogel nanoparticles encapsulated in alginate
microparticles were observed to be uniformly distributed through the volume of the
alginate microparticles by fluorescence microscopy (Figure 4.2A). Similarly, when alexa
fluor 594-labeled CCL20 was encapsulated inside the alginate microparticles along with
unlabeled hydrogel nanoparticles, fluorescence microscopy revealed that the
chemokine was distributed throughout the alginate microparticle and was retained
inside the microparticle despite the small size of the protein (Figure 4.2B).
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Figure 4.2. Fluorescence micrographs of alginate microparticles containing (A)
DQ-ova-containing hydrogel nanoparticles (B) Alexa fluor 594-labeled CCL20. (C)
Particle size distribution data and circularity of alginate microspheres obtained
by Vi-Cell Counter.
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The alginate microparticles had a mean diameter of ~20 ptm with a size range
from 15 pm to 35 ptm (Figure 4.2C). Hydrogel nanoparticles were encapsulated within
the alginate microparticles with a high efficiency of ~95%, as determined by analysis of
the synthesis supernatant using flow cytometry. Direct counting of the alginate
microparticle suspension estimated ~ 3.2 x 106 microparticles/mL corresponding to a
loading of ~1600 nanoparticles per alginate microparticle. The water content of alginate
microparticles was ~95% by weight with the remaining 5% comprising of encapsulated
nanoparticles, chemokine, carrier protein, and alginate polymer; this corresponds to a
swelling ratio (VwetNdry) of ~20 for the microparticles. The mesh size of alginate
microparticles can be calculated using the theory of Canal and Peppas [180] for an
alginate polymer with molecular weight 200 kDa and M/G (Mannuronic/ Guluronic) ratio
1.6 [243]. Alginate crosslinks are formed when guluronic acid from different polymer
chains bind the same calcium in an egg-box shaped structure; due to stochastic
distribution of the monomers, guluronic acid and mannuronic acid in the polymer chains,
the polymer chain comprises of mannuronic-mannuronic (MM), mannuronic- guluronic
(MG), or guluronic-guluronic (GG) motifs. Assuming that the polymer chain has GG
combination of 20% as observed for most alginate polymers with low G content, we
calculated ~100 GG combinations in each alginate polymer chain. Assuming all GG to
be placed equally apart, characteristic ratio and monomer size of alginate being same
as that of cellulose (Cn ~20 and bond length I ~5.5 A [246]), the mesh size is 19.5 nm.
However, due to the statistical distribution of location of guluronic acid and mannuronic
acid monomers in the alginate chain, the mesh size will correspondingly be statistically
distributed. This mesh size value agreed with our observation that when dendritic cells
were incubated with alginate microparticles containing 20 nm FITC-labeled
nanoparticles, 80% of the cells in culture were observed to contain nanoparticles after
24 h in contrast with 20% cells containing 500 nm-sized nanoparticles encapsulated in
alginate microparticles, indicating that nanoparticles that are as big as the mesh size will
be easily taken up by phagocytic cells such as dendritic cells. On the other hand,
protein molecules having much smaller dimensions may be released from the alginate
microparticles as observed for bovine serum albumin. When FITC-Bovine Serum
Albumin (BSA) doses of 1-10 mg per 4 mg sodium alginate were encapsulated in
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alginate microparticles, >90% of the BSA protein was released from alginate
microparticles during the first aqueous washing step resulting in a net encapsulation
efficiency of -5% for BSA. Previous studies that have reported BSA encapsulation in
alginate microspheres used significantly higher amount of calcium chloride followed by
dehydration of alginate matrix using isopropanol that resulted in extensive crosslinking
of alginate; however, BSA was released from the microparticles very quickly [243]. In
contrast, the chemokine, CCL20 was encapsulated with an encapsulation efficiency
ranging from 75% when 10 Vg CCL20 was encapsulated up to 90% when 10 ng CCL20
was encapsulated. Many chemokines are cationic in nature and CCL20, in particular
has a pl of -10 [247]. We hypothesized that the cationic nature of CCL20 supports
electrostatic binding of the protein to the anionic alginate polymer chains, causing the
chemokine to be encapsulated inside the polymer matrix with high efficiency. This
hypothesis was tested by mixing 1% sodium alginate and different quantities of
lysozyme. Like CCL20 and other chemokines, lysozyme is a small protein (14 kDa)
protein with a pl of 11 [248]; these properties make lysozyme a good model protein for
studying chemokine encapsulation in alginate microparticles. In support of potential
ionic interactions between such cationic proteins and alginate, we observed that as
lysozyme was added to 400 gL of 1% (wt/vol ) sodium alginate in increasing amounts,
100 tg lysozyme precipitated the polysaccharide, as evident from clouding of the
polymer solution.
Thought CCL20 was readily encapsulated, it was expected that it should be
slowly released from alginate microspheres by slow diffusion through the ionic alginate
matrix. We studied the kinetics of CCL20 release from alginate microparticles in
complete RPMI medium to incorporate effects of serum proteins and buffer conditions at
37 oC. Alginate microparticles release the chemokine with a burst release of -20%;
-50% of the encapsulated chemokine was released after 24 h. Release then continued
at a slower rate for several days further (Figure 4.3). After releasing chemokine from
alginate microparticles for one week, the release curve plateaued at 80%. This could
possibly be due to remaining chemokine being tightly bound to the alginate matrix,
preventing its complete release on this timescale.
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Figure 4.3. Release profile of CCL20 from alginate microparticles in complete
RPMI medium at 37 0C.
Dendritic cells are highly phagocytic and avidly take up particulate antigen by
phagocytosis. We hypothesized that dendritic cells might extract antigen-loaded
hydrogel nanoparticles from alginate microparticles by the process of phagocytosis. In
order to study uptake of hydrogel nanoparticles by DCs from the interior of alginate
microparticles, we incubated DCs with alginate microparticles loaded with fluorescent
DQ-ova-containing nanoparticles, and nanoparticle uptake was- visualized using
timelapse videomicroscopy. As shown in Figure 4.4, DCs that come into contact with
alginate microspheres extended their processes to reach the interior of the microsphere
and phagocytose fluorescent nanoparticles.
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Figure 4.4. Uptake of DQ-ova-containing nanoparticles loaded in alginate
microspheres by DCs visualized by timelapse videomicroscopy. Region where
DC phagocytoses the nanoparticle is encircled.
To understand uptake of nanoparticles from alginate microspheres, we
hypothesized that the access to the nanoparticles will be dependent on the mesh size of
alginate carriers, which is a function of the cross-linking density of the alginate polymer
chains. We thus studied the effect of the amount of calcium chloride used for cross-
linking the alginate chains on the uptake of nanoparticles by dendritic cells. As shown in
Figure 4.4, at low calcium chloride amounts (62.5 gg/mg sodium alginate), as many as
70% of maximal uptake of nanoparticles by dendritic cells (measured for DCs incubated
in collagen with unencapsulated nanoparticles for the same time period) was observed
after 24 h of culture; in addition, the encapsulation efficiency of nanoparticles was low.
On the other hand, with 12.5 mg calcium chloride /mg sodium alginate, only 30% of
maximal uptake of nanoparticles was observed. In the intermediate range of 0.25-2.5
mg calcium chloride/ mg sodium alginate, 50% of maximal uptake was observed after
24 h of culture. Plateauing of nanoparticle uptake in the calcium chloride amount of
0.25-2.5 mg/ mg sodium alginate is predicted since the RPMI medium used for washing
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the microparticles contains -10 mg/mL of calcium chloride, which results in the cross-
linking of alginate polymers attaining equilibrium state. Based on these data, we
decided to use 1 mg calcium chloride for microparticle formation.
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Figure 4.5. Antigen uptake by bone marrow dendritic cells from alginate
microparticles synthesized using different amounts of calcium chloride.
4.3.2 Chemoattraction of dendritic cells to alginate microparticles
Immature dendritic cells have a high expression of CCR6 on their surface, which
binds CCL20, resulting in migration of DCs in response to concentration gradients of the
chemokine [14,88]. Alginate microparticles release CCL20 into their microenvironment,
which by diffusion into the medium forms a gradient to chemoattract dendritic cells
toward the individual microparticles.
Once a suitable chemokine gradient is formed in the collagen gel, dendritic cells
from the surrounding environment of a given alginate microparticle will migrate toward it.
However, DCs are known to exhibit a non-monotonic response to the dose of CCL20
[249] in modified Boyden chamber assays (Figure 2.2), with reduced chemotaxis at high
chemokine concentrations. To determine the optimal dose of chemokine per
microsphere for maximal DC chemoattraction, we used the collagen gel model and
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analyzed the uptake of DQ-ova-containing nanoparticles by DCs interacting with
alginate microparticles loaded with different quantities of CCL20 ranging from -2.5
fg/microparticle to ~2.5 pg/microparticle. Bone marrow dendritic cells and alginate
microparticles with different CCL20 loadings and fluorescent nanoparticles were
suspended in 3D collagen gels as shown in Figure 4.6A, incubated for 24 hrs, followed
by digestion of the matrix to recover the cells and analysis of fluorescent nanoparticle
uptake by flow cytometry. As shown in Figure 4.6B, nanoparticle uptake by DCs
increased as chemokine loading was increased from 2.5 fg/microparticle to 250
fg/microparticle followed by a decrease on further increasing the loading to 2500
fg/microparticle (Figure 4.6B). Thus, 250 fg/microparticle was found to be the optimal
CCL20 loading and was used in subsequent experiments.
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Figure 4.6. (A) Schematic diagram of bone marrow dendritic cell migration to
alginate microparticles in 3D collagen gel set up. (B) Nanoparticle uptake by
dendritic cells as a function of CCL20 loading per particle. Dashed line represents
nanoparticle uptake with alginate microparticles without chemokine.
Using the optimized loading of CCL20 in alginate microparticles, we next
visualized migration of bone marrow dendritic cells towards individual alginate
microparticles by timelapse videomicroscopy using the same collagen gel assay. As
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shown in images obtained from timelapse videomicroscopy (Figure 4.7A), dendritic cells
in collagen are chemoattracted to a point source of chemokine. Microscopic
examination at low magnification after 24 h of incubation showed formation of cell
clusters around individual alginate microparticles throughout the collagen gel (data not
shown). Analysis of the paths of motile cells in the vicinity of individual alginate
microparticle revealed that dendritic cells within 200 pim of an alginate microsphere
were concentrated at a single location due to chemoattraction (Figure 4.7B). In contrast,
when control microparticles were used that contained the BSA carrier protein but no
chemokine, dendritic cells migrated randomly in the vicinity of microspheres. Some
dendritic cells that encountered alginate microparticles through random migration,
however, stayed next to the microparticle for short durations compared to that with
CCL20-loaded alginate microparticles. Further, dendritic cells migrated a mean distance
of ~ 150 pm towards the alginate microparticles in response to the chemokine gradient,
suggesting that dendritic cells can be attracted over significant distances (Figure 4.7C).
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Figure 4.7. (A) Images from timelapse videomicroscopy of bone marrow dendritic
cell migration to alginate microparticle in 3D collagen gel. Green fluorescence in
the overlay derives from fluorescent ova-labeled nanoparticles in the alginate
carriers. This example shows two alginate microcarriers near the center of the
image. (B) Cell paths for migration in response to CCL20-loaded alginate
microparticles (left) or control alginate microparticle (right) (C) Distribution of
distances migrated by BMDCs in response to CCL20 gradients created by
alginate microparticles in 3D collagen.
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4.3.3 Enhanced antigen delivery to dendritic cells by 'reverse-targeting'
Concentration of dendritic cells around individual alginate microparticles
increases the number of dendritic cells that have access to nanoparticles. This should
result in increased antigen delivery to dendritic cells and also an increase in the number
of dendritic cells receiving antigen. To test if that indeed was the case with alginate
microparticles, we digested collagen gels after 24 h incubation, stained dendritic cells
with anti-CD11c antibody, and analyzed uptake of DQ-ova-containing nanoparticles by
flow cytometry. As shown in Figure 4.8A, alginate microparticles containing
nanoparticles but no chemokine localized and retained nanoparticles very efficiently
with only -50% of dendritic cells in the culture containing antigen. However, when
CCL20 was co-encapsulated inside the alginate microparticles, more than 70% of all
cells in culture were observed to contain antigen resulting in ~200% increase in
dendritic cell targeting due to reverse-targeting. In addition, dendritic cells were
observed to contain 5-fold higher quantity of antigen per cell due to reverse-targeting of
DCs than when chemokine was absent (Figure 4.8B). In comparison to these, when
nanoparticles were suspended uniformly in collagen gel making them accessible to all
cells in culture, ~75% cells contained nanoparticles. This confirms our hypothesis that
'reverse-targeting' of dendritic cells by co-delivering CCL20 and antigen-loaded
nanoparticles could enhance antigen delivery to dendritic cells.
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Figure 4.8. (A) Nanoparticle uptake by CD11c*-BMDCs in collagen after 24 h
culture when incubated with alginate microparticles containing DQ-ova-
containing nanoparticles with or without CCL20. (B) Mean Fluorescence Intensity
of BMDCs (histograms) and percentage of CD11c + BMDCs containing antigen
(line).
Next, we looked at enhanced delivery of antigen when microparticle: cell ratio
was varied to study if similar enhancement is observed for a range of microparticle
doses. As shown in Figure 4.9A, antigen delivery to dendritic cells was significantly
higher in case of CCL20-loaded alginate microparticles compared to the alginate
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microparticles that did not contain the chemokine. We looked at CD86 expression of
cells containing CpG-coated nanoparticles to see if increased uptake of nanoparticles
results in effective maturation of dendritic cells. As nanoparticle dose was increased, the
percentage of dendritic cells containing high levels of DQ-ova-containing nanoparticles
and high CD86 expression increased and was consistently significantly higher for
CCL20-loaded alginate microparticles than for control microparticles (Figure 4.9B). As
expected, at high alginate carrier: DC ratios, chemoattraction had little effect on the
frequency of DCs internalizing nanoparticles. Alginate microparticles containing CCL20
and BSA only did not cause any CD86 upregulation indicating that alginate polymer or
chemokines did not mature the DCs.
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Figure 4.9. Flow cytometry analysis of dendritic cells after 24 h culture in collagen
gel with different doses of alginate microparticles with or without CCL20 for (A)
antigen uptake and (B) DC maturation.
4.3.4 Selective delivery of antigen to dendritic cells by 'reverse-targeting'
Dendritic cells are the only antigen presenting cells known to activate naYve T
cells [5,54]. Therefore, it is desired that in clinical application, most antigen is delivered
to the dendritic cells while minimizing antigen uptake by other phagocytic cells present
in tissues such as macrophages and neutrophils. Reverse-targeting of dendritic cells
was hypothesized to attract dendritic cells preferentially towards alginate microparticles
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and in the process increase the antigen delivery selectively to dendritic cells. To
demonstrate this concept, we co-cultured equal numbers of bone marrow-derived
macrophages (0.5 x10 5 cells/mL) and BMDCs (0.5 x10 5 cells/mL) in collagen gel with
alginate microparticles and analyzed nanoparticle uptake by each cells type by
timelapse videomicroscopy. BMDCs were labeled with 0.5 pM CFSE and BMDMs with 5
pg/mL Fura-2 dye, and were mixed 1:1 in collagen gel along with Alexa fluor 647-ova-
containing hydrogel nanoparticles-loaded alginate microparticles. As shown in images
obtained from timelapse videomicroscopy during the first 3 h (Figure 4.10A), dendritic
cells were preferentially attracted towards alginate microparticles and macrophages due
to random migration did not get access to alginate microparticles during the course of
experiment. During 3 h, as many as 8 BMDCs were observed to be localized around
single alginate microparticles compared to only 2 BMDMs in the same period of time, as
also shown in cell paths plots for BMDCs and BMDMs migrating in response to alginate
microparticles loaded with CCL20 (Figure 4.10B). This observation suggests that by
combining controlled release of chemokine with delivery of antigen by means of
nanoparticles, we were not only able to achieve enhanced delivery of antigen to
dendritic cells but selective delivery as well. This selectivity will be of significant
importance in physiological situation where dendritic cells being rare may not be able to
compete with other phagocytes, but reverse-targeting of dendritic cells can increase the
delivery of antigen to the dendritic cells relative to other non-responding cells.
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Figure 4.10. (A) Images from timelapse videomicroscopy for migration of
dendritic cells towards alginate microparticles (red) by CCL20 in a co-culture of
macrophages (blue) and dendritic cells (green). (B) Cell paths of BMDCs (left) and
BMDMs (right) in response to CCL20-containing alginate microparticle placed at
origin.
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4.4 Discussion
Dendritic cells are professional antigen presenting cells that play a key role in
immune system activation during an infection [5,54]. In homeostatic state, dendritic cells
are present at a low frequency of < 1% of all cells, with a significant fraction of
macrophages and neutrophils present in the tissues. To improve the efficacy of a
vaccine, it is therefore necessary to target vaccines to the dendritic cells [250]. Dendritic
cells can selectively receive antigen and maturation signals by using dendritic cell-
specific targeting ligand such as DEC205-ova, as demonstrated in the past [24,149,226].
However, we explored the ability of reverse-targeting to preferentially deliver
nanoparticles to dendritic cells. Reverse-targeting has been used in vivo through
intratumoral injection [42] of chemokine and transfection of tumor cells with a
chemokine-encoding plasmid [68,69]. Kumamoto et al. encapsulated MIP-30 inside
poly(thylene-co-vinyl) acetate rods and implanted them in mice to chemoattract mature
dendritic cells that were then loaded with antigen contained in another similar rod
[40,41]. In order to reverse-target DCs, we first needed to localize nanoparticles in an
injectable matrix followed by concentration of dendritic cells around the matrix. This was
achieved by co-encapsulation of CCL20 and nanoparticles in alginate microparticles to
reduce access of cells distributed in the tissue to nanoparticles, and then provide
access to cells in immediate vicinity of microparticles, which were primarily dendritic
cells through the process of reverse-targeting.
In order to specifically target dendritic cells and to deliver antigen to these cells,
we developed microparticles using a polysaccharide, alginate to co-deliver a chemokine
specific to immature dendritic cells, CCL20 and antigen-loaded nanoparticles. Alginate
is produced by various algae and certain bacteria that use this biopolymer to form a
capsule and protect the cells from unfavorable environmental conditions [251,252].
Alginate has also been proposed to be the cause of resistance to drugs and immune
response to a pathogen since it helps bacteria attach to basement membranes and also
hides the pathogen's antigens and surface molecules [253]. Alginate has been used for
various tissue engineering and biotechnology applications such as for encapsulation of
cells [254,255] and proteins in alginate matrices [243,251]. Alginate is a biodegradable
and biocompatible polymer with few side effects. Alginate has also been proposed to
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modulate immune response and has been shown to act as adjuvant in some studies.
Alginate polymer chains containing high mannuronic content cause activation of
macrophages resulting in secretion of inflammatory cytokines [256,257] though use of
alginate films was shown not to cause any DC maturation [258]. Similarly, alginate
polymer obtained from bacterial sources should be tested for endotoxin content due to
possibility of endotoxin presence in the alginate sample. Alginate is generally available
in a water-soluble form of sodium alginate; on addition of calcium to the alginate
solution, sodium is displaced and guluronic acid monomers cross-link between alginate
polymer chains to form an egg-box shape resulting in phase separation of calcium
alginate [255]. Alginate particles are usually formed by dropping sodium alginate
solution into an aqueous calcium chloride bath resulting in particles in the size range of
0.5-2 mm [251]. However, for making our vaccine injectable, we designed a water-in-oil
strategy modified from a previously reported protocol [243] to form microparticles.
Alginate microparticles thus formed were -20 pm mean diameter and encapsulated
nanoparticles and chemokine with high efficiency. We observed that microparticle size
could be easily modulated by changing the surfactant content or by changing the
homogenization speed during microparticle synthesis. The encapsulated nanoparticles
were well-retained and were not observed to be released in complete RPMI medium at
37 OC for a week. In contrast, CCL20 was released at a controlled rate for 4-5 days,
which would be sufficient for targeting significant number of dendritic cells based on
previous studies.
We studied dendritic cell responses to alginate microparticles by culturing DCs
with alginate microparticles in collagen. The density of nanoparticles per alginate
microparticle was chosen for all our experiments as cell: microparticle ratio of 30: 1;
based on encapsulation of nanoparticles in alginate microparticles, this cell:
microparticle density corresponds to each dendritic cell getting an average of 50
nanoparticles assuming all dendritic cells receive antigen. It has been shown in the past
that dendritic cells when incubated with -1 tm-sized particles can internalize up to -100
particles/cell [115], and using the density used in our experiments, we can provide
maximal quantities of antigen to each dendritic cell. We observed dendritic cell
migration towards alginate microparticles using timelapse videomicroscopy. Microscopic
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examination of DC migration revealed that dendritic cells migrated to the microparticles
from distances ranging from 50 gm to 400 gm with a mean distance migrated of 150 [Lm.
Dendtitic cells were observed to start migrating within 1 h of setting up collagen gels
and migration continued for up to 5-6 h; DC migration after 6 h was markedly reduced
thereafter. Reduced migration at later time could be due to chemokine gradients from
neighboring particles beginning to overlap thereby confusing the DCs in the process or
due to internalization of surface chemokine receptors are reduced response of cells to
chemokine gradients. Dendritic cells that migrated to the microparticles stayed attached
to the microparticle surface with few cells observed to extract nanoparticles from the
inside of alginate microparticle. During the course of microscopy, few cells were also
observed to leave the microparticle surface and migrate away from the particle. This
was possibly a result of CpG-induced maturation of dendritic cells upon uptake of CpG-
coated nanoparticles, resulting in downregulation of the immature dendritic cell
chemokine receptor, CCR6 [54]. In the culture, nearly 50% of cells were immotile or less
motile whereas the more motile cells were mostly observed to migrate to the alginate
microparticles. This is not unexpected as BMDC cultures contain contaminating
granulocytes, neutrophils, and macrophages that do not respond to CCL20. Based on
CD11 c staining of cells, these cells form -30% of the population in the culture after 7
days of culturing bone marrow progenitor cells, which possibly formed the immotile or
less motile cell population observed by microscopy. Cell clusters formed around CCL20-
loaded alginate microparticles varied in size ranging from 3-10 cells per cluster. In
contrast, fewer dendritic cells (-1-5 cells/cluster) were observed localized around
alginate microparticles lacking chemokine.
An increased presence of dendritic cells around alginate microparticles resulted
in an enhanced delivery of nanoparticles to the DCs. DCs could be brought directly to
the surface of microparticles from where they could extract the nanoparticles containing
antigen and CpG oligonucleotides. An increase in number of dendritic cells containing
antigen by -150% was observed in our experiments, and a significant fraction of cells
contained 2-3 times more antigen when CCL20-loaded microparticles were used
compared to control microparticles. Nanoparticles delivered antigen that was processed
and presented on DC surface and CpG oligonucleotides caused activation of DCs.
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Together, alginate microparticles increased the number of effectively activated DCs for
a strong subsequent T cell activation. When dendritic cells and macrophages were co-
cultured with CCL20-loaded alginate microparticles, macrophages were observed to
migrate randomly in collagen whereas dendritic cells migrated selectively towards
alginate microparticles thereby increasing the fraction of DCs in the immediate
microenvironment of alginate microparticles. By analyzing uptake of uniformly dispersed
hydrogel nanoparticles in collagen, we found that dendritic cells and macrophages are
nearly equally phagocytic; however, concentration of dendritic cells at the surface of
microparticles can help deliver antigen and maturation signals to dendritic cells
selectively and at higher doses.
Alginate microparticles can also be used to mimic and study dendritic cell
responses to a pathogen in vitro and in vivo. Chemokine release from microparticles
mimics inflammatory signals at site of infection, and sub-micron sized nanoparticles
closely mimic a pathogen by means of surface-displaying antigenic epitopes and Toll
like receptor ligands. Co-encapsulation of different chemokines can be used to
modulate dendritic cell trafficking and control the kinetics of immune response suitably.
Further, alginate being mucoadhesive [259] has a potential as a vaccine carrier for
various modes of delivery, and has been tested for oral [260,261] and nasal vaccination
[259,262] in some previous studies.
Cellular organization is an important aspect of organogenesis and tissue
engineering. Various morphogens have been proposed to form concentration gradients
and control differentiation and cell organization in three dimensions [263,264].
Controlled release of chemokine using microparticles can be used to study cell
differentiation and tissue organization, and can thus be used for various tissue
engineering applications.
4.5 Conclusions
Alginate microparticles were synthesized by using a single emulsion technique to
co-encapsulate CCL20 and hydrogel nanoparticles containing antigen and DC
maturation signal with very high encapsulation efficiency. Co-encapsulation created a
point source for chemokine and antigen; dendritic cells were chemoattracted to the
135
alginate microparticles and then were delivered nanoparticles to deliver and antigen and
maturation signal in concert. Reverse-targeting of dendritic cells resulted in
concentration of dendritic cells around alginate microparticles, which enhanced the
delivery of antigen to dendritic cells by 2-3 fold and selectively delivered antigen to
dendritic cells. Reverse-targeting not only provides an ultra-localized strategy for
targeting dendritic cells in contrast to searching for dendritic cells for targeted delivery of
antigen in a larger volume of a tissue but can also be used in tissue engineering for
organogenesis and cell differentiation.
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5. Summary and Future Work
5.1 Summary of results
Vaccines - therapeutic and prophylactic - are sought for a variety of diseases
such as HIV, influenza, and tuberculosis that require recruitment of both humoral and
cellular arms of the immune system. Currently, most commercially-available vaccines
are based on live or attenuated bacteria or viruses, which have been successful in
cases of certain infections, but are often associated with the risk of pathogenicity. Multi-
subunit vaccines are therefore believed to address the toxicity/pathogenicity issue with
the current vaccines while priming the immune system against the antigens of interest
effectively. The immune system has evolved over time to mount a strong response
against pathogens by means of cellular intermediates such as dendritic cells. These
cells phagocytose pathogens avidly, process the pathogen-associated antigens, and
receive maturation signals in the form of pathogen-associated molecular patterns. We
developed a pathogen-mimetic multi-subunit vaccine to take advantage of the efficiency
of the immune system to act against bacteria. Alginate-based carrier microparticles
were synthesized to encapsulate the immature dendritic cell-specific chemokine CCL20
and antigen-containing hydrogel nanoparticles. The microspheres were -20 [tm mean
diameter whereas nanoparticles were -500 nm in size. The gross structure of this
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system closely represents the physiological state during an infection; chemokine
release from alginate microspheres represented inflammatory signals in response to a
pathogen, whereas nanoparticles mimicked a pathogen through co-display of antigen
epitopes and TLR ligands on surface. Because this system is designed to elicit a
cascade of responses mimicking early events following infection, the system might be
used as an in vitro model to study dendritic cell responses during infection. We
demonstrated in vitro that through controlled release of CCL20, dendritic cells could be
chemoattracted specifically up to the point of contact with alginate microspheres, where
DCs extracted antigen-loaded nanoparticles from the interior of microspheres.
Chemoattraction of dendritic cells not only increased the number of dendritic cells
receiving antigen and TLR ligands on nanoparticles, but also increased the antigen
dose received by each DC. DCs upon phagocytosis of hydrogel nanoparticles process
the encapsulated antigen in their endosomal compartments and present the antigen on
MHC class II molecules for presentation to CD4 ÷ T cells. Nanoparticles were observed
to also induce effective cross-presentation of dendritic cells and consequently MHC
class I presentation of antigen for CD8 ÷ T cell priming. Co-display of antigen and TLR 9
ligand on the surface of nanoparticles resulted in strong maturation of DCs causing
secretion of pro-inflammatory cytokines and upregulation of MHC and co-stimulatory
molecules. In vivo, CpG-coated nanoparticles activated B cells, and IgG could be
detected as early as 1 week post-immunization of wild-type mice. The anti-ovalbumin
IgG titers rose quickly during the duration of the experiment (7 weeks) reaching levels
comparable to that with ova in CFA. CpG-coated nanoparticles were shown to activate
CD4 ÷ and CD8 ÷ nafve T cells in draining lymph nodes and spleen, and a significantly
higher ova-specific CTL frequency in splenocyte population of the immunized mice. In
addition to short term immunity, we also tested for a long term memory CD8 ÷ T cell
response, which was observed to be comparable to that with ova in CFA and higher
than that when nanoparticles were co-delivered with soluble CpG.
Based on these studies, we conclude that particulate system for delivery of
antigen and TLR ligands is significantly more effective than delivery of antigen and TLR
ligands in soluble form. However, we studied only CpG in these studies which acts in
the endosomes of dendritic cells, and therefore, it remains an interesting open question
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whether immunostimulatory ligands targeting surface-expressed TLR receptors (e.g.,
TLR4) would elicit different responses. We also found that co-display of antigen and
TLR ligands on the surface of nanoparticles was significantly more effective in activation
of T cells in vivo than delivery of antigen as nanoparticles along with soluble CpG.
Current vaccination strategies involve co-injection of antigen and adjuvants in soluble
form; we propose, that co-delivery of antigen and an adjuvant on a single particle can
boost immune responses several fold. Dendritic cells are the only cells capable of
priming naifve T cells and DCs are significantly superior to other APCs in antigen
processing and presentation. It is therefore desired to target antigen to DCs for a
stronger immune response. To achieve this objective, recent studies by other groups
have shown that by use of antigen conjugated to a targeting ligand such as CpG or
DEC205, antigen delivery to dendritic cells and resulting in vivo responses can be
enhanced manifold [24,149,152,153,226]. In parallel, other studies have demonstrated
complete tumor regression by employing chemoattraction of dendritic cells to the tumors
by means of using chemokine-encoding plasmid-transfected tumor cells [42,67] or
controlled release of mature dendritic cell-specific chemokine [40,41]. We created a
system that chemoattracted dendritic cells to the individual microparticles where the
DCs received antigen- and TLR9 ligand-containing nanoparticles. Selective and
enhanced antigen delivery to DCs is expected to enhance the immune responses to
antigen of interest compared to delivery of antigen alone.
The system developed in this work may be used for several applications ranging
from the study of DC trafficking to improved vaccines and tissue engineering. Labeled
nanoparticles can be used for studying DC trafficking and the kinetics of B cell and T
cell activation in vivo. Intravital imaging is used for studying processes occurring inside
lymph nodes, and the same technique may be employed for studying the processes that
occur at the site of infection. Chemokine delivery may be used for modulating DC
trafficking and control DC attraction of emigration, and understanding the role of
different chemokines at different stages of immune response. Chemokines have been
found to be involved in a variety of processes such as organogenesis, inflammation,
angiogenesis, metastasis, and autoimmune diseases. The system described here,
which allows modulation of chemokine gradients, can be used to unravel a wealth of
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information regarding how certain cells respond differently and may be controlled for
clinical applications. As described earlier, this system can be used as an effective
vaccine especially in cases of diseases where no characteristic epitope is currently
known. For example, we propose that tumor lysates may be encapsulated in hydrogel
nanoparticles and these nanoparticles coated with TLR ligands such as CpG or
poly(l:C) for priming the immune system to tumor-associated antigens. Conversely, self-
antigens may be delivered in conjunction with immunosuppressive signals to induce a
tolerance to the specific antigens or cell lysates to treat autoimmune diseases. In order
to enhance the 'clinicability' of our vaccine, a biocompatible and biodegradable vaccine
is highly desired. Presently, all the components of our vaccine are biocompatible and
did not show acute toxicity in vitro or in vivo. However, hydrogel nanoparticles are
nondegradable but can be made biodegradable using several strategies proposed in the
literature and as mentioned in Chapter 3.
This system also has several applications beyond the realm of immunology.
Concentration gradients of ligands play roles in tissue engineering [265], embryonic
development [263], and organogenesis [266]. Modulation of these gradients can not
only help understand these systems in great detail but also form basis for various
therapies. Such a system may also be used for arranging cells of interest in a specific
pattern by surface-patterning the chemokine-releasing microspheres. The all-aqueous
synthesis of protein-encapsulating nanoparticles can also have applications in delivery
of sensitive proteins and other biologics. Hormones, cytokines, growth factors, siRNA,
and peptides are some of the therapeutics that may be delivered without risking loss of
activity using the nanoparticles. Such a system for ultra-localized delivery of
encapsulated molecules along with chemoattraction of cells of interest may be applied
to medical devices as well. An example in this regard is a drug-eluting stent. Restenosis
is often caused by faster infiltration and proliferation of smooth muscle cells (SMC)
compared to endothelial cells. Current stent designs inhibit SMC proliferation but these
drugs have their associated side-effects. Instead, chemoattraction of endothelial cells to
the site of implantation may accelerate the process of healing with reduced restenosis
rates.
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Thus, the hydrogel-based system proposed here is highly applicable in a variety
of biological subsystems, and may be advantageous due to the biomimickry it brings in
to therapy designed with the system. The vaccine may be further improved for better
efficacy by making it biodegradable and by studying the effect of combination of
chemoattractants encapsulated in the alginate microparticles.
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APPENDIX 1 - Celli Culture Medium and Buffers
1.1 Complete RPMI Medium
1. Aseptically remove 70 mL of medium from 500 mL of sterile RPMI 1640 medium
(Invitrogen) containing sodium bicarbonate and 2 mM L-Glutamine,
2. Add 5 mL of 100X sodium pyruvate and 5 mL of 100X Non-essential amino acids
solution.
3. Add 10 mL of penicillin and streptomycin solution.
4. Add 500 pl of gentamicin antibiotic solution.
5. Thaw fetal calf serum at 37 OC and add 50 mL of FCS to the above medium.
6. Gently rock the medium to mix the components, cover with aluminum foil, and
store at 4 oC.
7. Keep the medium sterile and use only in sterile laminar hood.
1.2 Magnetic-Assisted Cell Sorting (MACS) Buffer
1. Prepare 1 I phosphate-buffered saline pH 7.2 using a PBS tablet in 1 I milliQ
water.
2. Add 5 g bovine serum albumin (BSA) to PBS and 1 g sodium azide.
3. Add 2 mM EDTA to prevent cell clumping or attachment to column.
4. Filter the buffer using 0.2 gm bottle-top sterile membrane filter.
5. Store buffer at 4 oC and degas using vacuum before use. Always use cold buffer.
1.3 Flow-Assisted Cell Sorting (FACS) Buffer
1. Prepare 1 I phosphate-buffered saline pH 7.2 using a PBS tablet in 1 I milliQ
water.
2. Add 10 g bovine serum albumin (BSA) and 50 g sucrose to PBS.
3. Add 500 mg sodium azide to above solution.
4. Filter the buffer using a 0.2 gm bottle-top Teflon filter.
5. Store the buffer at 4 oC.
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1.4 ELISA Buffers
1.4.1 Block Buffer
1. Prepare 1 I phosphate-buffered saline pH 7.2 using a PBS tablet in 1 I milliQ
water.
2. Add 10 g bovine serum albumin (BSA) and 50 g sucrose to PBS.
3. Add 500 mg sodium azide to above solution.
4. Filter the buffer using a 0.2 tm bottle-top Teflon filter.
5. Store the buffer at 4 oC.
1.4.2 Reagent Diluent
1. Prepare 1 I phosphate-buffered saline pH 7.2 using a PBS tablet in 1 I milliQ
water.
2. Add 10 g bovine serum albumin (BSA) to PBS.
3. Filter the buffer using a 0.2 tm bottle-top Teflon filter.
4. Store the buffer at 4 oC.
1.4.3 Wash Buffer
1. Prepare 1 I PBS using a PBS tablet in 1 I milliQ water
2. Add 500 p~Il tween 20 to PBS.
3. Mix well and use as wash buffer for ELISA.
1.510 x RPMI Medium for Collagen Gels
1. Dissolve 5.2 g RPMI medium in 20 mL milliQ water in a 50 mL conical tube
2. Add 1.25 g sodium bicarbonate to the above solution
3. Add 2 g Hepes acid to the above solution
4. Add 5 mL 100x sodium pyruvate and 5 mL of 100x nonessential amino acids
5. Add 10 mL penicillin/streptomycin solution and 500 tl of gentamicin solution.
6. Mix well and make up the volume to 50 mL with milliQ water
7. Sterile filter the solution using 0.2 im membrane filter
8. Store at 4 OC and keep sterile.
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APPENDIX 2 - Murine bone marrow-derived dendritic cell
culture
Bone marrow-derived dendritic cells were cultured using the protocol of Inaba et
al. [267]. The details of the protocol are as follows:
1. Euthanize a C57B1/6 mouse (6-10 weeks old) using CO2 asphyxiation
2. Pin down the mouse by laying the mouse on its back while stretching the limbs
3. Make a cut in the abdomen and continue cutting the skin to the ankles
4. Cut out the tendons that are attached to the bones, and remove femur and tibia
from both legs
5. Immediately put the legs in complete RPMI medium
6. Cut open the ends of each bone, and flush the bones thoroughly with complete
RPMI medium using a 26 ¾ gauge needle attached to 1 mL syringe
7. Collect the bone marrow in a 50 mL sterile centrifuge tube and break the cell
aggregates with pipette to form single cell suspension
8. Pellet down cells at 1400 rpm for 6 min
9. Aspirate supernatant and loosen the pellet using small amount of medium
10.Add 5 mL Tris acetate-ammonium chloride (TAC) buffer (0.02 M Tris-HCI
adjusted to pH 7.2, 0.14 M NH4CI, sterile-filtered) for hemolysis and incubate for
3 min at room temperature
11. Neutralize ionic strength using 20 mL of serum-free RPMI medium
12. Remove cell debris using 40 ýim cell strainer
13. Pellet cells at 1400 rpm for 6 min
14. Resuspend cells at 1.5 x 106 cells/mL in complete RPMI medium and add 10
ng/mL rmGM-CSF
15. Plate cells in a 24-well tissue culture treated plate at 1.5 x 106 cells/mL/well and
incubate at 37 oC, 5% CO2
16. Pipette out 800 p•l medium on days 2, 4, and 6 from each well and replace with
fresh complete RPMI medium supplemented with 10 ng/mL rmGM-CSF
17. Bone marrow-derived dendritic cells are loosely adherent cells and can be
extracted by pipeting; cells were used between days 6 and 8.
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APPENDIX 3 - Preparation of collagen gel for migration
studie
1. Keep acidic collagen solution, 10Ox RPMI medium, and 0.1 N NaOH on ice
2. Cool down the eppendorfs and conical tubes on ice used to handling collagen
3. Mix 800 pl of acidic collagen solution, 100 il of 0.1 N NaOH, and 100 gl 10x
RPMI medium in this order in cool eppendorf tube to prepare 1 mL of 2.4 mg/mL
collagen gel
4. To prepare a mould for creating chemokine source well, take a clean razor blade
and cut out at the wide-end of 200 il pipette tip, and place the wide-end part at
the center of a 35-mm or 2-well labtek chamber.
5. Mix 1 mL of collagen (2.4 mg/mL) and 1 mL cell suspension at desired cell
density (e.g., 2 x 106 cell/mL for final density 1 x 106 cells/mL) and pipette
collagen-cell suspension into the petridish or labtek chamber without disturbing
the mould
6. Gel the collagen-cell suspension at 37 OC for 30 min, and observe migration
using microscope
7. For migration studies involving two-wells (cell well and chemokine source well),
attach two identical moulds to the cover of the petridish, pour collagen (1.2
mg/mL) into the lower part of petridish and close the cover to create two wells.
For migration studies involving no well, pipette collagen-cell suspension into
petridish or labtek chamber and gel.
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APPENDIX 4- Magnetic-Assisted Cell Sorting for T cell
purification
4.1 Negative selection for CD4 + T cell isolation
1. Splenocytes were isolated from mouse spleen and hemolysed. Cell were pelleted
at 1400 rpm for 6 min and washed once with cold MACS buffer
2. Splenocytes were resuspended in 200 pl MACS buffer for all splenocytes
3. Add 50 pl antibody cocktail solution
4. Mix well and incubate for 15 min on ice
5. Add 150 il of medium and 100 p1 of Streptavidin-conjugated microbeads
6. Mix well and incubate on ice for 20 min
7. Add 10 mL of MACS buffer and pellet cells at 1400 rpm for 6 min
8. Aspirate supernatant completely and resuspend cells in 500 p1 MACS buffer
9. Install MiniMACS column on magnet and add 0.5 mL cold MACS buffer
10.Add cell suspension followed by addition of 500 p1 MACS buffer in three steps
11. Collect eluted cells, pellet them at 1400 rpm for 6 min, and wash cells in serum-
free RPMI medium 2x. Resuspend cells finally at desired cell density in complete
RPMI medium
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4.2 Positive selection for CD8* T cell isolation
1. Splenocytes were isolated from mouse spleen and hemolysed. Cells were
pelleted at 1400 rpm for 6 min and washed once with cold MACS buffer
2. Resuspend splenocytes in 400 il MACS buffer
3. Add 50 pl CD8a (Ly-2) microbeads to cell suspension
4. Mix well and incubate on ice for 20 min
5. Add 10 mL MACS buffer and wash cells lx
6. Resuspend cells in 500 [tl MACS buffer
7. Install MiniMACS column on magnet and add 500 p1 MACS buffer
8. Add cell suspension to column followed by addition of 500 p1 MACS buffer in
three steps
9. Add 1 mL MACS buffer and push trapped cells using plunger into a tube
10.Pellet cells at 1400 rpm for 6 min, and wash cells in serum-free RPMI medium 2x.
Resuspend cells finally at desired cell density in complete RPMI medium
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APPENDIX 5- Enzyme Linked Immunosorbant Assay (ELISA)
5.1 ELISA for cytokinelchemokine detection
1. Pipette 100 tl capture antibody solution in PBS to each well of MaxiSorp ELISA
plate and incubate the plate at room temperature overnight for antibody
adsorption. Seal the plate with plate sealant or parafilm to prevent evaporation
2. Wash plate with 400 pl/well wash buffer 4x
3. Add 300 pl block buffer and incubate plate at room temperature for 1 h
4. Wash plate with 400 pi/well wash buffer 4x
5. Prepare 7-8 standard dilutions in reagent diluent and suitable dilutions of
samples also in reagent diluent
6. Add 100 pl/well of standard dilution or sample dilution. Incubate the plate for 2 h
at room temperature
7. Wash plate with 400 pl/well wash buffer 4x
8. Add 100 ptl/well detection antibody solution in reagent diluent and incubate the
plate for 2 h at room temperature
9. Wash plate with 400 pl/well wash buffer 4x
10.Add 100 pl/well of 200x-diluted streptavidin-horse radish peroxidase, and
incubate for 20 min at room temperature in dark
11. Wash plate with 400 pl/well wash buffer 4x
12. Add 100 pl/well of substrate reagent containing 1:1 Solution A: Solution B and
incubate at room temperature in dark for 20 min
13.Add 50 pl/well of 2 N H2SO 4 to quench the color development
14.Read the absorbance of the plate at 450 nm and 540 nm using a plate reader
and compute A450 - A540. Plot the standard curve and use it to determine the
concentration of cytokine/chemokine in samples
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5.2 ELISA for determination of antibody titers in mouse sera
1. Pipette 100 il/well of 5 gg/mL ovalbumin solution in PBS. Cover the plate with
parafilm to avoid evaporation and incubate at room temperature overnight.
2. Wash plate with 400 gl/well wash buffer 4x
3. Centrifuge mouse blood samples in serum separator tubes at 10,000 rpm for 3
min.
4. Prepare 100x, 1000x, 10000x, and 100000x dilutions of all sera samples in
reagent diluent and add 100 dl/well. Incubate the plate at room temperature for
1.5 h
5. Wash plate with 400 il/well wash buffer 4x
6. Add 100 il/well of 5000x diluted HRP-conjugated goat anti-mouse IgG antibody
in reagent diluent and incubate plate for 1.5 h
7. Wash plate with 400 pl/well wash buffer 4x
8. Add 100 il/well TMB substrate and incubate plate in dark for 10 min
9. Quench color development by adding 50 gl/well of 2 N H2SO4
10. Measure absorbance at 450 nm, and calculate A450
11.Antibody titer was calculated by endpoint dilution as sample dilution at which
A450 is twice of A450 for PBS control
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APPENDIX 6 - Cell labeling with fluorescent dyes
6.1 Labeling with CFSE dye
1. Pipette cells in a sterile conical tube and pellet the cells at 1400 rpm for 6 min
2. Resuspend cells in serum-free medium at 10 x 106 cells/mL
3. Add suitable dilution of carboxyfluorescein succinimidyl ester (CFSE) dye to
obtain desired final concentration
4. Incubate cells at 37 OC, 5% C02 for 20 min
5. Quench free dye with excess volume of complete RPMI medium
6. Pellet cells at 1400 rpm for 6 min and wash in complete RPMI medium 2x
7. Resuspend cells to desired cell density in complete RPMI medium
6.2 Labeling with Fura-2 AM dye
1. Pipette cells in a sterile conical tube and pellet cells at 1400 rpm for 6 min
2. Resuspend cells in 200 [tl serum-free medium and add 5 g/mL fura-2 AM dye
3. Incubate cells for 20 min at 37 OC, 5% CO2
4. Quench free dye with excess volume of complete RPMI medium and wash cells
2x in complete RPMI medium
5. Resuspend cells to desired cell density in complete RPMI medium
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APPENDIX 7 - Protein/peptide modification: Labeling with a
fluorescent dye or PEGylation/ acrylation
1. Prepare suitable dilution of protein of interest in PBS or 50 tM sodium carbonate
buffer pH 8.5
2. Add 5x by molar ratio of fluorescent dye-succinimidyl ester, and incubate the
protein-dye solution at 37 oC for 2 h
3. Dialyze out the free dye using a 5000 MW cut-off dialysis membrane against
PBS overnight at 4 'C changing buffer at least once
4. Run size exclusion chromatography on the labeled protein to determine the ratio
of labeled: unlabeled protein measuring the absorbance at 280 nm.
5. Concentrate the labeled protein using Centricon protein concentrators, protein
lyophilization followed by reconstitution, or using Spectra/Gel absorbent
6. For PEGylation of protein, incubate the protein/peptide solution with PEG-NHS
as described above for protein labeling with fluorescent dye
7. For protein acrylation, incubate the protein or peptide solution with NHS-acrylic
acid for 2 h at 37 oC as described above
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APPENDIX 8- Cell staining and Flow-Assisted Cell Sorting
(FACS)
8.1 Cell staining with antibodies
1. Pipette up to 1 x 106 cells into a microtiter tube and pellet them at 16,000 g for 15
sec
2. Remove the supernatant and resuspend cells in 200 tl FACS buffer
3. Pellet cells again at 16,000 g for 15 sec
4. Resuspend cells in 100 il FACS buffer containing 100x dilution of anti-
CD16.CD32 antibody
5. Incubate cells over ice for 30 min
6. Pellet cells at 16,000 g for 15 sec, and wash them lx in 200 tl FACS buffer
7. Resuspend cells in 100 [tl FACS buffer containing 100x dilution of primary
antibodies (antibodies of interest or corresponding isotype controls)
8. Incubate cells over ice for 30 min
9. Pellet cells at 16,000 g for 15 sec, and wash cells 2x in 200 p]l FAGS buffer
10. Resuspend cells in 100 pl FACS buffer containing 100x dilution of fluorophore-
conjugated streptavidin, if applicable
11. Incubate cells over ice for 30 min
12. Pellet cells at 16,000 g for 15 sec, and wash cells 2x in 200 p1 FACS buffer
13. Resuspend cells in 200 p1 FACS buffer and keep on ice until flow cytometry
14. If cells need to be stored for long period of time, they may be fixed by addition of
100 p1l 4% paraformaldehyde to the cell suspension. Tubes must be covered well
with Saran wrap to prevent evaporation and with aluminum foil to prevent
photobleaching, and stored at 4 oC until analyzed
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8.2 Flow cytometry
1. Turn on the flow cytometer and restart computer. Flow cytometer must always be
turned on before computer
2. Start the CellQuest program and connect to the cytometer
3. Set up the plots and the gates, and set up the file names and folders for saving
data under Parameter Description menu
4. Enter the number of events to be counted in each cycle under Acquisition and
Storage menu
5. Select the compensation and voltage settings from a previous experiment with
similar antibodies and same cells. If this is the first time with cells being studied
or different fluorophore, run the unstained, single stained, and multiple stained
samples to set up the compensation
6. Run the isotype control samples and adjust the scatter plot gate position to
exclude cell debris. Keep the fluorescence of isotype samples under 101 intensity
units by adjusting the voltages
7. Run the samples and save the data for analysis later
8. At the end of data collection, run bleach through the system for 5 min followed by
water for 5 min
9. Turn the system to standby mode, and then shut down the flow cytometer
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APPENDIX 9- Epifluorescence microscopy
1. Turn on Xenon lamp followed by other components. Xenon lamp is needed for
fluorescence imaging but not for phase contrast. If only phase contrast images
are being taken, do not turn on xenon lamp
2. If environment needs to be controlled for cell culture, set up the chamber and
turn on the temperature and CO2 controllers
3. Start the program, MetaMorph on computer
4. Choose the objective lens appropriate for imaging and put a drop of immersion
oil on 40x and 100x objective lenses but not on 10Ox objective lens
5. Place your sample in sample placeholder and by direct observation, bring the
sample in focus
6. Using 'Show Live' option under Acquire menu, fine adjust the focus to get the
best quality image on the screen.
7. For fluorescence, select the exposure time and click the fluorescence tab to take
the image
8. Move to another plane of view in x - y plane using joystick
9. For running timelapse, set up a journal to move the stage by appropriate distance
and take images at every position, and finally home after taking the images
10. From Acquire Timelapse menu, select the frequency of images and total period
of timelapse, and journal to be used, and collect images
11. For Z-stack imaging, select the distance to be covered in each Z-stack, number
of planes in the Z-stack, exposure time, and click the tab for fluorescence Z-stack
imaging.
12.At the end of imaging, save the data on the computer hard disk or portable hard
drive, and close the MetaMorph program
13. Shut down all the components of microscope with Xenon lamp being the last
component to be turned off
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APPENDIX 10 - Synthesis of end-acrylated triblock
copolymer for hydrogel synthesis
10.1 Synthesis of PLGA-PEG-PLGA triblock copolymer
1. Dissolve 15 g of glycolide in 50 mL ethyl acetate (dried over molecular sieves) at
700C with continuous stirring. Precipitate glycolide in 300 mL Petroleum ether
cooled to 40C. If required, precipitate in diethyl ether as well
2. Repeat step 1 for D,L-lactide also
3. Dissolve 30 mg PEG in 50 mL acetone at 600C and precipitate in 300 mL
Petroleum ether/ diethyl ether
4. Dry all the three comonomers in the vacuum oven overnight
5. Take out dried two-necked 100 mL round bottom flask and Dean-Stark apparatus
from the oven
6. Assemble the set-up and seal it as soon as possible
7. Purge it with N2 for 5 min. Attach water connections
8. Add 100 mL of anhydrous toluene to the round bottom flask. Place the set-up in
silicon oil at 1300C. Stir the solution at 300 rpm
9. Add 16 g PEG and 2 g each of lactide and glycolide (for PLGA:PEG = 20:80) to
the round bottom flask
10. Dissolve the contents and purge N2 till ~10 ml of toluene is collected in the trap
11.Add 100 iL of 100 mM stannous diethyl hexanoate (162 pL stannous octoate in
5 mL toluene) to the reaction mixture drop wise
12. Keep purging nitrogen and periodically add more toluene to make up for any lost
toluene (due to purging)
13. Let the reaction go on for ~ 18 hours
14. Cool down the reaction mixture after 18 hours and in the process, remove some
toluene to reduce the volume to half
15.Precipitate the polymer in 300 mL diethyl ether at 40C. Decant the ether and
vacuum dry the polymer. Dissolve the polymer in DCM and repeat precipitation
few times (usually three times in total with diethyl ether) if the polymer is colored
(e.g., yellow)
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16. Dissolve the polymer in DCM and precipitate in 300 mL cooled Petroleum ether
17.Vacuum dry the polymer at 700C
10.2 Acrylation of triblock copolymer
1. Dissolve 3 g of triblock copolymer in 30 mL DCM in a round bottom flask (which
has been taken out of oven and purged with N2).
2. Cool the reaction mixture to 40C.
3. Add 0.2 mL triethylamine and purge N2 for 5 min.
4. Cool the reaction mixture to 40C.
5. Add 0.2 mL acryloyl chloride/ methacryloyl chloride drop wise.
6. Stir the reaction at 40C for 12 hours.
7. After 12 hours at 40C, let the reaction continue at room temperature for another
12 hours.
8. Filter the reaction mixture using a Whatmann/ membrane filter to remove the
TEA.HCI salt.
9. Precipitate the polymer in cooled diethyl ether.
10. Dissolve in DCM and precipitate in Petroleum ether.
11. Vacuum dry the polymer.
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APPENDIX 11- T cell blasts from ova-specific CD4* and CD8*
transgenic mice
1. Euthanize an OT-I or OT-II mouse for preparing CD8* or CD4* T cell blasts,
respectively
2. Isolate spleen and mince using frosted cover slips to obtain single cell
suspension
3. Hemolyse the erythrocytes, wash cells, and resuspend at 3 x 106 cells/mL in
complete RPMI medium
4. Plate T cells at 3 x 106 cells/mL/well in a 24-well tissue culture-treated plate along
with 100 gg/mL ovalbumin in case of OT-IlI cells or 250 pg/mL ovalbumin in case
of OT-I cells
5. Incubate cells at 37 0C, 5% CO2
6. After 48 h, split cells 1:3 and add 5 ng/mL rmlL-2 to the cell suspension
7. Incubate cells at 37 OC, 5% CO2 for 3-5 days after which they are ready to be
used as T cell blasts (> 98% purity as measured by CD4 expression)
8. To obtain high viability cells for experiments, ficoll the cells to remove dead cells
9. In a 15 mL sterile centrifuge tube, take 2 mL of ficoll reagent followed by addition
of 3 mL of cell suspension gently without disturbing the interface
10. Centrifuge cells at 1400 rpm for 10 min
11. Gently pipette off the top layer and the interface that are rich in viable cells
12. Transfer to another sterile centrifuge tube, add excess serum-free RPMI medium,
and wash cells 2x
13. Resuspend cells at desired density in complete RPMI medium
Note:- OT-I cells must be used on day 5 as cell viability decreases substantially
between days 5 and 7.
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